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Abstract 
Many patients undergoing high-risk major surgery suffer complications. 
Previous studies have shown that patients with low IgM Endotoxin Core 
Antibodies (EndoCAb) are more likely to have a complication, for relatively 
unknown reasons. Studying EndoCAb directly is difficult as it is a polyclonal 
group of antibodies. This thesis explored the relationship between EndoCAb 
and different measures of outcome using samples from previously conducted 
clinical trials and a series of basic laboratory studies.  A pilot human volunteer 
study was conducted to try to improve ways of assessing the response to an 
endotoxin challenge.  
 
An observational study on adults undergoing 1st time Coronary Artery Bypass 
Grafting was conducted using samples from a previous trial to see if the 
association between outcome and low EndoCAb IgM extended to this 
comparatively low-risk group and to examine whether this was clearly mediated 
by an exaggerated inflammatory response. Patients with low EndoCAb IgM had 
more complications, but had less interleukin-6 at 6 hours. 
 
To assess the relationship between low EndoCAb IgM and other antibodies a 
series of studies was conducted to examine the hypothesis that EndoCAb IgM 
is part of a wider ‘natural IgM antibody group’. Blood donors with low EndoCAb 
IgM had lower concentrations of the ‘natural IgM antibodies’. Furthermore, 
EndoCAb IgM and the ‘natural IgM antibody group’ had similar temporal 
patterns and were present at low concentrations in some umbilical cord blood.  
 
To further understand the clinical relevance of EndoCAb, the association 
between EndoCAb and the systemic inflammatory response syndrome was 
retrospectively measured in critically ill children undergoing another clinical trial. 
Low EndoCAb IgG was associated with early development of the systemic 
inflammatory response syndrome. The difficulty in determining which factors 
affect the response to an inflammatory challenge led me to develop a new low-
dose endotoxin human volunteer model: one in which there is the largest range 
of change, variability or dispersion in inflammatory markers.   
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1.1 Endotoxin 
The first use of the term endotoxin was reportedly used by Richard Pfeiffer in 
1904, referring to ‘bacterial products, not secreted, firmly fixed to the bacterium, 
but potentially set free if the bacteria undergoes lysis’ (Rietschel and Cavaillon 
2003). Today, after 100 years of research, we now use the word endotoxin to 
mean a specific chemical, lipopolysaccharide (LPS). Endotoxin is a vital part of 
the structure and function of the outer cell membrane of all natural gram-
negative bacteria. Luderitz and Westphal first elucidated of the it’s structure in 
the 1950’s by using acid treatment to give the first carbohydrate-free portion of 
endotoxin, called lipid A (Neter et al 1956). Subsequently, as mutants lacking 
the major part of the O-polysaccharide portion of the molecule (called ‘rough 
mutants’ as the colony morphology has a rough appearance) were found to 
retain biological activity, it was clear that the lipid portion contained the majority 
of endotoxin’s effects (Tanamoto et al 1984).  
 
1.1.1 Endotoxin structure 
Endotoxin has 3 structural parts: a hydrophobic lipid-A region, inner and outer 
core sugars which share broadly similar structures in most Gram-negative 
bacteria and a variable O-polysaccharide chain specific to the particular 
bacterial species, summarised in table 1.1 and figure 1.1 (Erridge et al 2002a). 
It is possible (though unproven) that endotoxin released into the human 
circulation may comprise both smooth and rough forms because of incomplete 
synthesis, organise into micelle-like formations or be associated with other 
membrane components (Erridge et al 2002a; Poxton 1995). The chemical 
method of endotoxin purification may also alter the structure. 
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Structure Basic 
Chemical units 
Conserved ‘Function’ 
O polysaccharide 0-20 
repeating 
units. May 
be absent 
1-8 sugars per 
unit 
No: almost limitless. 
Varying sugars, 
sequences, 
chemical linkage 
and substitutions eg 
over 160 E coli o-
serotypes 
Antigenic; 
prevents 
membrane 
attack 
complex, 
fixes 
complement 
Outer core 0-7 sugars More common 
sugars such as 
hexoses and 
hexosamines 
Relatively 
conserved e.g. only 
5 E coli core 
structures  
(R1–R4 and K12) 
Unknown 
Inner core 1-7 sugars; 
Kdo almost 
always 
present 
Unusual sugars 
such as ‘Kdo’ 
and ‘Hep’ 
Relatively 
conserved e.g. only 
5 E coli core 
structures  
(R1–R4 and K12) 
Unknown 
Lipid A Disaccharide 
attached to 
acyl groups 
Number and 
lengths of acyl 
chains and the 
state of the 
disaccharide’s 
phosphate both 
major 
determinants of  
toxicity 
Acyl groups 
conserved in 
species, but vary 
between species in 
nature, number, 
length, order and 
saturation. E.g. E 
coli  has only one 
lipid A  structure 
Majority of 
toxicity 
 
Table 1.1: Summary of the sub-structures of endotoxin 
Abbreviations: Kdo, 3-deoxy-D-manno-octulosonic acid; Hep, L-glycero-D-
manno heptose. Hexoses include glucose, galactose, N-acetyl galactosamine 
and N-acetyl glucosamine 
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1.1.2 Endotoxin: a potent stimulant of inflammation 
Both in-vitro and in-vivo, endotoxin is a potent stimulant of inflammation. With 
co-factors including CD14 and lipopolysaccharide binding protein (LBP) 
endotoxin binds to Toll-like receptor 4 (TLR-4), one of a family of 
transmembrane proteins expressed on key cells including macrophages, 
endothelial cells and neutrophils which recognise ‘pathogen-associated 
molecular patterns’ as part of the innate immune response (Medzhitov et al 
1997).  TLR-4 ligation initiates a complex series of intra-cellular signalling 
events (involving MyD88, IRAK, TRAF6, and NF-κB) resulting in the production 
of pro-inflammatory mediators including cytokines and adhesion molecules 
(McGettrick and O'Neill 2010).  
 
When injected into animals, or in small quantities (less than 4 ng/kg) into 
human volunteers, endotoxin causes an inflammatory reaction similar to the 
systemic inflammatory response syndrome (Suffredini et al 1999). Human 
volunteers experience symptoms such as headache, chills, myalgia, nausea, 
fatigue, and general malaise as well as cardiovascular, respiratory, 
gastrointestinal, immune and haematological effects (Suffredini et al 1999). For 
ethical reasons, because of the larger harmful doses required, there is no good 
direct evidence (apart from a case report and studies using very subtle 
measures) that endotoxin administration results in overt organ dysfunction in 
humans (Taveira da Silva et al 1993; Kumar et al 2004). Animals administered 
sufficient endotoxin however suffer significant cardiac, respiratory, renal and 
hepatic dysfunction (Albertini et al 2002; Astiz et al 1991; Collin et al 2004; Fink 
et al 1987; Gullichsen et al 1989; Pittet et al 2000; Stitt and DuBois 2001; Tsao 
et al 2004). 
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Figure 1.1 Diagrammatic representation of the structure of endotoxin 
Different colours represent the different sugars that comprise endotoxin’s 
structure.    
 
 
 
1.1.3 Endotoxin and outcome 
Overall, endotoxin concentrations in blood are only weakly associated with 
outcome in septic patients, but endotoxin studies in sepsis are difficult for 
several reasons  (Hurley 2003; Opal 2002). Firstly, endotoxin is not easy to 
quantify, has a short half-life and sample contamination can be a problem.  A 
newer test for endotoxin activity that detects neutrophils’ respiratory burst 
activity after priming with endotoxin and an anti-endotoxin antibody (the 
‘endotoxin activity assay’) may clarify this (Marshall et al 2002; Valenza et al 
2009).  Secondly, the process of sepsis often starts hours or even days before 
signs become manifest, so the inflammatory cascade has amplified greatly by 
the time the investigator has access to the patient. Lastly, many different 
factors are likely to influence outcome, and studies do not always measure all 
substances thought to comprise the natural anti-endotoxin defences (see later), 
or other modifying factors such as host genotype. In certain circumstances 
(such as Meningococcal disease) there is evidence of the link between 
endotoxin concentrations and severity of illness and even (in Meningococcal 
disease) outcome (Brandtzaeg et al 1989; Marshall et al 2004; Valenza et al 
2009).   
n 
   O-polysaccharide          outer core  inner core        lipid A 
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Figure 1.2 Summary hypothesis model of how hypovolaemia may result in 
organ dysfunction. 
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Besides sepsis, as mentioned above, there is merit in the hypothesis that 
endotoxin from the gastrointestinal tract is one of the triggers of the systemic 
inflammatory response syndrome, which may lead to organ dysfunction after 
surgery, trauma and burns. This is based on several observations, which at 
best amount to circumstantial evidence: 
 
• Firstly, the gastrointestinal tract contains a large amount of endotoxin 
(as part of natural commensal gram negative bacteria) and is 
therefore an important source of endotoxaemia. These bacteria place 
them at potential risk of exposure through intestinal leakage of either 
viable gram-negative cells, dead gram-negative cells, or shed free 
endotoxin.  Endotoxin may enter the bloodstream through an 
intestinal mucosa damaged by hypoperfusion during periods of 
hypovolaemia, trauma or physiological stress (Andersen et al 1993; 
Fink and Delude 2005; Lau et al 2000; Martinez-Pellus et al 1997; 
Oudemans-van Straaten et al 1996; Soong et al 1994). 
 
• Secondly, systemic endotoxaemia occurs in many patients 
undergoing major surgery (Andersen et al 1993; Aydin et al 2003; 
Berger et al 1995b; Berger et al 1995a; Boelke et al 2000; Bolke et al 
2001a; Bouter et al 2002; Foulds et al 1997; Lau et al 2000; Lequier 
et al 2000; Martinez-Pellus et al 1993; Myles et al 1996; Neuhof et al 
2001; Oudemans-van Straaten et al 1996; Riddington et al 1996; 
Rothenburger et al 2001; Soong et al 1994). The endotoxin 
concentrations  are also greater if the trauma is greater, for example, 
more invasive surgery or surgery involving cardiopulmonary bypass 
for reasons not fully understood (Aydin et al 2003; Bolke et al 2001a; 
Lau et al 2000). 
 
• Complications following surgery are usually remote from the surgical 
site (e.g. cardiac, respiratory, renal etc) and are not necessarily 
directly related to a surgical ‘mistake’ or to the presence of 
preoperative organ dysfunction (Bennett-Guerrero et al 1999; Grocott 
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et al 2007). This is consistent with the results of endotoxin on animals  
(Albertini et al 2002; Astiz et al 1991; Carpati et al 1992; Collin et al 
2004; Fink et al 1987; Gullichsen et al 1989; Pittet et al 2000; Tang et 
al 1998; Tsao et al 2004; Yao et al 1992). 
 
• Intravenous endotoxin can trigger inflammation in volunteers, of a 
similar nature and timing (but not degree) to that occurring following 
surgery in both humans and animal models (Ayala et al 1991; Elin et 
al 1981; Hammond and Potgieter 1996; Plebani et al 1999; 
Rothenburger et al 2001; Suffredini et al 1999; van Berge 
Henegouwen et al 1998). 
 
• Several studies have reported positive associations between peak 
endotoxin concentrations during major surgery or pancreatitis and 
outcome although these have not been consistent findings (Andersen 
et al 1987; Aydin et al 2003; Berger et al 1995b; Bolke et al 2001b; 
Donnelly et al 1994; Foulds et al 1997; Hoch et al 1993; O'Malley et 
al 2004; Rothenburger et al 2001; Soong et al 1994; Valenza et al 
2009). 
 
• Reducing the bacterial load (i.e. reducing the pool of bacteria 
available to generate endotoxaemia, Selective Digestive 
Decontamination) with oral antibiotics that have a low tendency to 
systemic absorption has been associated with a reduction in 
postoperative complications in some studies  (Silvestri et al 2007; 
Stoutenbeek et al 2007; Zandstra et al 2010).  
 
1.2 Natural defences against endotoxin 
As there is evidence that endotoxin is one of the causes of postoperative organ 
dysfunction, it makes sense to review the substances comprising our natural 
defences against endotoxin. Endogenous factors normally found in healthy 
human serum comprise the body’s natural defence against exposure to 
endotoxin. These factors may bind to and neutralise endotoxin thereby 
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minimising endotoxin mediated systemic inflammation. They include antibodies 
to endotoxin, high-density lipoprotein cholesterol (HDL-C), 
bactericidal/permeability-increasing protein (BPI) and some antimicrobial 
peptides (Beamer et al 1998; Poxton 1995; Ulevitch et al 1979; Warren et al 
2003). There is some less convincing data that other factors such as albumin, 
complement components and lysozyme may also play a role in the 
neutralisation of endotoxin. Of course other synthetic theraputic approaches 
using endotoxin binding polymyxin columns, lipid A analogues such as E5564 
and specific targets in the endotoxin signaling pathway such as CD14 have 
been tried  (Cruz et al 2009; Iwagaki et al 2000; Tidswell et al 2010). 
 
1.2.1 High Density Lipoprotein-Cholesterol  
Lipoproteins in plasma can reduce the activity of endotoxin (Kitchens et al 
2003). Intravenous recombinant High Density Lipoprotein Cholesterol (HDL-C) 
improves survival in animal models of sepsis (Goldfarb et al 2003; Levine et al 
1993). Surgical patients with low HDL-C concentrations have more interleukin 6 
(IL-6) release and more surgical infections, mainly attributable to gram-negative 
organisms (Bonville et al 2004; Delgado-Rodriguez et al 1997; Fujita et al 
2001). When volunteers are given intravenous endotoxin, reconstituted HDL-C 
greatly reduces the release of tumour necrosis factor alpha (TNFα) IL-6, and 
interleukin 8 (IL-8), while only modestly attenuating the secretion of ‘anti-
inflammatory’ cytokines interleukin 1 receptor antagonist (IL-1ra), soluble TNF 
receptors and interleukin 10 (IL-10)  (Pajkrt et al 1996).  Several lipid emulsions 
(such as GR270773) made from plant lipids were in clinical stages of 
development after animal studies showed improved survival in sepsis but this 
did not translate into benefit in humans (Dellinger et al 2009; Goldfarb et al 
2003; Gordon et al 2003; Winchell et al 2002). 
 
 
1.2.2 Bactericidal/Permeability-Increasing Protein 
Bactericidal/permeability-increasing protein (BPI) is naturally released from 
activated neutrophils, can reduce the binding activity of endotoxin and is 
cytotoxic for gram-negative bacteria  (Elsbach and Weiss 1998; Giroir et al 
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1997). It is protective in animal models of sepsis whilst in human volunteers it 
reduces the cardiovascular changes and cytokine concentrations associated 
with endotoxin administration (De Winter et al 1995; Von der Mohlen et al 
1995).  Two large interventional studies used a recombinant fragment of BPI, 
rBPI21 but were judged by a variety of criteria not to be successful 
(Demetriades et al 1999; Levin et al 2000; Wiezer et al 2001; Wu et al 2003). 
This may have been due to an unexpected reduction in mortality in the placebo 
control group, underpowering the study, or because a significant proportion of 
the deaths occurred before the complete course of rBPI21 had time to be given.  
 
1.2.3  Lactoferrin  
Lactoferrin, a non-haeme iron-binding transferrin glycoprotein is found in 
neutrophil granules and most mucosae. Whilst it’s exact mechanisms are yet 
unknown, it reduces endotoxins effects (such as oxidative damage) in animal 
models, is bactericidal and bacteriostatic and inhibits the progression of the 
systemic inflammatory response syndrome (SIRS) into sepsis in endotoxaemic 
mice  (Bellamy et al 1992; Kruzel et al 2002; Kruzel et al 2010; Zagulski et al 
1989). 
 
 
1.3 Antibodies 
Antibodies (immunoglobulins) are gamma globulin glycoproteins that are found 
in vertebrate body fluids. Traditionally considered part of the ‘adaptive’ immune 
system (in contrast to the ‘innate’ that also includes macrophages, natural killer, 
dendritic and mast cells) they identify and neutralize foreign antigens, such as 
bacteria and viruses (table 1.2) (Delves and Roitt 2000). 
 
 
1.3.1 Antibody Structure 
Antibody monomers consist of two large heavy chains and two small light 
chains (figure 1.3). The whole structure can be combined to form dimers with 
two units or pentamers with five units. Each ‘tip’ of the antibody (Fragment 
antibody binding, Fab) has one constant and one variable region: the variable 
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regions from the heavy and light chains together are sometimes called Fv 
regions or domains as their variety gives rise to the huge (variable) repertoire in 
paratopes – the area at the end of the Fab domain that binds an antigen’s 
epitope (see fig 1.3) (Jerne 1955). Structures in the paratope end of each 
variable heavy and light chain domains that bind to a specific antigen are 
referred to as complementary determining regions. 
 
 
 
 
 
 
 
‘Innate’ ‘Adaptive’ 
Non specific response Specific response to antigen 
Often triggered by repeated 
patterns 
Triggered by specific antigen 
structure 
Quick maximal response Delay between exposure and 
maximum response 
Primitive- some aspects are 
found across most of life 
Found only in vertebrates 
No memory response Exposure results in memory 
 
Table 1.2 Summary of the differences between the innate and adaptive 
aspects of the immune system. 
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Figure 1.3 Schematic structure of an antibody. Fab: fragment antigen 
binding; Fc: fragment crystallizable, Fv: fragment variable. The heavy chains 
are represented in blue and consist of 4 regions (VH, CH1, CH2, CH3), whilst 
the light chain is represented in pink and consists of 2 regions (VL and CL). The 
variable parts of an antibody referred to above are its V regions, and the 
constant part is its C region. Papain digestion yields two Fab fragments and 
one Fc fragment (Delves and Roitt 2000).  
 
 
Structural variety in the heavy and light chains’ variable domains comes from 
several mechanisms: combining different genes (VDJ for heavy chains or VJ for 
light chain combinations), somatic hypermutation in variable domain genes and 
selection of those combinations that result in antibodies with high affinity 
(affinity maturation) (Jerne 1955).  
Mammals have five different antibody isotypes or classes differing in the 
constant (C) regions of the immunoglobulin heavy chain (see table 1.3). Each 
isotype has a different structure, biological property, physical location and 
ability to direct the appropriate immune response for the types of foreign object 
encountered.   The classic immune response to a foreign antigen (for example 
following immunization or infection) involves ‘recognition’ by an antibody that 
triggers clonal B cell expansion, class switching from IgM to IgG, memory, and 
 27 
Isotypes Structure Summary of function 
IgA1  
IgA2 
Heavy chain α1 or α2 
Light  chain λ or κ 
MW 150 – 600 
Monomer to tetramer 
Found in mucosa (oral, 
gastrointestinal, respiratory and 
urogenital tract) preventing their 
colonisation by pathogens. Secreted 
in milk and is resistant to digestion. 
IgD Heavy chain δ 
Light  chain λ or κ 
MW 150  
Monomer  
Uncertain function but mostly bound 
to B cells. Involved in B-cell 
development with IgM.  
IgE Heavy chain ε 
Light  chain 
λ or κ 
MW 190  
Monomer 
When bound to allergens triggers 
mast cell degranulation (histamine 
and tryptase). Protects against 
parasitic worms. 
IgG1  
IgG2a and b 
IgG3  
IgG4 
Heavy chain γ1, γ2, γ3, γ4 
Light  chain λ or κ 
MW 150  
Monomer 
The main antibody based immunity 
against pathogens. Can cross 
placenta. 
IgM Heavy chain µ 
Light  chain λ or κ 
MW 900  
Pentamer 
Primary response antibody, 
eliminating pathogens in the early 
stages of B cell mediated immunity 
before there is sufficient IgG. Present 
both on B cells and in secreted form 
(sIgM) with high avidity.  
 
Table 1.3: A summary of the structure and function of mammalian 
antibodies. MW, Molecular weight in kilodaltons. 
 
 
 
a large increase in specific antibody production (Stavnezer 1996). Traditionally, 
interest has mainly focused on the change in IgG antibody concentrations after 
immunization, which, after all, is its aim, and is often associated with specific 
protection from disease (Khatami and Pollard 2010; Sinclair et al 2011; Zhang 
et al 2011). 
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1.3.2 Natural Antibody 
This approach however ignores the nature of antibodies present prior to 
exposure to a specific antigen. There has been recent interest in the role of 
these pre-existing antibodies, called ‘Natural antibodies’ (as opposed to 
‘immune’): in particular where they come from and what their function is  
(Ehrenstein and Notley 2010; Boes 2000). Present in ‘germ-free’ and ‘antigen-
free’ mice, there are various characteristics commonly attributed to natural 
antibodies: 
IgM  
IgM is the first immunoglobulin in the immune response, first in 
ontogeny, and is present in germ and antigen free mice at much higher 
concentrations than IgG (Haury et al 1997). Because of this natural 
antibodies are generally considered to be IgM isotype. IgM can be either 
a pentamer secreted (sIgM) or membrane bound (as a B cell receptor) 
and is the only immunoglobulin present in all vertebrates (Fellah et al 
1992). Classically IgM is described as having low affinity (the strength of 
a single bond) but because it is usually in a pentameric structure, high 
avidity, the combined strength of all the bond interactions (Delves and 
Roitt 2000). 
 
Measurable in umbilical cord blood 
IgM is measurable in umbilical cord blood: in contrast to the smaller IgG, 
IgM cannot cross the placenta from the maternal circulation and so must 
be usually of fetal origin (Brasher and Hartley 1969; Wuttke et al 1997). 
As (in a traditional sense anyway) the fetus is not exposed to external 
antigens prior to birth this is taken as evidence that natural IgM may be 
important in the initial protection of the newborn prior to developing an 
adult immune system and that external antigens (for example infectious) 
have not stimulated it’s production (Brasher and Hartley 1969). 
 
Reactive against self-antigens 
Although natural IgM appears to be directed at a range of antigens, most 
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studies have found reactivity against endogenous structures. These 
target structures can be substances that become exposed during 
processes such as apoptosis (e.g. phosphatidylserine) or ischaemia 
(e.g. annexin IV), have been ‘lost’ in evolution (e.g. gal) but remain 
present in other mammals, occur in some individuals and not others (e.g. 
specific ABO antigens), are nuclear structures or even other antibodies 
themselves (Chellingworth et al 1984; Galili et al 1987a; Halpern et al 
1991; Kremmer et al 2001; Kulik et al 2009; Wellmann et al 2005).  
Whether these antigens have originally driven their production or the 
antibodies arrive by chance as cross-reactive to other antigens (for 
example on bacteria) is not certain (Allen and Kabat 1959; Haury et al 
1997).  However, concentrations of some antibodies considered to be 
‘natural IgM’ such as the A and B antigens of the ABO blood group 
antigens can be raised by exposure to substances that share parts of 
their structure (Springer and Horton 1969).  
 
 
1.3.3 The role and functions of natural antibody 
Natural antibodies have many diverse functions, but it is not clear if they are all 
clinically relevant. However it does appear that natural IgM has a role in: 
 
Cell clearance during apoptosis  
Natural IgM can bind antigens newly exposed on the cell surface during 
apoptosis (Kim et al 2002). With complement, this enhances the 
apoptotic cell opsonization and accelerates its clearance by phagocytes. 
One of the key targets for natural IgM in this context is the 
phosphorylcholine epitope on lysophosphatidylcholine, formed during 
apoptosis when fatty acids are hydrolyzed by phospholipase A2 (Peng et 
al 2005).  This mechanism is often thought to be behind the observation 
that humans with low serum IgM antibodies to phosphorylcholine and 
oxidized low-density lipoprotein have more cardiovascular events  
(Sjoberg et al 2009; Tsimikas et al 2007). 
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Defence against infectious organisms   
There is a large body of evidence that natural IgM is involved in many 
processes that defend against microbiological organisms including 
bacteria, viruses, fungi and parasites, in particular Streptococcus 
pneumoniae and the Influenza virus (Baumgarth et al 2000; Boes et al 
1998b; Ghumra et al 2008; Ochsenbein et al 1999; Rajan et al 2005; 
Reid et al 1997; Subramaniam et al 2010). One well characterized 
antibody, phosphorylcholine IgM is part of the initial defence against 
Streptococcus pneumoniae and other gram-positive organisms that have 
phosphorylcholine as part of their outer cell wall (Baxendale et al 2008; 
Briles et al 1981; Brown et al 2002). 
Of particular relevance to surgery is the fact that mice deficient in 
secreted IgM (sIgM) are more likely to die (70% vs 20% at 32 hours) 
than wild type mice after experimental caecal ligation and puncture. The 
sIgM deficient mice in this study had decreased neutrophil recruitment, 
more bacteria in the peritoneum, and elevated concentrations of 
circulating endotoxin and TNFα. Addition of polyclonal IgM from normal 
mouse serum restored survival to caecal ligation and puncture in the 
sIgM-deficient mice. Interestingly, circulating IL-6 concentrations were 
similar between the two types of mice (Boes et al 1998b). This result 
should be interpreted with caution as these sIgM mice also have 
impaired IgG antibody responses (Boes et al 1998a). There is some 
evidence that IgM enriched immunoglobulin preparations reduce the 
severity of human sepsis (Norrby-Teglund et al 2006). 
 
Immune maintenance and development 
Although relatively putative, natural IgM may have a role in the 
development of the immune system (Ehrenstein and Notley 2010). One 
way this could happen is through natural IgM binding to the B cell 
receptor (a non-pentameric, membrane bound IgM) in turn influencing 
it’s differentiation and maintenance. 
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Cancer 
Organisms are continuously exposed to transformed (genetically altered) 
cells, which arise spontaneously or by inducing factors, some of which 
result in malignancy. There is evidence (with potential clinical benefit) 
that natural IgM is part of the recognition and elimination of 
precancerous and cancerous cells (Vollmers and Brandlein 2009). This 
surveillance may be mediated by natural IgM’s ability to bind tumour-
specific cell surface carbohydrate epitopes, which in turn can induce 
cellular stress and apoptosis (Brandlein et al 2003; Vollmers and 
Brandlein 2005).  
 
 
1.4 Antibodies to endotoxin 
Along with lipids and bactericidal/permeability-increasing protein, naturally 
produced antibodies are thought to provide protection against endotoxin in the 
circulation (Poxton 1995). Endotoxin antibodies are directed at the various parts 
of the endotoxin molecule: lipid A, core or o-polysaccharide. In theory, 
antibodies against the core or lipid A might be expected to bind to a greater 
range of endotoxins because these structures are relatively conserved between 
gram negative species compared to the o-polysaccharide region, which vary 
greatly (Poxton 1995). The trigger and timing for the production of endotoxin 
antibodies is unknown, but they may be the result of an overt clinical infection 
deliberate vaccination (for example with a conjugate vaccine such as E coli 
0111:B4 J5 mutant, a rough endotoxin complexed to group B meningococcal 
outer membrane protein) presumed sub-clinical infection or colonisation or they 
may represent ‘natural antibody’ from the preimmune antibody repertoire 
(Berczi et al 2000; Boes et al 1998b; Cross et al 2004; Cryz, Jr. et al 1997; 
Ehrenstein and Notley 2010; Hendry et al 2000; Maury et al 2003; Pollard and 
Frasch 2001; Stager et al 2003). 
 
Because of the role of endotoxin in initiating inflammation during gram-negative 
sepsis, many investigators have attempted to detect ‘cross reactive’ antibodies 
to endotoxin to use as a potential immunotherapy. These have depended on 
 32 
finding an antigen or a combination of antigens that are sufficiently cross-
reactive i.e. antibodies directed against it reacts with a range of other antigens. 
Because of it’s relatively conserved structure, many investigators have used a 
rough endotoxin, but even these techniques have differed in the method of 
antigen fixation, size of the endotoxin (i.e. how much of the core), which 
species and whether they have used more than one antigen (Cross et al 2004; 
DeMaria et al 1988; Di Padova et al 1993; Erridge et al 2002b; Fomsgaard et al 
1989; Freeman and Gould 1985b; Gould et al 1989; Hardy et al 1994; Hiki et al 
1995; Mattsby-Baltzer et al 1994; Takahashi et al 1992; Ward et al 1988; 
Weintraub et al 1994). 
 
 
1.4.1 Antibodies to endotoxin core, EndoCAb 
The Endotoxin Core Antibody Enzyme-Linked Immunosorbent Assay 
(EndoCAb ELISA) is one of many assays developed to attempt to detect cross-
reactive antibodies to the core region of endotoxin which is much more 
conserved than the O-polysaccharide (Andersen et al 1993; Angus et al 2000; 
Appelmelk et al 1985; Baumgartner et al 1985; Burd et al 1993b; Gould et al 
1989; Hiki et al 1995; Olds and Miller, III 1991; Pollack et al 1983; Young and 
Stevens 1977). This specific assay was developed in order to screen volunteer 
donors for plasma high in cross-reactive antibodies to use as an anti-endotoxin 
treatment in sepsis. It is a sandwich ELISA, with the solid (bound) phase 
consisting of an equimolar mixture of incomplete core endotoxins (i.e. Rc or Rb- 
an intact inner core and Lipid-A region) of Pseudomonas aeruginosa PAC-611, 
Salmonella typhimurium 878 (Rc), Escherichia coli K12 and Klebsiella 
aerogenes M10b (Rb) on polystyrene plates. This particular combination of 
endotoxins was arrived at by screening donor plasma samples with rough and 
smooth examples of 13 species of Salmonella, 14 species of E coli, 2 
Pseudomonas and one Klebsiella alone and in combinations (Scott et al 1990; 
Scott and Barclay 1990). Prior to coating, these incomplete core mutant 
endotoxins are reacted with polymyxin B, an antibiotic cationic polypeptide that 
binds to the inner core region of endotoxin, after which excess polymyxin is 
removed. The addition of polymyxin greatly improves inter-plate variability, 
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increases the optical density and yet still allows better binding with monoclonal 
antibodies to the inner core/lipid A compared to other methods such as 
Magnesium, Albumin and a pH 4.5 method (Appelmelk et al 1993; Scott and 
Barclay 1987). This polymyxin method has been used by other investigators 
although binding of rough endotoxin to other types of ELISA plates has been 
found not to need polymyxin (Bantroch et al 1994; Mertsola et al 1989; 
Takahashi et al 1992).  
 
As mentioned previously there have been several studies in patients 
undergoing surgery, with pancreatitis or sepsis that has shown these antibodies 
to be clinically relevant (Ammori et al 2003; Braun et al 2007; Foulds et al 1997; 
Goldie et al 1995; Hamilton-Davies et al 1997; Mathew et al 2003; Penalva et al 
2004; Rahman et al 2003; Soong et al 1999; Strutz et al 1999; Windsor et al 
1998). What is not known for certain is whether they are a marker for some 
other factor, or if they directly reduce endotoxin-mediated toxicity of if their 
mechanism depends on cross-reactivity with an unknown antigen. One study 
that supports the role of IgM EndoCAb in directly neutralizing endotoxin comes 
from an ‘endotoxin recovery study’ which demonstrated a strong association 
between the amount of endotoxin that could be recovered from a ‘spiked’ 
sample and IgM (and IgG) EndoCAb concentrations (Bennett-Guerrero et al 
2001a). Thus of course it could be that EndoCAb concentrations rise in parallel 
with an unknown factor also capable of neutralizing the LAL test (e.g. HDL 
cholesterol). There are several studies that have investigated the functional 
activity of purified IgG from serum high in IgG EndoCAb (Scott et al 1990; Scott 
and Barclay 1987; Scott and Barclay 1990). These examined various functional 
aspects (such as neutrophils chemiluminescence and bacterial phagocytosis) 
of ‘high IgG EndoCAb immunoglobulins’ from 3 different individuals compared 
with 2 from low IgG EndoCAb donors. In general the purified IgG from sera high 
in antibodies to endotoxin core were found to increase the opsonic activity 
against smooth and rough bacteria (Scott and Barclay 1990). 
 
There is a large 80-fold range in EndoCAb antibodies in healthy blood donor 
populations and both IgG and IgM EndoCAb are detectable in the first few 
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months of life (Barclay 1995; Oppenheim et al 1994). The concentrations of 
both IgG and IgM EndoCAb inversely reflect the amount of endotoxin that can 
be recovered by the conventional endotoxin assay, the Limulus Amebocyte 
Lysate (LAL), suggesting that, at least, it neutralises endotoxin as measured by 
this assay (Bennett-Guerrero et al 2001a).  
 
The majority of studies investigating the role of endotoxin antibodies on clinical 
outcome have been in septic patients. However, because of the evidence that 
endotoxin is a mediator of postoperative morbidity, especially in cardiac surgery 
involving cardiopulmonary bypass, several trials have examined the association 
between antibodies to endotoxin core and postoperative complications. The 
first of these used a qualitative assay (the presence or absence of antibodies to 
an endotoxin core from an E coli) to show that postoperative fever and/or gram 
negative infection was more common in those patients lacking the antibodies to 
endotoxin core (Freeman and Gould 1985a). This was followed by another 
similar study in patients undergoing gynaecological surgery with similar results 
(see table 1.4) (Gould et al 1989). Then, as part of a long term project to source 
plasma high in antibodies to endotoxin core, several studies appeared that 
investigated the role of the ‘EndoCAb’ assay in predicting complications 
following surgery.  These studies involving 2537 patients undergoing surgery 
are outlined in table 1.4. 
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First author Year n= Antibodies Patient group Main outcomes Significant Findings 
Freeman 1985 86 antibodies to E 
coli endotoxin 
‘Open heart 
surgery’ 
Postoperative fever & 
gram negative infection 
Patients with no antibodies (65%) had more postoperative 
fevers and postoperative Gram negative infection. 
Gould 1989 86 antibodies to 
endotoxin 
Major 
gynaecology 
surgery 
Postoperative and 
urinary tract infections 
Patients with no antibodies (76%) had more postoperative 
infections (p<0.05) and urinary tract infections (p<0.02) 
Mythen 1993 26 EndoCAb Major non-
cardiac surgery 
GI mucosal perfusion + 
complications 
Patients maintaining good Gastrointestinal mucosal perfusion 
had higher pre and postoperative IgG EndoCAb 
concentrations  (p=0.005) 
Bennett-
Guerrero 
1997 301 EndoCAb Cardiac 
surgery* 
Death in hospital or 
pLOS>10 days 
Higher IgM EndoCAb associated with good outcome 
(p=0.002) 
Hamilton-
Davies 
1987 59 EndoCAb Valve surgery* Composite endpoint++ Poor outcome associated with IgM EndoCAb < 100 MU/mL 
(p<0.025) 
Foulds 1997 21 EndoCAb IgG  tAAA repair Postoperative renal or 
respiratory failure 
Patients with complications had a greater rise in endotoxin 
(p=0.031) and a greater fall in IgG EndoCAb (p=0.001) 
Bennett-
Guerrero 
2001 1056 EndoCAb Major non-
cardiac surgery 
Death in hospital or 
pLOS>10 days 
Higher IgM EndoCAb associated with good outcome 
(p=0.006) 
Rothenburger 2001 100 IgG and IgM  
against lipid A 
and endotoxin 
CABG Postoperative 
ventilation time, 
endotoxin, IL-6 and  
IL-8. 
All antibodies decreased + endotoxin increased after CPB (p 
< 0.001). In patients with prolonged postoperative ventilation, 
preoperative endotoxin IgM IgG antibodies were lower, the 
fall in IgM greater and more sustained and the rise in 
endotoxin concentrations greater. 
Mathew 2003 460 EndoCAb CABG Cognitive function at 6 
weeks postoperatively 
Low preoperative IgM EndoCAb associated with cognitive 
deficit at 6 weeks (p=0.03) 
Moretti 2006 474 EndoCAb CABG 5 year all cause 
mortality 
Low preoperative IgM EndoCAb (<80 MU/mL)  significantly 
associated with mortality up to 5 years (p=.01) 
Braun 2007 140 EndoCAb Cardiac 
surgery* 
Organ dysfunction IgM, G + A EndoCAb fell after surgery, whilst IgG EndoCAb 
fell more in those developing organ dysfunction.  
 
Table 1.4 Previous adult surgical studies examining the association between preoperative endotoxin antibody concentration and the 
postoperative course *= includes valve and coronary artery bypass graft surgery or double valve surgery ++=Death or IABP or chest 
reopening other than gross surgical bleeding or major organ failure (Knaus et al 1985) or delay in ICU discharge  (>24 hr) or delay in hospital 
discharge (>48hr). Abbreviations: CABG=Coronary artery bypass graft, CPB= cardiopulmonary bypass, EndoCAb©= Endotoxin core antibodies, 
GI= gastrointestinal, IABP = intra-aortic balloon counterpulsation pump, IL-6 = Interleukin 6, IL-8= Interleukin 8, pLOS= postoperative length of 
stay, tAAA= Thoracoabdominal aortic aneurysm  
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1.4.2 EndoCAb and postoperative outcome 
In the first of the surgical studies to use the ‘EndoCAb’ assay, Mythen et al 
examined the relationship between gastrointestinal mucosal ischaemia, IgM 
and IgG EndoCAb concentrations, markers of neutrophil activation and 
postoperative organ dysfunction in 26 patients undergoing routine major non-
cardiac surgery (Mythen et al 1993). They found that all patients had a 
significant fall in EndoCAb from baseline to 24 hours following surgery and that 
those patients with good gastrointestinal perfusion following surgery had higher 
IgG EndoCAb at baseline and 24 hours and had evidence of less neutrophil 
activation. This study was not powered to look at the predictive power of 
EndoCAb concentration for postoperative complications. Bennett-Guerrero and 
colleagues in 301 patients undergoing cardiac surgery found that IgM EndoCAb 
was able to predict a postoperative complication, (defined as death in hospital 
or a postoperative hospital stay exceeding 10 days) above other perioperative 
risk factors such as duration of cardiopulmonary bypass, Parsonnet score (a 
risk prediction score in cardiac surgery), age and preoperative renal failure 
(p=0.002)  (Bennett-Guerrero et al 1997). In particular, 3.7% of patients in the 
highest IgM EndoCAb quartile compared to 23% of patients in the lowest IgM 
EndoCAb quartile experienced a complication. Interestingly IgG EndoCAb and 
total IgM were not related to outcome (p=0.7 and 0.1 respectively) and there 
was no relationship between Parsonnet score and EndoCAb (see appendix 3). 
Subsequent studies (see table 1.4) have found preoperative IgM EndoCAb to 
be related to better postoperative outcome (as judged by a variety of 
measures) but independent of total IgG and IgM, measures of risk in general 
surgery, height, weight, age and several indices of cardiovascular function 
(Bennett-Guerrero et al 2001b; Hamilton-Davies et al 1997). Using another 
measure of endotoxin antibodies (Lipid A or Re core from Salmonella 
minnesota R595) in 100 CABG patients Rothenburger and colleagues found 
that patients with complications had lower preoperative endotoxin antibody 
concentrations, more endotoxaemia and IL-8 following surgery (Rothenburger 
et al 2001).  The most recent published study to include EndoCAb, of only 140 
patients undergoing cardiac surgery found EndoCAb IgM, G and A to fall 
following surgery, but only preoperative EndoCAb IgG was associated with an 
outcome difference (Braun et al 2007).  
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Several in-vitro studies have shown that monoclonaI IgG antibodies to 
endotoxin core can increase the uptake of endotoxin to macrophages and in 
certain circumstances this was accompanied by an inhibition of TNF secretion 
(Burd et al 1993a; Scott and Barclay 1990).  The relevance of monoclonal 
endotoxin antibodies to likely polyclonal groups such as EndoCAb is of 
uncertain relevance although it does point to at least one potential mechanism. 
 
1.5 Uncertainties, successes and failures 
Studying EndoCAb is and has been challenging. Low EndoCAb IgM seems to 
be associated with a poorer outcome- but is this link causal, and what is the 
mechanism? The current idea is that EndoCAb IgM neutralises endotoxin 
(released from the GI tract), resulting in less inflammation around the time of 
surgery. One clinical approach is to try to examine if the measures of 
inflammation are higher in those with less EndoCAb. This I did in chapter 3 
using samples and data collected from patients enrolled in another study on IL-
6 levels after first time CABG, with IL-6 and CRP as the measures of 
inflammation. In chapter 5 I used the opportunity of another trial (examining the 
role of MBL in children) to see if patient with low EndoCAb had more SIRS- a 
clinical measure of inflammation.  
 
Another approach to studying EndoCAb’s effects may be to make a ‘pure’ 
concentrate and to examine its effects in an in-vitro system. To manufacture 
(for example by affinity purification) an ‘EndoCAb’ concentrate is technically 
difficult and was outside the scope of expertise I had available for this thesis.  
By its nature, EndoCAb is a mixture of antibodies (as the ELISA uses an 
equimolar mixture of 4 endotoxin cores), so it is not strictly possible to make a 
‘monoclonal EndoCAb’. As an alternative during my research time I tried to 
fractionate a serum from volunteers with high or low EndoCAb IgM to use in in-
vitro studies. These in-vitro studies involved both whole blood endotoxin 
stimulation (with serial cytokines as the outcome) and Flow Cytometric 
techniques (‘FACS’ using Neutrophil CD11b as the measure of cell activation).  
Unfortunately, although I mastered the in-vitro techniques and was able to 
make an IgM fraction from serum it was not possible for me to do this in a 
sterile environment. Because of these difficulties I decided to look at the 
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similarities between EndoCAb IgM and a panel of natural IgM’s and to try to 
see how much EndoCAb IgM had the characteristic of a natural IgM.  I 
reasoned that, if EndoCAb and natural IgM levels were linked, that reduced the 
likelyhood that the association between EndoCAb IgM and postoperative 
outcome was causal or specific to EndoCAb IgM. It also points to a new 
mechanism. 
 
Aside from clinical (chapters 3,5) and basic science (chapter 4) techniques, 
volunteer studies (chapter 6) may help elucidate the mechanism of EndoCAb’s 
association with outcome. However like all trials, endotoxin volunteer studies 
have to be conducted correctly, using appropriate doses and dose regimens 
depending on the outcome being measured.  Most human studies use a large 
endotoxin 4ng/kg bolus that causes robust clinical and immune markers of 
inflammation in all volunteers. I wondered if the range of responses could be 
increased if the dose of inflammatory stimulus was reduced. We wanted an 
endotoxin does that caused inflammation in some but not in all. Then we could 
use this in a later study to examine what the predictors of a large (or absent) 
inflammatory response are. 
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2.1 Introduction 
 
 
The experimental work in this thesis required the modification and subsequent 
validation of existing techniques. This chapter will describe the methods used in 
the thesis. I have not included the methods I learnt but did not use in the final 
thesis such as Flow Activated Cell Sorting, cell density centrifuge separation, 
Magnetic Activated Cell Separation, Cell culture, cell stimulation with endotoxin 
and molecular weight chromatography.  
 
 
 
2.2 Reagents and Equipment 
 
 
Reagent Supplier Address 
NaCl Sigma-Aldrich London, UK 
KCl Sigma-Aldrich London, UK 
Na2HPO4 Sigma-Aldrich London, UK 
KH2PO4 Sigma-Aldrich London, UK 
NaN3 Sigma-Aldrich London, UK 
Na2CO3 Sigma-Aldrich London, UK 
NaHCO3 Sigma-Aldrich London, UK 
Diethanolamine Sigma-Aldrich London, UK 
4-Nitrophenyl phosphate powder Sigma-Aldrich London, UK 
Tetramethylbenzidine Dihydrochloride Sigma-Aldrich London, UK 
Bovine Serum Albumin Sigma-Aldrich London, UK 
MgCl2 Sigma-Aldrich London, UK 
NaHPO4 Sigma-Aldrich London, UK 
Low Endotoxin Fetal Calf Serum Cambrex Charles City, USA 
Heparin Sulphate Celcus Cincinnati, USA 
 
Table 2.1: General Chemical Laboratory reagents 
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Reagent Supplier Address 
E coli Endotoxin 0111:b4  Sigma-Aldrich London, UK 
E coli Endotoxin K12 Prof I Poxton Edinburgh, UK 
E coli Endotoxin 0113 National Institutes of 
Health, USA 
Bethesda, USA 
Salmonella typhimurium 878 
Endotoxin 
Prof I Poxton Edinburgh, UK 
Klebsiella aerogenes M10b 
Endotoxin 
Prof I Poxton Edinburgh, UK 
Pseudomonas aeruginosa PAC-
611 Endotoxin 
Prof I Poxton Edinburgh, UK 
‘EndoCAb’ ELISA plates Dr R Barclay Edinburgh UK 
Phosphatidylserine Sigma-Aldrich London, UK 
Phosphatidylcholine Sigma-Aldrich London, UK 
Phosphorylcholine Biosearch 
Technologies 
Novato, USA 
Phosphorylcholine-Albumin Biosearch 
Technologies 
Novato, USA 
α1-3 Gal antigen (PAA-Bdi) Lectinity Holdings Moscow, Russia 
Blood Group A antigen (PAA-Atri) Lectinity Holdings Moscow, Russia 
Blood Group B antigen (PAA-Btri) Lectinity Holdings Moscow, Russia 
Tetanus toxoid List Biologicals Campbell, USA 
Rabbit anti-human IgM Dako UK Ltd Ely, UK 
Recombinant Human TNF Invitrogen Biosource Paisley, UK 
Recombinant Human IL-6 Invitrogen Biosource Paisley, UK 
Recombinant Human IL-10 Invitrogen Biosource Paisley, UK 
 
Table 2.2: Antigens and Endotoxins 
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Reagent Manufacturer Address 
TNFα anti-human capture 
antibody  
Invitrogen 
Biosource 
Paisley, UK 
TNFα anti-human detection 
antibody; biotinylated 
Invitrogen 
Biosource 
Paisley, UK 
IL-6 anti-human capture 
antibody 
Invitrogen 
Biosource 
Paisley, UK 
IL-6 anti-human detection 
antibody; biotinylated 
Invitrogen 
Biosource 
Paisley, UK 
IL-10 anti-human capture 
antibody 
Invitrogen 
Biosource 
Paisley, UK 
IL-10 anti-human detection 
antibody; biotinylated 
Invitrogen 
Biosource 
Paisley, UK 
anti-human IgM; alkaline 
phosphatase conjugated 
Sigma-Aldrich London, UK 
anti-human IgG; alkaline 
phosphatase conjugated 
Sigma-Aldrich London, UK 
anti-human IgA; alkaline 
phosphatase conjugated 
Sigma-Aldrich London, UK 
 
Table 2.3: Antibodies 
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Equipment Manufacturer Address 
ELISA reader: Dynatech MRX Dynatech 
Laboratories 
Billingshurst, UK 
ELISA Plate washer LP4 Adil Instruments Schiltigheim, 
France 
pH meter: HI-2211-02  Hanna instruments Leighton Buzzard, 
UK 
Weighing scales: Sartorius 
Basic  
Sartorius Gottingen Germany 
Biological safety cabinet Class 
2 BIOHIT NCB-D 
The Baker 
Company 
Maine USA 
Acetate ELISA plate adhesive MP Biomedicals Solon, USA 
Nunc Maxisorb 96 well ELISA 
plate 
Fisher scientific Loughborough, UK 
Nunc Polysorb 96 well ELISA 
plate 
Fisher scientific Loughborough, UK 
Linbro/Titertek ELISA plate ICN Biomedicals Aurora, USA 
MilliQ Water purification system Millipore UK LTD Watford, UK 
Centrifuge ROTANTA 460 R Hettich GmbH & Co Tuttlingen, 
Germany 
Falcon polypropylene 50 mL 
tubes 
BD biosciences Oxford, UK 
Eppendorf 1.5mL tubes Eppendorf UK Cambridge, UK 
 
Table 2.4: Equipment and disposables 
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2.3 Endotoxin Core Antibody Enzyme-Linked 
Immunosorbent Assay 
 
2.3.1 Reagents and solutions 
 
Name Constituent Amount 
Phosphate 
Buffered 
Saline 
NaCl 
Na2 HPO4.H20  
KH2P04  
KCl 
Distilled Water 
8g    
1.42g    
0.2g  
0.2g 
1L MilliQ 
pH whole solution to 7.4 
Wash buffer 0.1% ‘Tween20’ 
Sodium Azide 0.05% 
Phosphate Buffered Saline  
1mL  
0.5 g  
Make up to 1L  
Diluent 
  
Phosphate Buffered Saline 
Tablet 
0.1% ‘Tween20’ 
Sodium Azide 0.05% 
BSA 1% 
Polyethylene Glycol 8000 
4%  
Distilled H20 
5 per 1L 
 
1mL in 1L 
0.5 g in 1L 
10g in 1L 
40g in 1L 
Make up to 1L 
Substrate 
Buffer 
Diethanolamine 
MgCl2 
Sodium Azide 
Distilled H20  
97mL 
0.1g 
0.2g 
Make volume up to 1L; 
Adjust to pH 9.8 with 10 M 
HCL 
Conjugated 
Fc-specific 
antibodies 
Alkaline phosphatase–
conjugated IgG, IgM or IgA 
Diluted 1:500 
 
Table 2.5: Reagents for EndoCAb ELISA. 
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2.3.2 Method of the EndoCAb ELISA 
Blood samples were collected from patients or volunteers by venipuncture into 
nonadditive glass tubes, allowed to clot, centrifuged and the serum stored at     
-80°C until assayed. For some studies plasma was used. 
Antigen 
Serum IgM, IgG and IgA EndoCAb were measured with a sandwich ELISA.  
Equimolar amounts of an endotoxin from each of a selected Escherichia coli, 
Salmonella typhimurium, Klebsiella aerogenes, Pseudomonas aeruginosa 
rough mutant strain were complexed with polymyxin B in a carbonate 
bicarbonate buffer (pH 9.6), and coated on 96 well-polystyrene microplates by 
the manufacturer, Dr Robin Barclay PhD, Scottish National Blood Transfusion 
Service Cell Therapy Group, Edinburgh, UK. These 4 mutant strains lacked the 
endotoxin O-polysaccharide and part of the endotoxin outer core, but retained 
an intact inner core structure.   
Assay method 
All reagents were made up in glassware that has been baked at 1700 
centigrade for 2 hours. Following one 250µL plate wash in wash buffer, an 
eight-point standard curve was constructed using doubling dilutions in diluent of 
a calibrated serum that has an undiluted value of EndoCAb IgM of 165 MU/mL, 
an EndoCAb IgG of 784 MU/mL and an IgA EndoCAb of 226 MU/mL.  
Following the addition of 100 µL of the standards and samples, the plate was 
covered and incubated for 1 h at 37 °C. The samples are diluted 1 in 200, and 
the quality controls in 2 serial dilutions of 1 in 100 to 1 in 200.  All standards, 
quality controls, blanks (diluent only) and samples were run in duplicate. The 
top standard concentration was 1 in 50, if the concentration of EndoCAb in the 
sample was high, the standard or sample concentration was altered and 
repeated. The ELISA plates were then washed three times with wash buffer 
and finally blotted dry. Alkaline phosphatase conjugated goat antihuman IgM, 
IgG or IgA antibody (Sigma-Aldrich Chemical Co; Poole, UK) was diluted 1 in 
1000 with dilution buffer, and 100 µL of conjugated antibody was added to each 
well; the plates were covered and incubated for 1 h at 37 °C. After incubation at 
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37 °C, the plates were washed three times with wash buffer, rinsed twice with 
distilled water, and blotted dry on absorbent tissue.  
P-Nitrophenyl Phosphate Substrate (Sigma-Aldrich Chemical Co; Poole, UK) 
(5mg p-Nitrophenyl Phosphate per 5mL Diethanolamine substrate buffer; 180 
µL per well) was added to each plate and incubated at room temperature in the 
dark for approximately 20 minutes for IgM, 10 min for IgG and 30 minutes for 
IgA. The reaction was stopped with 2M NaOH. The plate was read at 405 nm 
wavelength using an automated plate reader (Dynatech MRX, Virginia, USA). A 
standard curve was constructed at 405 nm optical density against EndoCAb 
concentration and the result of test samples was deduced from the curve. 
 
Results 
Results were expressed as median units (MU) per milliliter, where 100 MU/mL 
is the median value of the original population of 1,000 healthy volunteers as 
determined by Dr Robin Barclay (Barclay 1990). The assay was standardized 
using a calibrated pooled-serum standard of a predetermined EndoCAb IgM, 
IgG and IgA concentration and by the use of a quality control serum included 
on each plate. Results from the whole plate were rejected if the concentration 
of the control sample varied by more than 15% from the known value or the 
correlation coefficient (r2) for the standard curve was less than 0.98. Individual 
sample results were rejected and repeated if the coefficient of variation of the 
samples were greater than 15% or the optical density of the sample is outside 
the range of the standard curve. 
Assay consistency (intra-assay and inter-assay variation) was measured by 
running 5 duplicate samples on each of two plates and calculating the 
coefficient of variation (standard deviation/mean expressed as a percentage). 
The intra-assay coefficient of variation was 9.0, 8.7 and 8.3%, whilst inter-assay 
variation was 11.3, 10.3 and 8.2% for EndoCAb IgM, IgG and IgA respectively.  
 
Because of the relatively high EndoCAb values seen in other surgical studies, 
and the fact that there is no published data on IgA EndoCAb concentrations, a 
new standard for the study on EndoCAb and outcome after first time Coronary 
Artery Bypass Graft surgery was manufactured. After screening 24 consenting 
healthy volunteers four with the highest IgA EndoCAb values were selected. 
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15mL blood was taken from each allowed to clot and spun separately, then the 
serum mixed together. The resulting mixture was then filtered with a 30 
kilodalton filter (to remove excess solvent) to 2/3 it’s original value. The 
resulting new standard had an IgA EndoCAb value of 306 MU/mL compared to 
the original of 226 MU/mL. 
Blinding 
All laboratory measurements were performed on coded samples so as to blind 
the investigators to the patients’ identity and outcome. 
Statistical Analysis 
The distribution of EndoCAb is non-Gaussian with positive skew: nonparametric 
methods were therefore used, or the data was log transformed, to permit 
parametric analysis.  
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2.4 Cytokine Enzyme-Linked Immunosorbent Assay 
 
2.4.1 Reagents 
 
Name Constituent Amount 
Phosphate 
Buffered 
Saline  
 
NaCl 
Na2 HPO4.H20  
KH2P04  
KCl 
distilled water 
8 g    
1.42 g    
0.2 g  
0.2 g 
1 L distilled water 
pH whole solution to 7.4 
Wash Buffer Phosphate Buffered Saline  
0.1% ‘Tween20’ 
1 L 
 
1 mL 
‘Blocking 
Solution’ 
Bovine Serum Albumin 
Phosphate Buffered Saline 
5 g    
1 L 
Diluent 
  
Phosphate Buffered Saline  
0.1% ‘Tween20’ 
BSA 1% 
100 mL 
 
0.1 mL 
0.1 g  
Phosphate 
Citrate 
Buffer 
0.2 M Na2HPO4 
0.1 M C6H8O7 (Citric Acid) 
14.196 g in 500mL distilled 
water 
10.51g per 500mL distilled 
water 
 
5.14 mL of 0.2 M Na2HPO4 
and  
4.86 mL of 0.1 M Citric Acid 
above and 10 mL distilled 
water to make Phosphate 
Citrate Buffer 
Substrate 
Buffer 
Tetramethylbenzidine  
H2O2  
Phosphate Citrate Buffer 
1 mg Tablet 
2 µL 
10 mL 
Streptavidin-
Horse 
Radish 
Peroxidase 
4 µLStreptavidin-Horse 
Radish Peroxidase 
10 mL of Phosphate Buffered 
Saline  
  
Stop 
Solution 
H2SO4  
distilled H20 
55 mL  
445 mL 
 
Table 2.6: Reagents for Cytokine ELISA 
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2.4.2 Conduct of the Cytokine ELISA 
Cytokine Enzyme linked Immunosorbent Assays (ELISA) to Tumour Necrosis 
Factorα (TNFα), Interleukin-6 (IL-6) and Interleukin-10 (IL-10) were performed 
according to previously published methods using paired commercial capture 
and detection antibody sets  (Allen 2006). 
 
ELISA Plate coating with capture antibodies 
Capture antibodies were reconstituted according to the manufacturer’s 
instructions (Cytoset, Invitrogen Biosource, Paisley, UK). 11 µL of the capture 
antibody concentrate was added to 11 mL of Phosphate Buffered Saline on the 
day of use: this dilute solution is then at 1 µg/mL, except Tumour Necrosis 
Factor α (TNF-α) at 5 µg/mL. Using a multichannel pipette, 100 µl of this dilute 
capture antibody solution was added to each well of a 12 x 8 format Nunc 
Maxisorb flat bottomed ELISA plate. These were covered with plate adhesive 
and put in 4oc refrigerator overnight for 12-18 hours. 
 
Blocking 
The next day, the coating antibody was aspirated from the wells, which were 
washed once with wash buffer. 300 µL of blocking solution was added to each 
well and the plate gently agitated at room temperature for a minimum of 2 
hours. The blocking solution was aspirated and the plate washed 4 times. 
 
Standards, Quality Control and Samples  
Standards were reconstituted from powder according to the manufacturer’s 
instructions (Cytoset, Invitrogen Biosource, Paisley, UK). The powdered 
antibody was diluted to a concentration of 10,000 pg/mL in blocking solution 
and diluted as appropriate. The top concentration for the standards was 5,000 
pg/mL, apart from Tumour Necrosis Factorα (TNFα) that was started at 10,000 
pg/mL. The standards were added to the plate in doubling dilutions, 12 dilutions 
in all, giving a concentration range 10,000 pg/mL to 4.88 pg/mL (TNFα) and 
5000 pg/mL (IL-6 and IL-10) to 2.44 pg/mL. Plates were covered, put on a plate 
shaker (2 Hz) for 1 hour and refrigerated at 4 oc overnight.  
Blood samples were collected from patients or volunteers by venipuncture into 
plain glass tubes, allowed to clot, centrifuged, and the serum stored at -80 °c 
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until assayed. Defrosted serum samples were mixed, then centrifuged (5 
minutes at 2400 revolutions per minute) to pellet any particulate matter. 100 µL 
of the samples, diluent alone (for ‘negative controls’, blanks) or the quality 
controls were added in duplicate to each well as appropriate. Samples were 
added to wells neat. 100 µL of diluent as a ‘negative control’ or ‘blank’ were 
added in duplicate to two wells. 
Secondary antibody and Substrate 
Plates were then washed 4 times. The respective appropriate biotinylated 
detection antibody solution was diluted 1 in 1250 in diluent; 50 µL of this dilute 
solution added to each well and the plate incubated at room temp for 2 hours 
on a rotational shaker. Plates were again washed 4 times. 100 µL of diluted 
Streptavidin-Horse Radish Peroxidase was added to each well, the plate was 
put on a rotational shaker for 45 minutes and washed 4 times. 2µL Hydrogen 
peroxide was mixed with 10mL of the Phosphate Citrate Buffer and 1mg 
Tetramethylbenzidine (TMB) tablet was added. 100 µL of this TMB substrate 
solution was added to each well. The plates were protected from light with foil, 
and placed on a rotational shaker for 45 to 60 min. The solution was stopped 
by 100µL4M sulfuric acid per well when the highest concentration standard 
developed a blue- green appearance and some colour development started in 
the most dilute standard. Plates were read at 450 nm, aiming for the range 0 to 
2 Optical Density Units. 
 
Validation and Quality Control 
A quality control serum was generated to ensure plate to plate consistency. 
20mL of volunteer anticoagulated blood was mixed in a 1:1 ratio with RPMI with 
L-glutamine culture media, and 10 ng/mL E. coli 0111:b4 in a 50 mL Falcon 
tube. This was gently mixed and incubated at 37 0C with 5%CO2 for 1.5 hours. 
This was spun (at 4 0C and at 2000 rpm for 15 minutes) after which the 
supernatant was removed into sterile tubes and frozen at -80 0C. This quality 
control serum was used on each ELISA plate. Assay consistency (intra-assay 
and inter-assay variation) was determined by running 5 identical duplicate 
samples on each of two plates on one day and calculating the coefficient of 
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variation (standard deviation/mean value expressed as a percentage). The 
intra-assay coefficient of variation was 3.6, 7.5 and 3, whilst inter-assay 
variation was 8.1, 12.5 and 10.8 for TNFα, lL-6 and IL-10 respectively. If optical 
density readings were greater than 2.0 at the highest dilution used in the assay, 
the sample was reassayed after additional dilution. Results from the whole 
plate were rejected and repeated if the concentration of the control sample 
varied by more than 15% from the known value or the correlation coefficient (r2) 
for the standard curve was less than 0.98. Individual sample results were 
rejected and repeated if the correlation of variance of the samples were greater 
than 15% or the optical density of the sample is outside the range of the 
standard curve.  
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2.5 Gal, A, B and phosphorylcholine IgM Enzyme-Linked 
Immunosorbent Assay 
  
 
 
2.5.1 Buffers and Reagents 
 
Name Constituent Amount 
Phosphate 
Buffered Saline  
 
NaCl 
Na2 HPO4.H20  
KH2P04  
KCl 
distilled water 
8 g    
1.42 g    
0.2 g  
0.2 g 
1 L distilled water 
pH whole solution to 7.4 
Wash Buffer Phosphate Buffered 
Saline  
0.01% ‘Tween20’ 
1 L  
 
0.1 mL 
‘Blocking 
Solution’ 
Bovine Serum Albumin 
Phosphate Buffered 
Saline 
20 g    
1 L  
Diluent Buffer 
  
Phosphate Buffered 
Saline  
0.1% ‘Tween20’ 
BSA 1% 
100 mL 
 
0.1 mL 
0.1 g  
Coating buffer 0.1 M Carbonate buffer 
 
Na2CO3 3.11 g 
NaHCO3 5.94 g 
distilled water to 1 L 
pH 9.6 
Substrate Buffer Diethanolamine 
MgCl2 
Sodium Azide 
Distilled H20  
97 mL 
0.1 g 
0.2 g 
Make volume up to 1 L; 
Adjust to pH 9.8 with 10 M 
HCL 
Conjugated Fc-
specific 
antibodies 
Alkaline phosphatase–
conjugated IgM  
Diluted 1:1000 
 
Table 2.7: Reagents for Gal, A, B and phosphorylcholine ELISA 
 
 
 
 
 
 
 
 
 
 
 
 
  53 
2.5.2 Conduct of the ELISA 
The conduct of the ELISA follows previously published methods (Fan et al 
2004; Padilla et al 2004; Rieben et al 1997; Rieben et al 2000). Nunc Maxisorb 
96 ELISA well plates were coated with 50 µL of antigen, A (4 µg/mL), B (4 
µg/mL), gal (5 µg/mL) or phosphorylcholine (2.5 µg/mL) diluted in coating 
buffer, covered and incubated overnight at 4 °C. The next day after washing 4 
times with wash buffer, phosphorylcholine plates alone were blocked for 1.5 
hours at room temperature with blocking solution. 
 
Standards 
As there are no agreed units for antibodies to the blood group antigens A and 
B, to α1-3 Gal or Phosphorylcholine, I developed my own standard from pooled 
serum. Blood from 4 volunteers with high concentrations of IgM antibodies to 
these antigens after screening was allowed to clot and the serum removed. 
After centrifuging (2000 rpm for 15 minutes) to remove larger particles it was 
concentrated by running though a 30 kilodalton filter. The subsequent pooled 
serum was then run as a standard for the four ELISAs. The units are expressed 
as arbitrary units/mL in all the studies, where the top standard (at 1 in 50) has 
arbitrarily been allocated a value of 128.  Thus any sample diluted 1 in 50 with 
the same optical density as the top standard (which was diluted 1 in 50) would 
be given a value of 128 arbitrary units/mL.  
 
Samples  
Blood was collected from volunteers by venipuncture into plain glass tubes, 
allowed to clot, centrifuged, and the serum stored at -80 °C until assayed. 
Samples were mixed, then centrifuged for 5 minutes at 3000 revolutions per 
minute to bring down any particulate matter. 50 µL of the samples, diluent 
alone (for ‘negative controls’, blanks) or the quality controls were added in 
duplicate to each well as appropriate. Samples and quality controls (50 µL 
diluted 1 in 50 in diluent buffer) were added to wells whilst diluent buffer as a 
‘negative control’ or ‘blank’ was added in duplicate. Standards (see below) had 
a top concentration of 1 in 50 in diluent buffer from the neat serum, and were 
diluted downwards 1 in 2 to construct a ‘standard concentration curve’.  
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Samples, standards, blanks and quality control samples were incubated for 90 
minutes at 37 °C, after which they were washed 4 times. Goat Anti-Human IgM 
(50 µL/well) diluted 1 in 1000 was added and the plates incubated for 60 
minutes at 37 °C, then washed 4 times.  
Colour was developed by adding substrate (100 µL per well) and the plates 
incubated for 30 min at 37 °C. Plates were then read at 405 nm, aiming for the 
range 0 to 2 Optical Density Units. Sample and quality control concentrations 
were calculated from the standard curve.  
 
ELISA consistency 
Assay consistency (intra-assay and inter-assay variation) was determined by 
running 5 identical duplicate samples on each of two plates on one day and 
calculating the coefficient of variation (standard deviation/mean value 
expressed as a percentage). The intra-assay coefficient of variation was 6, 7.8, 
4.3 and 5.4 %, whilst inter-assay variation was 5.6, 8, 4.8 and 8.1 % 
respectively for A, B, α1-3 Gal and phosphorylcholine IgM.
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Chapter 3 
 
Antibodies to Endotoxin core and outcome after 
first time Coronary Artery Bypass Graft surgery 
 
 
3.1 Introduction 
3.2 Hypothesis 
3.3 Aims  
3.4 Methods 
3.5 Results 
3.6 Discussion 
3.7 Conclusion 
3.8 Further work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  56 
3.1 Introduction 
Whilst the mortality following Coronary Artery Bypass Graft (CABG) is low, 
under 2% in-hospital after 1st time CABG, complications occur in at least 20% 
of patients, causing suffering and extending hospital stay  (Keogh and Kinsman 
2009). Patients may experience a poor outcome for several reasons, but many 
complications are thought to result from an exaggerated systemic inflammatory 
response.  Endotoxin is a potent trigger of systemic inflammation (see 
introduction chapter 1) and is thought to be one of the causes of inflammation 
after CABG surgery. Endotoxin is detectable in the blood of majority of patients 
undergoing cardiac surgery involving cardiopulmonary bypass although the 
origin of the endotoxin is controversial (Aydin et al 2003). The cardiopulmonary 
bypass circuit, contaminated intravenous fluids, and an underperfused 
gastrointestinal tract leading to increased translocation of bacterial products 
have all been suggested as potential causes (Andersen et al 1987). 
 
Previous studies (see table 1.4, introduction, chapter 1) involving a total of 
2537 patients have shown that low preoperative IgM EndoCAb is associated 
with a poor outcome following both cardiac and non-cardiac surgery  (Bennett-
Guerrero et al 1997; Bennett-Guerrero et al 2001b; Hamilton-Davies et al 1997; 
Mathew et al 2003; Mythen et al 1993). These 5 studies have all used different 
definitions of a complication or a poor outcome and have involved cardiac 
surgical patients (including high risk groups such as repeat surgery, cardiac 
valve and Coronary Artery Bypass Grafts or two simultaneous cardiac valve 
replacements) or general surgical patients undergoing major surgery (e.g. 
radical prostatectomy, hip surgery revision or colon surgery). Only one of these, 
the smallest, attempted to elucidate any connection between EndoCAb and 
inflammation. In this study involving patients undergoing major general surgery, 
Mythen (n=26) found an association between higher preoperative and 24 hour 
IgG EndoCAb, better gut perfusion, reduced activation of the contact 
coagulation system, evidence of less neutrophil activation and organ failure. 
One study investigated the link between endotoxin antibodies and inflammation 
after CABG but comparisons with UK cardiac surgical practice are difficult 
because a different antibody assay to EndoCAb was used and a different risk 
stratification system not used in the UK (Higgins et al 1992; Rothenburger et al 
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2001).  A further study measured EndoCAb in cardiac surgical patients but 
appeared not to be designed to examine its predictive power on postoperative 
outcome (Braun et al 2007). 
 
There are several reasons why patients undergoing elective 1st time CABG are 
an appropriate group to study. Firstly, it is not known if the associations 
between IgM and outcome seen in the other studies, which generally involved 
higher risk patients (such as valve surgery or revision surgery) would extend to 
lower risk groups such as patients undergoing elective 1st time CABG.  
Compared to other cardiac surgical patients, this group would be expected to 
have a relatively low rate of complications  (Keogh and Kinsman 2009). In 
theory it might be much harder to detect the consequences of endotoxin-
mediated inflammation in these individuals because they have fewer co-
morbidities, better cardiac function, are younger and have lower ‘risk scores’  
(Keogh and Kinsman 2009). Surgery and cardiopulmonary bypass times should 
be shorter, and as the patients are in better health they should be better able to 
withstand the effects of tissue trauma, cardiopulmonary bypass, hypovolaemia 
and endotoxaemia compared to patients undergoing longer, more complex or 
repeat procedures (Keogh and Kinsman 2009). Secondly, the previous studies 
in UK cardiac surgical patients were published over 14 years ago since when 
practice has changed  (Hamilton-Davies et al 1997; Mythen et al 1993). The 
relevance of comparisons with cardiac surgical today practice is unknown. 
Thirdly whilst two of these surgical studies (the smallest two; involving just 75 of 
the 1902 patients studied) were performed in the UK, the vast majority of the 
patients were from the USA.  Along with differences in clinical practice, the 
population in the USA may also have different EndoCAb concentrations making 
comparisons with the UK even harder (Down et al 2004). Lastly since patients 
undergoing 1st time CABG are the largest cardiac surgical group, they are the 
largest potential group in which one could use a theraputic intervention (Keogh 
and Kinsman 2009).  
 
To investigate the hypothesis that the relationship between low preoperative 
EndoCAb IgM and poor postoperative outcome may be explained by increased 
postoperative inflammation, I used interleukin-6 (IL-6) and C-reactive protein 
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(CRP) as general markers of postoperative inflammation, already being 
measured as part of the larger ‘CASIS’ (Coronary Artery Surgery Inflammation 
Study) trial.  IL-6 and CRP concentrations are associated with mortality and 
complications after a variety of traumatic events although this has not been a 
universal finding (Fernandez-Serrano et al 2003; Giannoudis et al 2008; Kilciler 
et al 2008; Marti et al 2007; Mei et al 2007; Nieman 1997; Pape et al 2008; 
Simmons et al 2004).  
Other secondary outcomes were measured either because of previous reported 
associations between them and EndoCAb (i.e. progression of heart failure) or 
because they are potentially confounding variables (Bolger et al 2001).  
 
 
3.2 Hypothesis 
The primary hypothesis was that low concentrations of EndoCAb are 
associated with a poorer clinical outcome and raised concentrations of 
postoperative inflammatory markers. 
 
 
3.3 Aims 
Primary Aims 
To examine the relationship between IgM, IgG and IgA EndoCAb and clinical 
outcome (‘complications’) after 1st time elective CABG. 
To examine the relationship between EndoCAb and markers of postoperative 
inflammation (IL-6 and CRP) after 1st time elective CABG. 
 
Secondary Aims 
To examine the relationship between IgM, IgG and IgA EndoCAb and 
• Surrogate markers of preoperative cardiovascular dysfunction (New York 
Heart Association functional class, ejection fraction) 
• Post operative haemorrhage 
• High Density Lipoprotein-cholesterol (HDL-C) 
• Age, Gender and ABO blood group 
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3.4 Methods  
Approval for this study was obtained from our institution's ethics committee 
(REC ref. number 99/0099 The Joint UCL/UCLH Committees on the Ethics of 
Human Research: Committee α and A). Patient data was stored according to 
the requirements of the Data Protection Act. The clinical data, samples and 
blood for EndoCAb in this chapter were obtained from a double blind, 
observational cohort study (‘CASIS’ Coronary Artery Surgery Inflammation 
Study) part of a wider prospective investigation into the effects of key 
genotypes on concentrations of inflammatory mediators. CASIS was conducted 
by the Centre for Cardiovascular Genetics Department of Medicine, Royal Free 
and University College London Medical School, UK. The Centre for 
Anaesthesia and the Centre for Cardiovascular Genetics, both at University 
College London, jointly ran this part of the study. The idea for this chapter, 
analysis and EndoCAb measurement were mine. 
 
Subject selection  
All adult patients undergoing elective first-time Coronary Artery Bypass Grafting 
at University College London Hospitals (London, UK) were invited to take part 
in the CASIS study. Exclusion criteria included evidence of a pre-existing 
inflammatory state (infection, active arthritis, malignancy); systemic use of anti-
inflammatory agents other than aspirin (e.g. steroids); surgery other than 
bypass grafting during the procedure (e.g. surgery on a ventricular aneurysm 
discovered at the time of operation); the requirement for chronic renal 
replacement therapy; surgery performed off cardio-pulmonary bypass and 
refusal to consent for the study. 
 
Study Course 
After written consent, citrated blood samples (4.5 mL) were drawn before 
surgery and then again at 6 and 24 hours after cardiopulmonary bypass. These 
were centrifuged immediately (3000 rpm, 10 minutes) and the plasma 
separated and frozen at -20°C until analysis. Surgery was performed by 4 
experienced senior cardiac surgeons via a midline sternotomy and using 
standard surgical procedures. Hypothermic cardiopulmonary bypass was 
instituted after cannulation of the right atrium and ascending aorta. Myocardial 
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protection was maintained by cross-clamp fibrillation. Perioperative 
anticoagulation with heparin was reversed after cardiopulmonary bypass with 
protamine sulfate. 
 
Clinical Measurements  
Clinical and demographic information was prospectively collected for outcome 
measurement, risk scoring and to measure other potential confounding 
variables. The primary outcome (‘complications’) was death in hospital (after a 
continuous period of hospitalization between surgery and death) or a length of 
stay more than 10 days after surgery. If a patient both died in hospital following 
surgery and stayed longer than 10 days, they were only counted once as a 
‘complication’. To investigate the hypothesis that low IgM EndoCAb is 
associated with raised inflammatory markers we used IL-6 and CRP at 
baseline, 6 and at 24 hours, already being measured in a subset of patients in 
the CASIS study. Markers of preoperative cardiovascular dysfunction (cardiac 
ejection fraction and the preoperative New York Heart Association 
classification, NYHA) and evidence of postoperative haemorrhage (defined as 
a need to return to theatre for excessive bleeding or a decision by the clinician 
that excessive bleeding had occurred) were also measured. Investigators 
collecting clinical data were blinded to the laboratory measurements and vice-
versa. Total mortality was obtained by ‘tracking’ patients with the UK Office of 
National Statistics who gave us data (including the date of death) each time a 
patient died. The median length of follow up was 990 days after surgery.   
 
Antibodies to endotoxin core, EndoCAb 
Preoperative antibodies to endotoxin core (EndoCAb IgM, IgG and IgA) were 
measured according to methods previously described in ‘Methods’, chapter 2.  
 
IL-6 and CRP  
IL-6 concentrations were measured preoperatively and at 6 and 24 hours after 
bypass in a subset of the CASIS study using a standard commercial assay 
(R&D Systems, Minneapolis, USA) whilst CRP was measured at the same 
timepoints on a BN Prospec machine (Dade Behring, Illinois, USA). Inter- and 
intra-assay coefficients of variation and assay sensitivity were 5%, 3% and 0.70 
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pg/mL respectively for IL-6 and 4%, 2% and 0.20 mg/L respectively for CRP. 
For this study both IL-6 and CRP were measured in a commercial contract 
laboratory. 
 
Statistics 
As EndoCAb concentrations are not normally distributed, medians and 
interquartile ranges have been reported. EndoCAb quartiles were used firstly to 
enable comparison with the previous studies (Bennett-Guerrero et al 2001, 
Hamilton-Davies et al 1997) that had reported quartiles. Secondly I chose to 
compare the lowest EndoCAb IgM quartiles in this cohort with other quartiles as 
previous authors had found this quartile to have the highest complication rate. I 
therefore reasoned it would be a sensible threshold to choose as a way of 
detecting the effects of low EndoCAb IgM on outcome and markers of 
inflammation.  
Non-parametric analytical statistics (Mann-Whitney U test, Chi squared test, 
Kruskal-Wallis test and Spearman's Rank Correlation Coefficient) were used 
apart from linear regression where data were log transformed. Normal 
distribution of the transformed data was confirmed using the Kolmogorov-
Smirnov test. Statistical analyses were conducted using SPSS (SPSS 15, 
Chicago, IL, USA). 
 
3.5 Results 
Of 448 consented patients we were able to obtain full plasma, demographic 
and clinical measurements with confounding variables from 337 patients for 
EndoCAb IgM and IgG and 272 for EndoCAb IgA. IL-6 and CRP 
measurements were taken from a subset of these patients (for numbers and 
results see Table 3.4) 
 
3.5.1 EndoCAb IgM and clinical outcome 
A full dataset of preoperative IgM and potential confounding variables 
(EuroSCORE, Cardiopulmonary bypass times, NYHA scores) was measured in 
337 patients. Their characteristics are shown in table 3.1. Those patients with a 
low preoperative EndoCAb IgM (the lowest quartile, <32.3 MU/mL) had more 
complications (27.4% vs 13.8%; p= 0.007; Chi squared test) than those with 
higher EndoCAb IgM. They were also older (69 vs 64 years; p<0.01), had 
higher EuroSCORE values (3 vs 2; p = 0.03) but included fewer patients with 
hypertension (34.5% vs 52.6%; p = 0.004, table 3.2).  
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Characteristic     n=337 Result 
Age (years)  65 (59-71) 
Gender (%, number of males) 81.6 (275) 
EuroSCORE 2 (1-4) 
Hypertensive (%, number) 48.1 (162) 
Family History (%, number)                                      yes 
unknown 
54.6 (184)  
3.3 (11) 
Preoperative HDL cholesterol (mmol) 1.2 (1-1.5) 
Diabetes (%, number)                                                yes 
unknown 
18.7 (63) 
0.3 (1) 
Smokers (%, number)                               never smoked  
current smokers  
ex-smoker  
unknown 
22.6 (76)  
15.7 (53)  
61.4 (207)  
0.3 (1) 
Preoperative NYHA  grade (%, no with grade)              1 
2  
3  
4  
40.1 (135) 
43.3 (146)  
15.7 (53)  
0.9 (3)  
Preoperative Ejection fraction  (%, number)       >50% 
 30-49%  
 <30% 
71.5 (241) 
21.7 (73) 
6.8 (23) 
Preoperative EndoCAb (MU/mL)                                 IgM 
              IgG 
57 (32-99)  
196 (101-381) 
Cardiopulmonary bypass time (minutes)   66 (56-82) 
Postoperative bleeding (%, number) 5.6 (19) 
Length of ITU stay (days)* 2 (2-3) 
Length of hospital stay (days)* 6 (5-8) 
Length of hospital stay > 10 days (%, number)* 14.2 (48) 
Mortality: total (%, number) 5.6 (19) 
Mortality after hospital discharge (%, number) 2.3 (8) 
Mortality in this hospital admission (%, number) 3.3 (11) 
Complication+ (%, number) 17.2 (58) 
 
Table 3.1 Characteristics of the 337 patients.  
Data presented are median and interquartile ranges unless specified. 
Complications+ were defined as an in hospital death or a postoperative stay 
exceeding 10 days. *In those that survived to discharge i.e. survivors only. 
Abbreviations: CRP = C reactive protein; IL-6 = Interleukin 6; EndoCAb= 
Endotoxin core antibody; HDL cholesterol = High density Lipid Cholesterol; 
Preoperative NYHA class= Preoperative New York Heart Association 
Functional class (1 to 4, see appendix 1). For EuroSCORE see appendix 2. 
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Characteristic     n=337 EndoCAb IgM <32.3 MU/mL      >32.4 MU/mL p value 
Number of patients 84 253  
Age (years)  69 (63-74) 64 (57-71)  <0.010 
Gender %, (number of males) 81.0 (68) 81.8 (207) 0.859 
EuroSCORE  3 (1-4) 2 (1-4) 0.030 
Hypertensive (%, number) 34.5 (29) 52.6 (133) 0.004 
Family History                                 yes 
(%, number)                              unknown 
51.2 (43) 
2.4 (2) 
55.7 (141) 
3.6 (9) 0.344 
Preoperative HDL cholesterol (mmol) 1.3 (1.1-1.5) 1.2 (1-1.5) 0.383 
Diabetes (%, number)                     yes 
unknown 
19 (16) 
0 (0) 
18.6(47) 
0.4 (1) 0.936 
Smokers (%, number)     never smoked 
current smokers  
ex-smoker  
unknown 
21.4(18)  
10.7 (9)  
67.9 (57) 
0 
22.9 (58)  
17.4 (44)  
59.3 (150)  
0.4 (1) 
0.538• 
Preoperative NYHA grade                   1 
(%, no with grade)                                2  
3  
4  
33.3 (28) 
44 (37) 
20.2 (17) 
2.4 (2) 
42.3 (107) 
43.1 (109) 
14.2 (36) 
0.4 (1) 
0.062• 
Preoperative Ejection fraction   >50% 
(%, number)                                 30-49% 
<30%  
69 (58) 
23.8 (20) 
7.1 (6) 
72.3 (183) 
20.9 (53) 
6.7 (17) 
0.580 
Cardiopulmonary bypass time 
(minutes)  66 (55-78) 66 (56-83) 0.359 
Postoperative bleeding (%, number) 9.5 (8) 4.3 (11) 0.075 
Length of ITU stay (days)* 2 (2-3) 2 (2-3) 0.713 
Length of hospital stay (days)* 7 (6-9) 6 (5-8) 0.081 
Length of hospital stay > 10 days  
(%, number)* 22.6 (19) 11.5 (29) <0.010 
Mortality: total (%, number) 11.9 (10) 3.6 (9) <0.010 
Mortality after hospital discharge  
(%, number) 4.8 (4) 1.6 (4) 0.098 
Mortality in this hospital admission  
(%, number) 7.1 (6) 2 (5) <0.010 
Complication+ (%, number) 27.4 (23) 13.8 (35) 0.007 
 
Table 3.2 Patient characteristics by EndoCAb IgM ‘threshold’.  
Patients are classified according to whether the patient had a preoperative 
EndoCAb IgM more or less than 33.2 MU/mL. Data presented are the median 
and interquartile ranges unless specified. Complications+ were defined as an in 
hospital death or a postoperative stay exceeding 10 days. Continuous, bivariate 
variables and categorical variables were compared to IgM EndoCAb with the 
Mann-Whitney U, chi-squared tests and Kruskal-Wallis test• respectively. For 
abbreviations see the text of Table 3.1. *In those that survived to discharge i.e. 
survivors only.  
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Only low EndoCAb IgM (<32.3 MU/mL), EuroSCORE, Diabetes, age, New York 
Heart Association grade and preoperative cardiac ejection fraction were 
individually associated with development of a complication in a univariable 
binary logistic regression. New York Heart Association grade, age and cardiac 
ejection fraction were not included in the final model as they are components of 
the EuroSCORE.  
The individual odds ratios and those in the final model of low EndoCAb IgM, 
EuroSCORE and Diabetes are shown in table 3.3. A low EndoCAb IgM 
remained independently associated with the development of a complication in a 
binary logistic regression analysis after adjusting for the effects of EuroSCORE 
and Diabetes; patients with a low EndoCAb IgM were 1.89 (95% confidence 
intervals 0.99 to 3.6) times as likely to have a complication as those with higher 
EndoCAb IgM (p=0.052). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3: Binary logistic regression of the effects of EuroSCORE, low 
EndoCAb IgM and Diabetes on complications after first time CABG. The 
individual univariate unadjusted relationships (and their confidence intervals) 
between EuroSCORE, low EndoCAb IgM or Diabetes and complications are 
presented as odds ratios in the left hand columns. The odds ratios of 
complications in the final mutually adjusted model including all three variables 
are presented to the right (‘adjusted’). For example, a patient with low 
EndoCAb IgM has 2.3 times more likely to have a complication than a patient 
with higher EndoCAb IgM. After taking into account the independent 
association of EuroSCORE and Diabetes, this likelihood is reduced to 1.89 
(95% confidence intervals 0.99 to 3.6). Abbreviations: OR, Odds Ratio; +95% 
CI, 95% confidence interval of the odds ratio. 
Factor unadjusted adjusted 
 *OR +95% CI p= * OR +95% CI p= 
EuroSCORE 1.42 1.22- 1.64 <0.001 1.41 1.21- 1.64 <0.001 
IgM EndoCAb 2.32 1.29- 4.35 0.005 1.89 0.99-3.57 0.052 
Diabetes 2.33 1.23- 4.42 0.01 2.64 1.34- 5.24 0.005 
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3.5.2 EndoCAb IgM and markers of postoperative inflammation 
IL-6 and CRP was available in 212 and 192 patients respectively. In those 
patients, preoperative EndoCAb IgM overall as a continuous variable was 
positively albeit weakly associated with preoperative IL-6 (0.161, p=0.019 
Spearman’s correlation coefficient) but not at any other time.  
 
The lowest preoperative EndoCAb IgM quartile (less than 32.3 MU/mL, which 
was associated with a poorer clinical outcome, above) was associated with a 
lower IL-6 at 6 hours (158 vs 209 pg/mL; p=0.015 Mann Whitney U test) shown 
in table 3.4 and figure 3.1. Patients with a low preoperative EndoCAb IgM (less 
than 32.3 MU/mL) had a lower IL-6 rise from 0 to 6 hours (153 vs 205 pg/mL; 
p=0.016) but a larger rise between 6 and 24 hours (34 vs -39 mg/mL; p=0.001). 
 
A low preoperative EndoCAb IgM (less than 32.3 MU/mL) was not associated 
with a CRP difference at any timepoint (table 3.3). Patients with a low 
preoperative EndoCAb IgM (less than 32.3 MU/mL) had trends to a smaller rise 
in CRP from 0 to 24 hours (68 vs 80.5 mg/mL; p=0.058) and between 6 and 24 
hours (68.9 vs 80.7 mg/mL; p=0.096) compared to patients with normal or high 
EndoCAb IgM. 
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     EndoCAb IgM  
 <32.3 MU/mL >32.4 MU/mL 
p value+ 
IL-6 (pg/mL) n=51 n=161  
Preoperative 4.4 (2.7- 5.9) 4.7 (3.0- 6.4) 0.271 
6 hour 158 (117- 238) 209 (135- 307) 0.015 
24 hour 203 (108- 301) 165 (119- 246) 0.195 
Δ 0 -6 hours 153 (112- 237) 205 (127- 304) 0.016 
Δ 0 -24 hours 199 (104- 298) 160 (111- 242)  0.179 
Δ 6 -24 hours 34 (-56- 120) -39 (-150- 44) 0.001 
CRP (mg/mL)  n=45 n=147  
Preoperative 1.79 (1.22- 4.14) 2.07 (0.85- 4.43) 0.893 
6 hour 2.3 (1.34- 5.72) 2.62 (1.21- 5.56) 0.974 
24 hour 72.4 (52.9- 95.9) 84 (67.1- 98.2) 0.104 
Δ 0 -6 hours -0.13 (-1.35-1.91) 0.04 (-0.75- 1.61) 0.604 
Δ 0 -24 hours 68 (50.4- 92) 80.5 (64.5- 94.8) 0.058 
Δ 6 -24 hours 68.9 (48.9- 93.3) 80.7 (65.3- 92.3) 0.096 
 
Table 3.4 IL-6 and CRP classified by EndoCAb IgM in a subset of patients. 
IL-6 and CRP concentrations at baseline, 6 and 24 hours following 
cardiopulmonary bypass according to whether the patient’s preoperative 
EndoCAb IgM was more or less than 32.3 MU/mL. Patients were only included 
that had IL-6 or CRP measured at all 3 timepoints. Data presented are the 
median and interquartile range.  +Mann-Whitney U test. For abbreviations see 
the text of Table 3.1   
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Figure 3.1 IL-6 classified by EndoCAb IgM in a subset of patients 
undergoing CABG. IL-6 concentrations at baseline, 6 and 24 hours following 
cardiopulmonary bypass according to whether the patient’s preoperative IgM 
EndoCAb was more or less than 32.3 MU/mL. Patients were only included that 
had IL-6 measured at all 3 timepoints. Solid lines are the median.  P values are 
calculated by the Mann-Whitney U test. For abbreviations see the text of table 
3.1   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p=0.271 
p=0.015 
p=0.195 
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3.5.3 EndoCAb IgM and secondary outcomes 
No EndoCAb IgM measurement was significantly associated with any of the 
other secondary study outcomes: surrogate markers of preoperative 
cardiovascular dysfunction, postoperative haemorrhage or High Density 
Lipoprotein- cholesterol (table 3.2).  
 
Increasing age was associated with a decreasing EndoCAb IgM (-0.18 
p=0.001; Spearman’s correlation coefficient): the median age of those patients 
with a low EndoCAb IgM (below 32.3 MU/mL) was greater than those with a 
higher EndoCAb IgM (69 vs 64 years p<0.01; Mann Witney U test).  
Preoperative EndoCAb IgM was positively associated with IgA but not IgG 
EndoCAb (0.321, p<0.001 and 0.086, p=0.105 respectively with Spearman’s 
correlation coefficient).   
 
 
3.5.4 EndoCAb IgG and primary outcome 
A full dataset of preoperative EndoCAb IgG and potential confounding variables 
(EuroSCORE, Cardiopulmonary bypass times, NYHA scores) was measured in 
337 patients (table 3.1). 
 
Overall, IgG EndoCAb was not associated with a subsequent complication 
(p=0.26; Mann Whitney U test). Patients with a low EndoCAb IgG (below 101 
MU/mL; the lowest quarter) did not have more complications than those with 
normal or high EndoCAb IgG (16.7% vs 17.4% p=0.879 Mann Whitney U test), 
nor different IL-6 or CRP concentrations at any timepoint (tables 3.5 and 3.6). 
Between EndoCAb IgG values of 10 to 200 MU/mL there was no detectable 
threshold below which an increased complication rate could be detected.  
 
3.5.5 EndoCAb IgG and secondary outcomes 
EndoCAb IgG was not associated with any secondary outcome aside from 
there being more postoperative bleeding events in patients with low EndoCAb 
IgG (10.7 % vs 4% p= 0.02). Patients with low EndoCAb IgG were more likely 
to have a lower EuroSCORE but were more likely to give a family history of 
ischaemic heart disease (table 3.5).  
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Increasing age was associated with an increasing EndoCAb IgG (0.106 
p=0.051; Spearman’s correlation coefficient), but the ages of patients with a low 
EndoCAb IgG (below 101 MU/mL) was no different to those with a higher 
EndoCAb IgG (63 vs 65 years p<0.12; Mann Witney U test).  
 
Preoperative EndoCAb IgG was positively associated with IgA but not IgM 
EndoCAb (0.197, p=0.001 and 0.092, p=0.092 respectively with Spearman’s 
correlation coefficient).   
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Characteristic     n=337 EndoCAb IgG <101 MU/mL      >101.1 MU/mL p value 
Number of patients 84 253  
Age (years)  63 (58-71) 65 (59-72) 0.120 
Gender (%, number of males) 84.5 (71) 08.4 (204) 0.426 
EuroSCORE  2 (1-4) 3 (1-4) 0.046 
Hypertensive (%, number) 46.4 (39) 48.6 (123) 0.706 
Family History                              yes 
(%, number)                          unknown 
64.3 (54) 
4.8 (4) 
51.4 (130) 
2.8 (7) 0.022 
Preoperative HDL cholesterol 
(mmol) 1.2 (1-1.5) 1.2 (1-1.5) 0.419 
Diabetes (%, number)                  yes 
unknown 
15.5 (13) 
0 
19.8 (50) 
0.4 (1) 0.375 
Smokers                        never smoked 
(%, number)               current smokers  
ex-smoker  
unknown 
16.7 (14) 
19 (16) 
64.3 (54) 
0 
24.5 (62) 
14.6 (37) 
60.5 (153) 
0.4 (1) 
0.110 
Preoperative NYHA grade                1 
(%, no with grade)                            [ 2  
3  
4  
34.5 (29) 
46.4 (39) 
17.9 (15) 
1.2 (1) 
41.9 (106) 
42.3 (107) 
15 (38) 
0.8 (2) 
0.226 
Preoperative Ejection fraction>50% 
(%, number)                            30-49% 
<30%  
76.2 (64) 
15.5 (13) 
8.3 (7) 
70 (177) 
23.7 (60) 
6.3 (16) 
0.363 
Cardiopulmonary bypass time 
(minutes)  64 (50 -81.8) 67 (58-82) 0.105 
Postoperative bleeding  
(%, number) 10.7 (9) 4 (10) 0.020 
Length of ITU stay (days)* 2 (2-4) 2 (2-2) 0.064 
Length of hospital stay (days)* 6 (5-8) 6 (5-8) 0.238 
Length of hospital stay > 10 days  
(%, number)* 14.3 (12) 14.2 (36) 0.991 
Mortality: total (%, number) 6 (5) 5.5 (14) 0.886 
Mortality after hospital discharge  
(%, number) 3.6 (3) 2 (5) 1.000 
Mortality in this hospital admission  
(%, number) 2.4 (2) 3.6 (9) 0.886 
Complication+ (%, number) 16.7 (14) 17.4 (44) 0.879 
 
Table 3.5 Patient characteristics by EndoCAb IgG ‘threshold’.  
Patients are classified according to whether the patient had a preoperative 
EndoCAb IgG more or less than 101 MU/mL. The median and interquartile 
ranges are presented unless specified. Complications+ were defined as an in 
hospital death or a postoperative stay exceeding 10 days. Continuous, bivariate 
variables and categorical variables were compared to IgG EndoCAb with the 
Mann-Whitney U, chi-squared tests and Kruskal-Wallis test• respectively. For 
abbreviations see the text of table 3.1.  *In those that survived to discharge i.e. 
survivors only.  
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EndoCAb IgG  Cytokine <101 MU/mL >101.1 MU/mL p  value
+ 
IL-6 (pg/mL) n=49 n=163  
Preoperative 4.6 (2.7-6.3) 4.6 (2.9-6.3) 0.835 
6 hour 161 (118-281) 204 (134-306) 0.100 
24 hour 184 (133-268) 166 (112-264) 0.554 
Δ 0 -6 hours 157 (112-272) 200 (126-303) 0.097 
Δ 0 -24 hours 179 (129-263) 160 (106-260) 0.555 
Δ 6 -24 hours -2.3 (-95-102) -32 (-132- 56) 0.185 
CRP (mg/mL)  n=44 n=148  
Preoperative 1.8 (1.0-4.5) 1.9 (1.2-5.6) 0.742 
6 hour 3.2 (1.3-5.6) 2.6 (1.2-5.6) 0.698 
24 hour 79.2 (59.6-97.7) 83.1 (66.6-97.5) 0.663 
Δ 0 -6 hours 0.1 (-1.1-2.3) -0.1 (-1 (1.7) 0.736 
Δ 0 -24 hours 75.2 (58.1-95) 80 (64.8-92.5) 0.702 
Δ 6 -24 hours 74.4 (57.9-94.7) 77.3 (63.5-92.7) 0.647 
  
 
Table 3.6 IL-6 and CRP classified by EndoCAb IgG in a subset of patients. 
IL-6 and CRP concentrations at baseline, 6 and 24 hours following 
cardiopulmonary bypass according to whether the patient’s preoperative 
EndoCAb IgG was more or less than 32.3 MU/mL. Patients were only included 
that had IL-6 or CRP measured at all 3 timepoints. Data presented are the 
median and interquartile range.  +Mann-Whitney U test. For abbreviations see 
the text of table 3.1   
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3.5.6 EndoCAb IgA 
Preoperative IgA was measured in 318 patients. Overall as a continuous 
variable EndoCAb IgA was not associated with a subsequent complication 
(p=0.298; Mann Whitney U test). However those patients with a very low 
preoperative EndoCAb IgA (<34.3 MU/mL; n=31) had significantly more 
complications (32% vs 20%; p= 0.035; chi-squared test) than those with normal 
or high EndoCAb IgA. This effect did not persist however once the 46 patients 
who had not had a full dataset of potential confounding variables (EuroSCORE, 
Cardiopulmonary bypass times, NYHA scores) were excluded (28.1% vs 
18.3%; p=0.155, n=272, tables 3.7 and 3.8). IgA was not associated with any of 
the potential confounding variables, any marker of cardiovascular dysfunction, 
with IL-6 or CRP at any timepoint (tables 3.8 and 3.9). 
 
Preoperative EndoCAb IgA was positively associated with IgM but not IgG 
EndoCAb (0.321, p<0.001 and 0.086, p=0.105 respectively with Spearman’s 
correlation coefficient).  Increasing age was not associated with IgA EndoCAb 
(-0.167 p =0.234; Spearman’s correlation coefficient).  
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Characteristics       n=272 Result 
Age (years)  65.4 (58.5-71) 
Gender (%, number of males) 82.4 (224) 
EuroSCORE  2 (1-4) 
Hypertensive (%, number) 48.5 (132) 
Family History (%, number)                                   yes 
unknown 
55.9 (152) 
3.3 (9) 
Preoperative HDL cholesterol (mmol) 1.2 (1-1.4) 
Diabetes (%, number)                                             yes 
unknown 
17.8 (48) 
0.7 (2) 
Smokers (%, number)                           never smoked 
                                                              current smokers  
ex-smoker  
unknown 
22.4 (61) 
15.1 (41) 
61.8 (168) 
0.7 (2) 
Preoperative NYHA  grade (%, no with grade)         1 
2  
3  
4  
39 (106) 
43.4 (118) 
16.5 (45) 
1.1 (3) 
Preoperative Ejection fraction  (%, number)    >50% 
 30-49%  
 <30% 
69.9 (190) 
22.8 (62) 
7.4 (20) 
Preoperative EndoCAb (MU/mL)                                           IgM 
IgG 
IgA 
57.7 (32.4 (94.6) 
198.8 (99.6-380) 
74.7 (48.5 -115.4) 
Cardiopulmonary bypass time (minutes)  57 (67-81) 
Postoperative bleeding (%, number) 17.6 (48) 
Length of ITU stay (days)* 2 (2-3) 
Length of hospital stay (days)* 6 (5-8) 
Length of hospital stay > 10 days (%, number)* 15.4 (42) 
Mortality: total (%, number) 6.3 (17) 
Mortality after hospital discharge (%, number) 2.9 (8) 
Mortality in this hospital admission (%, number) 3.3 (9) 
Complication+ (%, number) 19.5 (53) 
   
Table 3.7 Characteristics of the 272 patients in whom EndoCAb IgA and 
confounders were measured. The median and interquartile ranges are 
presented unless specified. Complications+ were defined as an in hospital 
death or a postoperative stay exceeding 10 days. *In those that survived to 
discharge i.e. survivors only. Abbreviations: CRP = C reactive protein; IL-6 = 
Interleukin 6; EndoCAb= Endotoxin core antibody; HDL cholesterol = High 
density Lipid Cholesterol; Preoperative NYHA class= Preoperative New York 
Heart Association Functional class (1 to 4). 
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Characteristics     n=272 EndoCAb IgA <34.3 MU/mL       >34.4 MU/mL 
p 
value 
Number of patients 31 241  
Age (years)  64.9 (59.7 -70.8) 65.8 (59 -70.7) 0.119 
Gender (%, number of males) 87.1 (27) 81.7 (197) 0.487 
EuroSCORE  3 (1- 4) 2 (1- 4) 0.421 
Hypertensive (%, number) 22.5 (7) 51.9 (125) 0.050 
Family History                          yes 
(%,number)                        unknown                                        
67.7 (21) 
6.5 (2)
51.4 (131) 
2.9 (7) 0.092 
Preoperative HDL cholesterol 
(mmol) 1.2 (1- 1.4) 1.2 (1- 1.4) 0.635 
Diabetes (%, number)               yes 
unknown 
6.5 (2)  
3.2 (1) 
19.1 (46) 
0 (0) 0.105 
Smokers                     never smoked 
(%, number)            current smokers  
ex-smoker or unknown 
5.9 (2)  
73.5 (25)  
20.6 (7) 
16.7 (46)  
60.4 (166)  
22.9 (63) 
0.370 
Preoperative NYHA grade              1 
(%, no with grade)                           2  
3  
4  
32.3 (10) 
48.4 (15) 
16.1 (5) 
3.2 (1) 
39.8 (96) 
42.7 (103) 
16.6 (40) 
0.8 (2) 
0.440 
Preoperative Ejection            >50% 
fraction                                30-49% 
(%, number)                            <30%  
64.5 (20) 
22.6 (7) 
4 (12.9) 
70.5 (170) 
22.8 (55) 
6.6 (16) 
0.400 
Cardiopulmonary bypass time 
(minutes)  68 (60- 75) 68 (56- 83) 0.925 
Postoperative bleeding (%, 
number) 16.1 (5) 5.4 (13) 0.020 
Length of ITU stay (days)* 2 (2- 4.5) 2 (2- 2) 0.028 
Length of hospital stay (days)* 7 (6- 11) 6 (5- 8) 0.495 
Length of hospital stay > 10 days  
(%, number)* 22.6 (7) 14.1 (34) 0.126 
Mortality: total (%, number) 9.7 (3)  5.8 (14) 0.403 
Mortality after hospital discharge  
(%, number) 3.2 (1) 1.7 (4) 0.088 
Mortality in this hospital 
admission (%, number) 6.5 (2) 4.1 (10) 0.558 
Complication+ (%, number) 29 (9) 18.3 (44) 0.155 
 
Table 3.8 Patient characteristics by EndoCAb IgA ‘threshold’.  
Patients are classified according to whether the patient had a preoperative 
EndoCAb IgA more or less than 34.3 MU/mL. Data presented are the median 
and interquartile ranges unless specified. Complications+ were defined as an in 
hospital death or a postoperative stay exceeding 10 days. Continuous, bivariate 
variables and categorical variables were compared to IgM EndoCAb with the 
Mann-Whitney U, chi-squared tests and Kruskal-Wallis test• respectively. For 
abbreviations see the text of Table 3.1.  *In those that survived to discharge i.e. 
survivors only.  
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EndoCAb IgA 
 <34.3 MU/mL >34.3 MU/mL p value
+ 
IL-6 (pg/mL) n=23 n=147  
Preoperative 3.9 (2.7- 7.3) 4.7 (2.5- 6.6) 0.146 
6 hour 186 (129- 249) 179 (113- 290) 0.76 
24 hour 175 (108- 229) 173 (118- 282) 0.57 
CRP (mg/mL)  n=18 n=128  
Preoperative 2.7 (0.67- 6.7) 1.8 (1- 4.6) 0.93 
6 hour 4.1 (1.29- 6.3) 2.6 (1.2- 5.5) 0.37 
24 hour 79.8 (65.2- 101) 78.1 (56.2- 93) 0.63 
 
Table 3.9 IL-6 and CRP classified by EndoCAb IgA in a subset of patients. 
IL-6 and CRP concentrations at baseline, 6 and 24 hours following 
cardiopulmonary bypass according to whether the patient’s preoperative 
EndoCAb IgA was more or less than 34.3 MU/mL. Patients were only included 
that had IL-6 or CRP measured at all 3 timepoints. Data presented are the 
median and interquartile range.  +Mann-Whitney U test. For abbreviations see 
the text of Table 3.1   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  76 
3.6  Discussion 
This study has shown that for patients undergoing elective coronary artery 
bypass grafting for the first time, a low IgM EndoCAb is associated with a 
poorer outcome. This is consistent with the work of the previous studies 
showing an association between EndoCAb and outcome after surgery. 
Furthermore, contrary to my expectation, we found a low IgM EndoCAb to be 
associated with a reduced rise in interleukin-6 in the initial postoperative period 
compared to patients with higher IgM EndoCAb, six hours after 
cardiopulmonary bypass (figure 3.1 and table 3.4).  
 
  
There are several interesting aspects to this study. This is one of the first 
studies to investigate a possible link between IgA EndoCAb and postoperative 
outcome.  Secreted IgA is thought to be in the first line of defence against 
enterobacteriae, and whilst the load of secreted IgA may not relate to the 
plasma level, there have been very few studies examining the effect of serum 
IgA concentrations on outcome in non-oral conditions (Chia et al 2000; 
Engstrom et al 2002; Fagarasan and Honjo 2003). The association between 
low IgA EndoCAb (<34.3 MU/mL) and more complications (p=0.035) was 
reduced once individuals without a full dataset were excluded to reduce 
potential bias and examine for confounding variables (table 3.7). 
 
Inflammatory Markers 
We found that patients with a low EndoCAb IgM had lower IL-6 concentrations 
at 6 hours (p=0.015) but a larger rise in IL-6 (p=0.001) between 6 and 24 hours 
compared to those with higher EndoCAb IgM (table 3.4). This group of patients 
also had more complications. This suggests that low concentrations of 
EndoCAb IgM are associated with a reduced initial inflammatory response 
which has subsequently increased by 24 hours (as judged by IL-6 
concentrations) whilst the opposite is true of those with normal-high EndoCAb 
IgM: their IL-6 peaks at 6 hours and had fallen by 24 hours (figure 3.1 and table 
3.4). As this was not the original intent of the study any retrospective analysis 
must be interpreted with caution especially as IL-6 and CRP were measured in 
a subset of patients only. 
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Many investigators have measured CRP or IL-6 as manifestations of systemic 
inflammation. Preoperative CRP concentrations relate to short term outcome 
and long term survival in patients with ischaemic heart disease whilst intra or 
post-operative IL-6 concentrations relate to clinical manifestations of SIRS, 
complications or death after a variety of insults including surgery, pneumonia 
and acute renal failure and appears to be related to the degree of trauma 
(Biancari et al 2003; Kolsuz et al 2003; Lenderink et al 2003; Mythen et al 
1993; Schwenk et al 2000; Simmons et al 2004).  
 
Age 
Increasing age was associated with decreasing IgM EndoCAb: this is a new 
finding not commented on in the previous studies (table 3.2). There is very little 
data on IgM antibodies to specific antigens. Most of the literature is concerned 
with IgG responses to Pneumococcal vaccination as IgG concentrations are 
IgG levels are thought to relate to protection against invasive Pneumococcal 
disease (Moberley et al 2008).  However, some studies have found the elderly 
to have similar total IgM concentrations to younger adults whilst others have 
found them to be lower (Challacombe et al 1995; De Nardin et al 1991), so the 
reduction in IgM EndoCAb may just be a reflection of a reduced total IgM. Most 
studies indicate that older adults have similar pre-vaccine IgG concentrations to 
those of younger cohorts. Interestingly older volunteers have a different 
response when challenged in-vivo with endotoxin: they had a longer fever, 
more hypotension and larger rises in CRP  (Artz et al 2003; Krabbe et al 2001a; 
Krabbe et al 2001b). Whilst some of this variation appears in serum-free in-vitro 
systems it is possible that part of the altered response of elderly people may be 
due lower EndoCAb IgM concentrations in older volunteers (Von Haehling et al 
2003). 
 
Study limitations 
There are several potential limitations to this retrospective study; a number of 
factors need to be considered when interpreting this data. The CASIS study 
was originally designed to examine the effects of IL-6 gene polymorphisms on 
IL-6 levels, so any retrospective analysis must be regarded cautiously. 
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To limit the amount of blood in the original parent study, samples were taken 
prior to surgery and 6 and 24 hours after the start of cardiopulmonary bypass, 
similar to other published studies (Damgaard et al 2010; Diegeler et al 2000; 
Weis et al 2009). Rothenburger at al sampled at 11 perioperative timepoints 
and found that both IL-6 and IL-8 both peaked within 2 hours of our 6 hour 
sample. (Rothenburger 2001). However it is possible that, as fewer samples of 
inflammatory markers were taken, we may have missed significant differences 
in timing and concentrations between those patients with low or normal/high 
EndoCAb IgM concentrations. 
 
A possible concern in all studies is selection bias. The design of the parent 
study (‘CASIS’) specifically excluded patients from 6 and 24 hour samples if 
one of a set of pre-defined intra or postoperative complications occurred.  
Therefore some blood tests in patients that experienced complications (and 
were therefore excluded from the main analysis) are missing (i.e. 6 or 24 hour 
IL-6 and CRP), leading to smaller numbers. However, all patients that gave 
consent and had initial blood samples taken for EndoCAb were followed up to 
death, complication or discharge from hospital (including our primary outcome), 
even though they may not have had a full range of 6 and 24 hour samples 
taken.  For this reason the CRP and IL-6 results were considered separately as 
a subgroup and the results regarded as hypothesis generating. The majority of 
patients that were excluded from the parent study still had the full range of 
potential confounding variables measured (see table 3.1).  
 
One potential limitation is that fact that as no control IgM (i.e. an IgM to another 
antigen) and total IgM were not measured we do not know if the relationship 
between EndoCAb IgM and outcome is specific and unique or present with 
other IgM antibodies. 
   
Some investigators have criticised the choice of length of stay as a marker of 
postoperative morbidity (Grocott et al 2007). Currently approximately 20% of 
patients undergoing CABG in the UK experience a postoperative hospital stay 
more then 10 days (Keogh and Kinsman 2009). Our primary outcome (death in 
hospital-after a continuous period of hospitalisation following surgery -or a 
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postoperative stay exceeding 10 days) was used for several reasons. Two 
previous studies involving EndoCAb (from the USA) have used these 
endpoints, allowing comparisons with them (Bennett-Guerrero et al 1997; 
Bennett-Guerrero et al 2001b). Secondly clinicians at our institution regard 10 
days as a length of stay generally associated with a clinically important 
complication rather than a social issue related to suitability for discharge from 
hospital. There is evidence that the majority of patients with a length of stay of 
greater than 10 days suffered complications that could be consistent with an 
exaggerated mediated inflammatory response to endotoxin (Welsby et al 
2002). We included death in our assessment of morbidity because it is an 
important patient-centred endpoint, may preclude the diagnosis of other serious 
morbidities and may shorten the length of stay (Higgins et al 1997).  
 
3.7  Conclusion 
This study has shown that, even in the lowest-risk group undergoing adult 
cardiac surgery, a low EndoCAb IgM is adversely associated with outcome. A 
low preoperative EndoCAb IgM was also associated with a lower IL-6 level 6 
hours following cardiopulmonary bypass in this dataset. EndoCAb IgA is 
associated with outcome following surgery though to a lesser extent than 
EndoCAb IgM. This study has not answered the question as to why EndoCAb 
IgM is associated with outcome, or if it is a causal relationship. These questions 
will be investigated in chapter 4. 
 
3.8 Further Work 
This chapter, whilst broadly confirming that low EndoCAb IgM is associated 
with a poorer postoperative outcome, only touches on the possible mechanism.  
 
It is possible that the association between clinical outcome and antibody level 
may hold for several antibodies, or that EndoCAb IgM may be associated with 
other antibodies. An initial piece of work to investigate this may be to answer 
the question ‘is EndoCAb IgM independent of other antibodies?’ Unfortunately 
in this CABG cohort that was not possible as it would have required new 
consent from every patient, but it was possible to explore that in chapter 4 in a 
different cohort. 
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Another pathway is to investigate whether patients with low EndoCAb are more 
likely to have the systemic inflammatory response syndrome (SIRS) after an 
insult. Because cardiac surgery induces SIRS in the many patients (as judged 
by conventional clinical criteria) cardiac surgical patients are not an ideal group 
to study.    
A third line of enquiry may be to ask: Is there anything different about the group 
of people with a lower EndoCAb IgM compared to those with normal/high 
concentrations? Certainly this study has shown they are older, with a higher 
EuroSCORE, whilst one small study found lower concentrations in those with 
advanced heart failure  (Bolger et al 2001). It may be that people with low 
EndoCAb IgM have poorer exercise tolerance because of worse cardio-
respiratory function. This hypothesis could be tested with cardiopulmonary 
exercise testing (CPET).   
Lastly, it would be ideal to repeat this study in a prospective fashion with more 
data collection points to ensure that the correct cytokine peak was not missed, 
to exclude bias in selected subpopulations and to measure other ‘neutral’ 
antibodies.   
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Chapter 4  
 
EndoCAb IgM and ‘Natural antibody’ 
 
 
4.1 Introduction 
4.2 Hypothesis  
4.3 Aims 
4.4 Methods 
4.5 Results 
4.6 Discussion 
4.7 Conclusions 
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4.1 Introduction 
In chapter 3 I showed that, consistent with previous studies, low preoperative 
EndoCAb IgM was associated with a poor clinical outcome after 1st time cardiac 
surgery (see table 1.4). It has always been assumed that this association is 
causative as patients with low EndoCAb IgM have less endotoxin-neutralising 
antibody and might therefore be expected to experience more of the 
inflammatory effects of endotoxin, leading to complications (Bennett-Guerrero 
et al 2001a). However, for a variety of reasons this may be too simplistic. 
Firstly, no study has validated or demonstrated the complete chain of events 
described in figure 1.2 linking tissue trauma, reduced gastrointestinal blood 
flow, endotoxaemia and consequent inflammation-induced organ dysfunction. 
Secondly, as suggested by the results in chapter 3, patients with low EndoCAb 
IgM do not have higher postoperative inflammatory markers at than those with 
higher EndoCAb concentrations.  This suggests that whilst endotoxin induced-
inflammation may be attenuated by EndoCAb IgM, the response is not a simple 
dose-dependent interaction. Thirdly a synthetic lipopolysaccharide compound 
E5564 (Eritoran, Eisai Medical Research, New Jersey, USA) that acts as a 
lipopolysaccharide antagonist at the Toll-4 receptor and attenuates the 
inflammatory response in endotoxin-challenged volunteers has failed to 
significantly alter any clinical or inflammatory postoperative marker in patients 
undergoing cardiac surgery (Bennett-Guerrero et al 2007; Hawkins et al 2002; 
Lynn et al 2003; Mullarkey et al 2003; Rossignol and Lynn 2002; Wong et al 
2003). Whilst Toll-4 receptors are not the only route through which endotoxin 
induces inflammation, these studies suggest that endotoxin may not be a major 
direct cause of the postoperative inflammatory response, and the improved 
clinical outcome described previously in patients with high EndoCAb IgM may 
not be directly attributable to endotoxin neutralisation. 
 
One non-clinical approach to studying EndoCAb’s effects may be to make a 
‘pure’ concentrate, and to examine its effects in an in-vitro system. 
Manufacturing an ‘EndoCAb’ concentrate is technically difficult, would not 
represent a real life scenario and was outside the scope of expertise I had 
available for this thesis. EndoCAb is a mixture of antibodies (at least 4 as the 
ELISA uses an equimolar mixture of 4 endotoxin cores), so a ‘monoclonal 
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EndoCAb’ strictly cannot be made. A second option is to make an IgM fraction 
from serum taken from volunteers with a range of IgM EndoCAb levels. I had 
tried to fractionate a serum from volunteers with high or low EndoCAb IgM to 
use in in-vitro studies. These in-vitro studies involved both endotoxin 
stimulation of whole blood (with serial cytokines as the outcome) and Flow 
Cytometric techniques (‘FACS’ using Neutrophil CD11b as the measure of cell 
activation).  Unfortunately, whilst I mastered the in-vitro techniques and was 
able to make an IgM fraction from serum it was not possible for me to do this in 
a sterile environment- thus rendering any cell stimulation studies pointless. 
 
Because of this I decided to look at the similarities between EndoCAb IgM and 
a panel of natural IgM’s and to try to see how much EndoCAb IgM had the 
characteristics of a natural IgM.  I reasoned that, if EndoCAb and natural IgM 
levels were linked, that reduced the likelihood that the association between 
EndoCAb IgM and postoperative outcome was causal or specific to EndoCAb 
IgM. It also points to a new mechanism. This alternative viewpoint proposes 
that EndoCAb IgM is just a surrogate marker, simply associated with other 
factors that are themselves the cause of an improved clinical outcome.  
 
These natural antibodies have had a variety of functions ascribed to them (see 
chapter 1.3.2). They arise from germline DNA, may recognise ‘self’ antigens, 
are often ‘promiscuous’, can be IgG or IgM and have been detected in the 
absence of specific external antigens. The origin of these human natural 
antibodies is not well defined, but is most similar to the murine B-1a B-cell 
populations in the pleural and peritoneal cavities. This population forms the 
preimmune repertoire of natural antibody with low-grade polyspecificity for both 
bacterial and self antigens. The natural antibody group includes antibodies 
directed against A and B red blood cell antigens, antibodies against the 
terminal disaccharide Gal α1-3 Gal and against cell wall phospholipids such as 
phosphorylcholine, phosphatidylserine and phosphatidylcholine (Alaniz et al 
2004; Baumgarth et al 2005; Binder and Silverman 2005; Buonomano et al 
1999; Cabiedes et al 2002; Galili et al 1987a; Galili et al 1988; Hamadeh et al 
1992; Janczuk et al 1999; Parker et al 1996; Peng et al 2005; Rieben et al 
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1991; Rieben et al 1992; Rieben et al 1995; Sharma et al 2001; Spalter et al 
1999; Su et al 2005; Teranishi et al 2002; Weiser et al 1998). 
 
Their functions have been described as widely as clearing apoptotic cells and 
bacterial antigens, mediating ischaemia-reperfusion injury, participating in 
immune defence prior to the development of specific antibody, regulating the 
immune response and confining enteric bacterial infectious injury to prevent 
systemic spread  (Boes et al 1998b; Chen et al 2009; Melero et al 1997; Peng 
et al 2005; Reid et al 1997; Stahl and Sibrowski 2003; Zhang et al 2008). Many 
of these functions could contribute to regulating the inflammatory response 
after surgery and affect outcome.  
 
EndoCAb has been previously assumed to be an ‘immune’ antibody, specific 
for endotoxin and generated by the adaptive immune system after exposure to 
a range of exogenous endotoxins in the environment after birth however it may 
also be part of the natural or pre-immune antibody pool that facilitates early 
protection against infection and regulation of the inflammatory and adaptive 
immune response.   
 
In order to further understand the mechanism of EndoCAb IgM’s protective 
effects after surgery, I wanted to investigate whether EndoCAb IgM was part of 
a polyreactive natural antibody pool or a specific adaptive one. If EndoCAb IgM 
had no features in common with natural IgM, this strengthens the idea that it 
may play a specific role in modulating postoperative outcome. However, if 
EndoCAb IgM and natural IgM concentrations were strongly associated for 
example, concerted efforts into raising EndoCAb in order to reduce 
perioperative morbidity may be flawed  (Bennett-Guerrero et al 2000; Hamilton-
Davies et al 1996) as the mechanism of protection may not necessarily involve 
EndoCAb IgM (Bennett-Guerrero et al 2000; Hamilton-Davies et al 1996).  
 
Hence I decided to try to evaluate what characteristics EndoCAb IgM shares 
with the natural IgM antibody pool.   
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In this series of linked studies described below I investigated the relationship 
between serum IgM binding to EndoCAb IgM and a panel of natural antigens. I 
then looked at the EndoCAb binding properties of human monoclonal 
antibodies that were characterised as natural antibodies (Baxendale et al 
2008).  
 
Firstly, in study 4A, I measured concentrations of the natural IgM panel, 
EndoCAb IgM and total IgM in blood donor volunteers. This allowed me to see 
how closely EndoCAb and natural IgM concentrations are linked, gave me 
baseline reference concentrations, observe the spread of values, and 
potentially, compare with a clinical cohort. If EndoCAb IgM concentrations are 
associated with other ‘natural IgM’ antibody concentrations I reasoned that it 
may be the case that natural IgM concentrations might also be associated with 
postoperative outcome. Secondly in study 4B I examined the binding of 
germline IgM human hybridomas to endotoxin and a panel of endogenous 
antigens to which natural antibodies are known to bind (Baxendale et al 2008). 
These hybridomas had variable immunoglobulin genes in germline (i.e. non-
mutated) configuration and shared many characteristics with natural antibodies 
from the pre-immune and early post natal period  (Baker and Ehrenstein 2002). 
Thirdly, as natural IgM antibodies are said to be measurable in human umbilical 
cord blood, I measured EndoCAb IgM and natural IgM concentrations in the 
blood of mothers and their newborn (study 4C). Lastly, as it has been 
hypothesized that natural IgM concentrations are a relative constant throughout 
life, I measured EndoCAb M and natural IgM concentrations over a 6 month 
period (study 4D). 
 
 
4.2 Hypothesis  
EndoCAb IgM shares many characteristics with the wider natural IgM antibody 
group. 
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4.3 Aims 
Study 4A 
To measure the relationship between EndoCAb IgM and IgM binding to blood 
groups antigens A and B, Gal α1-3 Gal, phosphorylcholine and total IgM 
concentrations in a blood donor population.  
Study 4B 
To characterise the binding of seven germline IgM human hybridomas to 
endotoxin core and the natural antigen panel.  
Study 4C 
To measure EndoCAb IgM and natural IgM concentrations in the blood of 
mothers and the umbilical cord veins of their newborn.  
Study 4D 
To measure EndoCAb M and natural IgM concentrations at 0, 2 and 6 months 
in human volunteers. 
 
4.4 Methods 
These studies were performed at the departments of Immunobiology, Infectious 
Disease and Microbiology and Portex Units, Institute of Child Health, University 
College London.  
 
Populations 
The samples for study 4A were taken from established adult ambulant blood 
plasmapheresis donors presenting to two London National Blood Service 
centres as part of a larger study into the development of a plasma product high 
in antibody activity to endotoxin. After ethical approval (North West MREC 
01/8/58) donors who had given informed consent were screened by the NHS 
blood transfusion screening programme consisting of a focussed history and 
testing for evidence of exposure to Human Immunodeficiency Virus 1 and 2, 
Hepatitis B and C, Syphilis, Human T-cell lymphotropic Viruses 1 and 2 and 
(where indicated) Malaria and Trypanosoma cruzi. Donors were excluded if 
they had any known autoimmune condition, any haematological malignancy or 
were taking any drugs to reduce their systemic immune response. Blood for 
studies 4B and 4E were taken from healthy ambulant male and female 
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volunteers.  Blood from mothers and their newborn (study 4C) was obtained 
from a ‘control’ arm of a separate study investigating the role of infection and 
inflammation in neonatal brain injury (UCL/UCLH Joint Research Committee A’ 
REC ref number 03/0179).   
   
 
Study course 
Study 4A: Concentrations in a blood donor population 
After informed consent, a single 5mL clotted serum sample was taken off at the 
initial stage of plasmapheresis along with other samples collected by the 
National Blood Service. Demographic data (age and gender) and ABO blood 
group were supplied by the National Blood Service. Donors were free to eat 
and drink at any time.  
 
 
Study 4B: IgM human Hybridomas 
The human germ-line IgM monoclonal antibodies described in this study were a 
kind gift from Dr Helen Baxendale, Institute of Child Health, University College 
London.  They had been generated from a series of human hybridomas derived 
from Peripheral Blood Mononuclear Cells isolated from four healthy volunteers 
on day 7 (n=4) and day 28 (n=1) following immunisation with a single dose of 
pneumococcal 23 valent plain polysaccharide vaccine, ‘Pneumovax’ (Sanofi 
Pasteur MSD, Maidenhead, UK) or a 7 valent polysaccharide conjugate 
vaccine, ‘Prevenar’ (Wyeth, Maidenhead, UK) and were originally selected on 
the basis of reactivity to pneumococcal capsular polysaccharides (Baxendale et 
al 2000; Jessup et al 2000). Specificity analysis and immunoglobulin variable 
gene sequencing demonstrated that these antibodies were in germ-line 
configuration and had the antigen binding characteristics of natural antibodies 
(Baxendale et al 2008). The monoclonal antibodies were prepared from 
concentrated supernatants of clonal hybridoma cultures and IgM concentration 
was assessed by IgM ELISA as described previously.  Reactivity of the IgM 
monoclonal antibodies with the endotoxin cores and the natural antigen panel 
was assessed by ELISA as described for human sera, standardised for IgM 
concentration based on IgM capture ELISA.  
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Study 4C: Mothers and their newborn 
Mothers were approached at antenatal clinic, given information sheets and had 
a discussion with an investigator. When they subsequently came in at term 
either for a planned caesarian section or in labour they were asked if they were 
willing to give consent. The maternal blood sample was taken, spun and the 
plasma frozen and stored at this point.  Once the mother had delivered (by 
either elective caesarian section, emergency caesarian section or vaginally) 5 
mL of umbilical cord venous blood was taken as soon as practicable. Routinely 
collected clinical data was recorded.  
 
Study 4D: Longitudinal concentrations 
Blood was taken from 21 healthy ambulant volunteers at baseline, 2 and 6 
months and the serum frozen for later analysis. Age, gender, vaccinations, 
travel outside the UK or illnesses 2 months prior to the study and during it were 
recorded. 
 
Measurement of antibody concentrations 
After venepuncture, blood was allowed to clot (unless specified) then spun at 
3000rpm for 10 minutes and the serum removed.  All samples were stored in 
0.5mL in Eppendorf tubes (Eppendorf AG, Hamburg, Germany) and frozen at -
80°C until subsequent analysis. Concentrations of blood group A, B, Galα1-3 
Gal (gal), phosphorylcholine (Pc), total IgM and EndoCAb IgM were measured 
according to the methods detailed in Chapter 2 from the thawed samples. 
 
Ethics 
Ethical approval was obtained from the relevant Research Ethics Committee 
(North West MREC 01/8/58 and UCL/UCLH Joint Research Committee A’ REC 
ref number 03/0179) and informed consent from each subject. 
 
Statistics 
Normal distribution of data was not assumed and was tested for by examining a 
histogram of the antibody concentrations and with the Kolmogorov–Smirnov 
test of the naïve and log-normalised data. Correlations between log-normalised 
antibody concentrations were tested with the Pearson product-moment 
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correlation coefficient. Antibody concentrations in studies 4A, B and D were 
tested with the Mann-Whitney U 2-tailed test. Linear regression was performed 
using the logged test antibody (A, B, gal, phosphorylcholine) as the dependent 
variable and EndoCAb IgM as the independent, firstly without, then with the 
addition of total IgM. Serial changes in concentrations between 3 timepoints 
were compared with the Friedman test. All statistical tests were calculated 
using SPSS (Statistical Package for the Social Sciences 16, Chicago, IL, USA).  
 
4.5 Results  
4.5.1 Study 4A Concentration in a blood donor population 
Consent, demographic data and a full set of A, B, gal and phosphorylcholine, 
total IgM and EndoCAb IgM concentration was obtained from 179 blood 
donors. Their age, gender and ABO blood group characteristics are shown in 
table 4.1 and the antibody concentrations in table 4.2. There was a large 
concentration range in all antibodies measured (table 4.2). The distribution was 
positively skewed (but log-normalised) for all antibodies apart from total IgM, 
which was normally distributed. As expected, donors with blood groups O and 
B (i.e. no A antigen) had more A IgM antibodies than those with groups A and 
AB (p<0.01;t-test, table 4.2). Likewise donors with blood groups O and A (i.e. 
no B antigen) had higher B IgM antibody concentrations than those with blood 
groups B and AB. (p<0.01; t-test, table 4.2).  
 
 
Characteristic Result 
Age: median (interquartile range) in years 47 (40-52) 
Gender: % males, females 72, 28 
ABO Blood group*: number (% of total)                            O 
                                  A 
AB 
B 
84 (46.9) 
68 (38.0) 
18 (10.1) 
9 (5.0) 
 
Table 4.1:  Basic demographics of the 179 blood donors. *This is similar to 
the overall UK blood group distribution of 44% O, 42% A, 10% AB and 4% B in 
the population (Blood Transfusion Service 2008). 
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Antibody Median Interquartile range n = 
A IgM (arbitrary units)                         All 
                                                  O and B 
                                                A and AB 
19.9 
50 
3.9 
4.2-51.9 
7.9 – 424.2 
2.4- 9.7 
179 
93 
86 
B IgM (arbitrary units)                         All 
                                                  O and A 
                                                B and AB 
13.9 
16.2 
3.8 
6.3 - 23.7 
8.6-25.9 
1.9 - 6.7 
179 
152 
27 
gal IgM (arbitrary units) 29.4 16.9- 47.8 179 
phosphorylcholine IgM (arbitrary units) 28.6 18.1 - 45.9 179 
Total IgM (mg/mL) 1.17 0.85- 1.52 179 
EndoCAb IgM (MU/mL) 100.6 65.3 – 159.2 179 
 
Table 4.2: IgM antibody concentrations in 179 blood donors. Median and 
interquartile range for A, B, gal, phosphorylcholine, total IgM and EndoCAb. 
Concentrations of the blood group antibodies A and B are shown for the whole 
donor group and according to their appropriate blood group.  
 
To estimate whether patients with low EndoCAb IgM were also likely to have 
low concentrations of A, B, gal, and phosphorylcholine IgM, the donors were 
split up into 2 groups: those with EndoCAb IgM below or above 33.2 MU/mL. 
This EndoCAb IgM threshold was taken from Chapter 3 and represented the 
level of EndoCAb IgM below which a poor postoperative outcome was more 
likely in that CABG cohort. Analysed in this way (figure 4.1) there were 
statistically significant differences in the concentrations of A, B, gal, 
phosphorylcholine and total IgM antibodies in donors with low compared to 
those with normal-high EndoCAb IgM. Donors with EndoCAb IgM below 33.2 
MU/mL had between 1.8 to 4 times lower concentrations of the natural antibody 
panel than those with higher EndoCAb IgM (figure 4.1). 
There were significant associations between both IgM and EndoCAb IgM and 
the natural antibody panel A, B, gal, and phosphorylcholine. The association 
strength was greater between EndoCAb and the other antibodies (figures 4.2 
and 4.3) than between total IgM and the other antibodies.  In a linear 
regression model EndoCAb IgM concentrations were independently associated 
with concentrations of the other antibodies, after adjusting for total IgM (table 
4.3). As shown in table 4.3, 36.8% to 43.7% of the variability in A, B, gal, and 
phosphorylcholine IgM is accounted for by this model that includes both 
EndoCAb and total IgM. 
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Figure 4.1: A, B, gal, phosphorylcholine or total IgM concentrations 
according to an EndoCAb IgM threshold.  Concentrations of A, B, gal, 
phosphorylcholine and total IgM are shown according to whether the EndoCAb 
IgM level of that individual is less or greater than 33.2 MU/mL. All results apart 
from total IgM are shown on a log scale. Each circle represents the antibody 
concentrations of one donor. Only results for the relevant blood groups have 
been shown. i.e. values for donors with blood groups B and O for A IgM and 
groups A and O for B IgM. Lines are shown for the median values, apart for 
total IgM, where the mean is shown. ‘P values’ are shown for a Mann-Whitney 
U 2-tailed test apart from Total IgM, where an unpaired t-test is used.  
 
p=0.019 p<0.001 
p<0.001 p=0.015 
p=0.0003 
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Figure 4.2: Associations and correlation coefficients between 
concentrations of EndoCAb IgM and A, B, gal, phosphorylcholine or total 
IgM. Each circle represents the antibody concentrations of one donor. 
EndoCAb IgM is on the x axis and A, B, gal, phosphorylcholine or total IgM are 
on the y axis. All results apart from total IgM have been logged. Only results for 
the relevant blood groups have been shown. i.e. values for donors with blood 
groups B and O for A IgM and groups A and O for B IgM. *= p< 0.001 using the 
Pearson correlation coefficient, r.  
*r=0.63 
*r=0.57 
*r=0.63 *r=0.65 
*r=0.61 
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*r=0.46 
*r=0.46 
*r=0.39 
*r=0.52 
*r=0.61 
Figure 4.3: Associations and correlation coefficients between 
concentrations of total IgM and A, B, gal, phosphorylcholine or EndoCAb 
IgM. Each circle represents the antibody concentrations of one donor. All results 
apart from total IgM have been logged. Only results for the relevant blood 
groups have been shown. ie values for donors with blood groups B and O for A 
IgM and groups A and O for B IgM. *= p< 0.001 using the Pearson correlation 
coefficient, r.  
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Antibody 
Unadjusted 
with EndoCAb IgM 
Adjusted with EndoCAb 
and total IgM 
 
*β +95% CI p= R2 * β +95% CI p= R2 
A 0.792 0.589- 0.995 <0.001 0.398 0.682 0.44 - 0.924 <0.001 0.415 
B 0.97 0.791- 1.139 <0.001 0.367 0.917 0.663-1.171 <0.001 0.368 
gal 0.81 0.67  - 0.951 <0.001 0.422 0.721 0.55 - 0.891 <0.001 0.432 
Pc 0.998 0.816- 1.118 <0.001 0.398 0.780 0.565-0.995 <0.001 0.437 
Table 4.3: Regression between EndoCAb IgM and the natural IgM 
antibodies without (left) and with (right) adjusting for total IgM. 
*Unstandardised β regression coefficient. +95% confidence intervals for the B 
coefficient. R2: coefficient of determination the proportion of variability in 
antibody level accounted for by the model. Only results for the relevant blood 
groups have been shown. i.e. values for donors with blood groups B and O for 
A IgM and groups A and O for B IgM. For example, for every increase in 1 
MU/mL EndoCAb unit there is a 0.792 (β) arbitrary unit increase in A IgM 
antibody level. EndoCAb IgM alone accounts for 39.8% (R2) of the variability in 
A IgM. Once both total IgM and EndoCAb are included, the model accounts for 
41.5% of the variability in A IgM antibody level (adjusted R2). Pc = 
phosphorylcholine. 
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4.5.2 Study 4B: IgM Human Hybridomas 
The binding of the seven IgM monoclonal antibodies to endotoxin cores and the 
natural antigen panel was measured standardised for total IgM concentration 
and is displayed in figure 4.4.  
 
Two of the seven monoclonal antibodies, DM17 and BCL which were derived 
from the same donor, bound to the endotoxin cores. All of the monoclonal 
antibodies except 6b5B12 bound to at least one endogenous antigen. DM17, 
BCL and 6b1A7 bound most strongly to the natural antigens A, B, Gal and 
phosphorylcholine (figure 4.4).  
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Figure 4.4: IgM binding activity of 7 monoclonal germ-line derived 
antibodies.  The ELISAs were performed at standardised total IgM 
concentration of the monoclonal (see above total IgM graph) to antigens A, B, 
gal, phosphorylcholine and EndoCAb IgM.  The plates, coated with antigens A, 
B, gal, phosphorylcholine, EndoCAb IgM or total IgM were exposed to the 
monoclonal antibodies, washed and a secondary anti-IgM antibody added. The 
results shown are for the different monoclonal antibodies in optical density units 
at 405 nm above background. Each colour represents one of the different 
monoclonal antibodies. 
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4.5.3 Study 4C: Mothers and their newborn  
Blood samples were obtained from 18 mothers and 12 umbilical cords. Nine 
mothers had elective caesarean sections, whilst 9 were in labour when their 
blood was taken.  A, B, Gal, phosphorylcholine, total IgM and EndoCAb IgM 
concentrations in the 18 mother’s samples were comparable to those from the 
179 blood donors in study 4A (figure 4.5 left hand side).  Although total IgM 
was present in cord blood with a median level approximating 1/10 normal adult 
values concentrations (maternal 1466 µg/mL, fetal 143 µg/mL) concentrations 
of A, B, Gal, phosphorylcholine and EndoCAb IgM were either undetectable or 
very low (figure 4.5 right hand side), even accounting for the lower total IgM 
concentration. 
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Figure 4.5 Concentrations of Maternal and Umbilical cord IgM antibodies. 
Individual concentrations (with the median as a solid line) are shown for the 12 
paired samples in arbitrary units (for A, B, gal and Pc), median units per mL 
(EndoCAb) and µg/mL (for display purposes, total IgM) on log scales. Only 
results for the relevant blood groups have been shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  99 
4.5.4 Study 4D: Longitudinal concentrations 
Samples were collected from 21 volunteers. Only 17 volunteers were available 
for all 3 timepoints and their results are presented here. The majority were 
female (13 females, 4 males) and they had a median age of 30 (range, 23 - 
45). No volunteer received a vaccination during the study, and there was no 
obvious relationship between reporting symptoms of mild illnesses (‘sort throat’ 
etc) in the study period and antibody level changes. One volunteer went on 
holiday out of the UK to India.  
 
There was no statistically significant change in any of the antibody 
concentrations over the 6 month period (table 4.4). Of interest, the one 
individual who went to India during the study period had a 3 fold rise in 
EndoCAb IgA, but no rise in EndoCAb IgG or IgM, whilst there was not enough 
sample to measure the natural antibody panel (data not shown).  
 
 
 
 
 
 
Antibody Baseline 2 Months 6 Months CV * p= 
A              34.0 (11.8 - 45.6) 39.2 (13.6 - 46.4) 37.6 (14.1 - 52.3) 9 (4 -10) 0.12 
B             23.9 (8.8 - 54.1) 24.4 (8.2 - 65.4) 23 (8.0 - 62.2) 8 (6 -11) 0.16 
Pc 36.2 (23.6 - 68.0) 41.2 (23.4 - 78.4) 38.8 (23.5 - 98.8) 8 (6 -14) 0.94 
Gal 37.6 (28.1 - 88.9) 36.6 (27.3 - 91.1) 33.6 (27.4 - 90.3)  8 (4 -12) 0.33 
EndoCAb M 272 (174 - 402) 304 (172 - 416) 260 (164 - 388) 11 (7 -14) 0.81 
EndoCAb G 344 (250 - 432) 336 (224 - 442) 328 (252 - 438) 8 (6 -13) 0.55 
EndoCAb A 78 (37 - 117)  72 (40 - 105) 67 (36 - 114) 9 (7 -13) 0.26 
 
Table 4.4: Volunteers antibody concentrations at baseline, 2 and 6 
months. Antibody concentrations (median, interquartile range) in 17 volunteers 
for A, B, gal, phosphorylcholine and EndoCAb IgM, IgG and IgA. Results for all 
blood groups have been included as blood groups were not measured. Values 
for EndoCAb are presented in median units/mL and for all others as arbitrary 
units/mL. *Friedman test. CV= Coefficient of variation (median, interquartile 
range). 
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4.6 Discussion 
In this set of studies I have examined the idea that EndoCAb IgM shares some 
characteristics with the pre-immune B cell population that produces natural 
antibodies specific for A and B blood group antigens, gal and 
phosphorylcholine. Overall, EndoCAb IgM and natural IgM were present in 
similar concentrations, did not change significantly with time and were found in 
a proportion of cord blood samples. In addition two of the germline monoclonal 
hybridomas, which bound to the majority of the natural antigen panel, bound to 
endotoxin core.  Taken together this suggests that EndoCAb IgM may come 
from the same pre-immune B cell population of cells that make the IgM natural 
antibodies to A, B gal and phosphorylcholine.    
 
4.6.1 Study 4A: Concentrations in a blood donor population 
Concentrations of EndoCAb IgM were associated with concentrations of A, B, 
gal and phosphorylcholine IgM antibodies, over and above their association 
with total IgM. Furthermore, donors with concentrations of EndoCAb IgM 
identical to the group that had a poor clinical outcome (in chapter 3) had lower 
concentrations of A, B, gal and phosphorylcholine IgM antibodies to those with 
higher EndoCAb IgM concentrations. 
 
These findings are interesting for several reasons. Firstly they point to a new 
potential mechanism linking EndoCAb IgM to postoperative outcome. Were the 
patients in chapter 3 undergoing cardiac surgery to have had similar 
concentrations of natural antibodies to this cohort, there would be lower 
concentrations (of A, B, gal and phosphorylcholine IgM) in the poor outcome 
group. This raises the possibility that lower concentrations of these natural 
antibodies themselves may be causing the poor outcome. As mentioned 
previously, there are several functions ascribed to natural antibodies that might 
plausibly be linked to mechanisms that could alter postoperative outcome.  
Secondly, low concentrations of phosphorylcholine IgM has been associated 
with development of cardiovascular disease possibly by interacting with 
oxidised low density lipoprotein (Su et al 2005). Interestingly low EndoCAb IgM 
is associated with lower 5 year survival after hospital discharge following 
cardiac surgery: 12.8% vs 5.4% deaths in the low and high EndoCAb IgM 
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groups respectively (figure 4.6) (Moretti et al 2006). Although the authors did 
not state the reasons for excess deaths, they do speculate that low EndoCAb 
IgM ‘may have a genetic predisposition to unfavourable outcomes’. As low 
concentrations of EndoCAb IgM are associated with low phosphorylcholine 
IgM, as shown in this chapter, then the low phosphorylcholine IgM may a 
possible cause. 
 
 
 
 
 
 
Figure 4.6: Kaplan-Meier estimates of the probability of 5-year survival 
based on high vs low antiendotoxin core antibody (EndoCAb IgM) 
concentrations. Taken from Moretti et al (Moretti et al 2006). Reproduced with 
permission. 
 
 
Thirdly these findings suggest that there is a group of people with low 
concentrations of a range of natural IgM antibodies that may have altered 
postoperative outcomes: this area has not been well studied previously.  The 
structural similarity of blood group B and gal antigens (figure 4.7), their role in 
rejection of transplanted animal organs and the question of the origin of natural 
antibodies has led others to investigate interactions between antibodies 
directed at these antigen (Chen et al 2009; Galili et al 1987a; Gerber et al 
2001; Kuwaki et al 2004; Nordenstam et al 1990; Sandrin et al 1993). Other 
investigators have reported an association between concentrations of blood 
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group B and gal, and between blood group B and phosphorylcholine IgM 
antibody concentrations  (Nordenstam et al 1989).  
 
The structural similarity between the blood group B antigen and strains of 
Escherichia and the link between gal antibodies, Klebsiella, and Salmonella (all 
similar to components of the EndoCAb ELISA) has been previously reported. 
However, concentrations of these IgM antibodies have not previously been 
measured in the same human subjects nor compared with an antibody 
associated with outcome (i.e. EndoCAb IgM) following non-transplant surgery 
(Andersson et al 1989; Galili et al 1988; Kochibe and Iseki 1968). 
 
Figure 4.7: Gal and B antigen structure.  Schematic representation of the 
structure of Galα1-3Gal (‘Gal’), left and Galα 1-3 (Fuc α 1-2) Gal, right, of the 
blood group B antigen. 
 
 
Lastly, there have been several attempts at reducing the consequences of 
perioperative endotoxaemia founded on the observed association between low 
EndoCAb IgM and poor outcome (Bennett-Guerrero et al 1997; Hamilton-
Davies et al 1997; Mathew et al 2003; Mythen et al 1993). These have involved 
either donor plasma high in endotoxin antibodies, a synthetic endotoxin 
antagonist or polyclonal commercial gammaglobulin (Bennett-Guerrero et al 
2007; Friedrich et al 2002; Hamilton-Davies et al 1996). None of these studies 
was without risk and have either been stopped prematurely or not significantly 
altered outcome. If EndoCAb and natural IgM concentrations are related, the 
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situation is more complex. It is possible that the natural IgMs themselves may 
alter the immune response regardless of what has triggered it.  
 
Previous studies have noted a considerable spread or range of values in 
apparently healthy individuals for EndoCAb IgM, gal, phosphorylcholine and A 
and B blood group IgM antibodies comparable to the population of donors 
reported here (table 2) (Barclay 1990; Buonomano et al 1999; Padilla et al 
2004; Rieben et al 1991; Spalter et al 1999). Aside from a few uncommon 
primary and acquired immune conditions there is little literature discussing the 
reason for this range. However, an endogenous enzyme from Neutrophils, 
acyloxyacyl hydrolase, that detoxifies endotoxin can modulate the B cell 
proliferation and level of polyclonal antibody response to gram negative 
infection in mice (Erwin and Munford 1990; Hagen et al 1991; Lu et al 2008; 
Munford and Hall 1989; Shao et al 2007). It is not currently possible to measure 
this enzyme in humans.  
 
In any study one must consider the possible sources of error. It is possible that 
the associations described may have resulted from a systemic error, such as 
sample haemodilution. For example, if blood samples were diluted (e.g. with 
saline, an anticoagulant or overhydration) then an apparent association 
between concentrations of antibodies would result.  I think this is unlikely for 
several reasons. Firstly, the median total IgM concentrations are very similar 
with previously published values: the median level here is 1.2 mg/mL compared 
to a median of 1.04mg/mL at 40 years of age in a study of over 110,000 
samples (Ritchie et al 1998). Furthermore, the median EndoCAb IgM value 
here of 100.6 MU/mL is similar to the reference median of 100 MU/mL in blood 
donors and in other populations (Barclay 1990; Down et al 2004). The blood 
group A and B antibody concentrations are consistent with their respective 
blood groups, for example higher A antibody concentrations in volunteers with 
O and B groups compared to those with A and AB groups (50 arbitrary units vs 
3.9 arbitrary units; table 4.2). Lastly, the association between EndoCAb IgM 
and total IgM is similar to that found in a previous study by Bennett-Guerrero 
and colleagues (0.57 vs 0.65 respectively) (Bennett-Guerrero et al 2001b). 
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These facts suggest that the assays were working correctly and that there was 
no haemodilution.  
 
There are several limitations to this study. This study does not answer why 
there is an association between these antibodies. They may recognise, in part, 
a similar antigen. Their production may be stimulated by a common event or 
factor, such as previous surgery or illness, present to different degrees in 
individuals, although this does not answer why all the antibodies might be 
elevated (Munford 2005). There may be a common control of these antibody 
concentrations, suggested by the discovery that acyloxyacyl hydrolase alters 
the level of polyclonal antibody response to gram negative infection in mice (Lu 
et al 2008; Shao et al 2007).  One significant improvement would be the 
addition of a characteristic ‘immune’ antibody- e.g. one present as the 
deliberate result of vaccination such as tetanus. If concentrations of this 
‘immune’ antibody had no association with EndoCAb IgM this would strengthen 
the links between EndoCAb IgM and natural IgM. 
 
Conclusion of study 4A 
In this study I showed that EndoCAb IgM concentrations are associated with 
concentrations of other natural IgM antibodies, blood group A, B, gal, and 
phosphorylcholine, over and above any effect of total IgM.  If replicated in a 
surgical cohort, individuals with low EndoCAb IgM, at the same threshold that 
defined a poor outcome in chapter 3 would have statistically lower 
concentrations of the natural antibodies. Whether they themselves would be 
associated with outcome is not yet known: that question must be answered in 
another study.    
 
 
4.6.2 Study 4B: IgM human Hybridomas 
In this study I showed that a panel of monoclonal antibodies were able to bind 
to a panel of natural antigens to varying degrees but only two were able to bind 
to endotoxin core. These hybridomas had previously been shown to share 
many characteristics with natural antibodies: they used distinctive Ig V(D)H 
genes in germline (non mutated) conformation and were able to provide 
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protection in a model of bacterial infection (Baxendale et al 2008). The 
discovery that they have a broad specificity strengthens the similarity with 
natural IgM. That some bind to endotoxin core supports the hypothesis that 
EndoCAb IgM is part of the natural antibody group.   
 
Similarity between these mAbs and natural IgM must be taken with caution. 
The original clones were selected on the basis of binding to pneumococcal 
antigens after immunisation and although they have some features in common 
with natural IgM they may not be representative of the wider group. Most of our 
knowledge about the origin and specificity of natural IgM comes from the mice, 
where discrete populations of B cells are more clearly identified (Ehrenstein 
and Notley 2010). 
 
4.6.3 Study 4C: Mothers and their newborn  
I was able to demonstrate the presence of IgM and blood group A, B, EndoCAb 
and Gal, but not phosphorylcholine IgM in cord blood samples (figure 4.7 and 
table). The concentrations were low, all less than the 5th adult centile of the 171 
blood donors in study 1, even though total IgM concentrations were normal for 
age, approximately 1/10 of that in the adults and similar to other studies on 
cord blood (Shah and Yadav 1977; Vick et al 1995). The total IgM 
concentrations were similar to previously published studies suggests this was 
not due to a technical error.  
 
One of the often quoted features of natural antibodies is that they are present in 
umbilical cord blood although when measured this has not been a universal 
finding (Boes 2000; Doenz et al 2000; Gyorgy et al 2008). Several studies have 
examined the structure, reactivity, origin and persistence into infancy and adult 
life of natural IgM found in umbilical cord or neonatal blood (Dighiero et al 1985; 
Guigou et al 1991; Kantor et al 1997; Mouthon et al 1995; Mouthon et al 1996; 
Wuttke et al 1997).  
 
The IgM antibodies of the specificity measured in this study have been either 
not measured before in cord blood or found in some cord samples at low 
concentrations. There are no published papers of EndoCAb IgM in cord blood, 
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although it was detected in 59% of neonates at 3 months of age in a study of 
samples submitted to a virology laboratory for other clinical investigations 
(Oppenheim et al 1994). Wuttke found 11% of 36 cord blood samples 
(compared to 50% here) had IgM antibodies to A or B blood group antigens, 
rising to 100% at 8 months of age (Wuttke et al 1997). Gal IgM could not be 
detected in any of 16 cord blood samples whilst phosphorylcholine IgM does 
not appear to have been detected before 4 months of age in humans (Doenz et 
al 2000; Gray et al 1983). The presence of EndoCAb IgM in some cord 
samples is consistent with the hypothesis of it being a ‘natural IgM’.  
 
4.6.4 Study 4D: Longitudinal concentrations 
I showed that concentrations of EndoCAb IgM along with A, B, gal and 
phosphorylcholine IgM in 17 healthy volunteers varied little over a 6 month 
period. I had previously hypothesized that if EndoCAb IgM changed little over 
this period (like the ‘natural antibody‘ group) that would support its inclusion as 
a natural antibody.   
 
Few investigators have examined the longitudinal course of natural IgM in the 
same individual. Padilla found that phosphorylcholine changed little over 6 
weeks with a range of coefficient of variation from 6 to 25% in 40 healthy 
donors. Over a much larger timeframe, 20 years, there is a decline in B and 
phosphorylcholine IgM concentrations (Nordenstam et al 1989). Aside from the 
arena of pig to human and ABO incompatible solid organ transplants in which 
both gal and ABO antibodies are important, there is little literature on 
longitudinal concentrations of natural IgM in healthy humans.    
 
There is certainly evidence that external events can influence concentrations of 
natural antibody. In an elegant series of experiments that would probably be 
considered unethical today, Springer and Horton showed that blood group B 
antibodies (they was not able to determine which isotype) could be induced by 
feeding infants under 1 year (many of whom were orphans with diarrhoea) and 
adults live or killed E. coli 086B7 that has structural similarity with the B antigen 
(Andersson et al 1989; Springer and Horton 1969). Infants’ phosphorylcholine 
antibodies rise after pneumococcal carriage and infection, whilst adults do not 
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change after pneumococcal vaccination  (Brown et al 1984; Gray et al 1983). 
Padilla showed falls in phosphorylcholine IgM independent of total IgM in 
patients after isolated limb perfusion, a procedure that causes necrosis and 
apoptosis to tumour cells (Padilla et al 2004). Similarly, Hamilton-Davis showed 
falls in EndoCAb IgM, independent of total IgM immediately after coronary 
artery bypass graft surgery. Both these studies suggest that the antibodies can 
be consumed after exposure to large amounts of the congnate antigen. 
 
 
4.7 Conclusion 
EndoCAb IgM shares some features with natural IgM antibodies. There are 
positive associations between natural IgM and EndoCAb IgM concentrations, 
even after accounting for the association with total IgM. Likewise EndoCAb IgM 
has a similar unfluctuating temporal pattern to the natural IgM group and is 
present, albeit at low concentrations in some umbilical cord blood samples. 
Taken together, with caveats, these studies suggest that antibodies directed 
against endotoxin cores are probably part of both the ‘natural’ and ‘immune’ 
IgM antibody group.  
 
4.8 Further work 
There are many possible strands of work that could come from these sets of 
studies. As demonstrated in chapter 3, low EndoCAb IgM is associated with a 
poorer postoperative outcome and low EndoCAb IgM is associated with low 
concentrations of the natural IgM panel, it would be interesting to look at the 
relationship between the natural IgM panel and clinical postoperative outcome. 
In the same study it would be possible to see whether postoperative 
concentrations of A, B, gal, phosphorylcholine and EndoCAb IgM remain 
similar to those seen preoperatively, whether they are depressed or boosted by 
surgery.  
 
One area of uncertainty is the characteristic cellular origin of natural IgM in 
humans.  One approach could be to sort B cells (e.g. by Fluorescence-
activated cell sorting according to surface markers e.g. CD27), culture and 
examine the antibody concentrations made in the supernatant.   
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As I mentioned in Chapter 1, a useful tool in elucidating the role of EndoCAb 
IgM would be the manufacture of an EndoCAb IgM concentrate. This is a big 
undertaking, but one of the difficulties is that EndoCAb IgM is by necessity a 
polyvalent/ heterogeneous group of antibodies as it is the result of a 4-antigen 
‘cocktail’.  
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Chapter 5 
 
Endotoxin immunity and the systemic 
inflammatory response syndrome in critically ill 
children 
 
 
5.1 Introduction 
5.2 Hypothesis 
5.3 Aims  
5.4 Methods 
5.5 Results 
5.6 Discussion 
5.7 Conclusion 
5.8 Future work 
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5.1 Introduction 
Aside from cytokines (chapter 3) and fever response (chapter 6) another way of 
examining EndoCAb’s ability to alter inflammation is by examining the 
prevalence of the systemic inflammatory response syndrome (SIRS).  
Multiple organ failure resulting from systemic inflammation is the main cause of 
morbidity and mortality on intensive care units, irrespective of the initial illness 
or insult precipitating admission. The systemic inflammatory response 
syndrome (SIRS), which may lead to organ dysfunction, can be caused by a 
variety of clinical scenarios, including trauma, major surgery, infections, 
cerebral haemorrhage and infarcts, burns, and pancreatitis (Brun-Buisson 
2000). However, even when patients are subjected to similar procedures, 
illnesses or insults, not all of them go on to develop SIRS. Furthermore, whilst 
the prevalence of SIRS is high not every patient with SIRS goes on to incur 
measurable organ dysfunction (Brun-Buisson 2000). Common genetic 
polymorphisms which influence the concentrations of key mediators including 
mannose-binding lectin (MBL) and TNFα have recently been implicated in 
determining the incidence and severity of systemic inflammation in critically ill 
patients  (Fidler et al 2004; Garred et al 2003; Stuber et al 1996).   
 
Endotoxin is an important trigger of SIRS. Experimentally, endotoxin can initiate 
a systemic inflammatory response and is found in large quantities in the 
colonized human gut. Critically ill patients as well as those undergoing surgery 
may be exposed to endotoxin from leakage into the systemic circulation via an 
impaired gastrointestinal barrier, gram-negative infection or as a result of bowel 
manipulation during surgery.  
 
All adult humans have antibodies directed against the core of endotoxin 
(EndoCAb) although observed concentrations vary by more than eighty-fold 
(Barclay 1990). EndoCAb IgG is present at birth, and is probably of maternal 
origin, acquired trans-placentally. EndoCAb IgM is almost absent in the first 
month but increases to approximately adult concentrations by a year 
(Oppenheim et al 1994). Higher preoperative concentrations of EndoCAb IgM 
in adults are associated with a good outcome following surgery (see chapter 1) 
whilst higher EndoCAb IgG concentrations have been linked to survival in 
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sepsis (Goldie et al 1995; Strutz et al 1999). It is not known if this is a causal 
association with EndoCAb acting to modulate systemic inflammation, or if high 
EndoCAb titres are simply a marker of a favourable immune state (e.g. via 
associations with natural antibodies) in patients at risk of systemic 
inflammation.  
 
I took the opportunity afforded by a previously conducted study (on the 
relationship between MBL levels and SIRS in critically ill children) to look at the 
levels of EndoCAb levels in the same population. 
 
Because of the previous literature on EndoCAb, we defined two sub-groups 
according to the primary reason for Paediatric Intensive Care Unit (PICU) 
admission: infection and non-infection.  The analyses were performed on the 
combined group and the individual sub-groups.  
 
5.2 Hypothesis 
My hypothesis was that children who develop SIRS in their initial period on 
PICU have lower concentrations of antibodies to endotoxin core.  
 
5.3 Aims  
Primary Aims 
To examine the relationship between EndoCAb (IgM and IgG) and the 
development of a Systemic Inflammatory Response Syndrome within 48 hours 
of admission to a PICU in children with more than one organ failure.  
 
Secondary Aims 
To examine the relationship between EndoCAb (IgM and IgG) and 
• Serum concentrations of mannose-binding lectin 
• Age 
• Initial diagnosis on the Paediatric Intensive Care Unit 
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5.4 Methods 
Approval for this observational study was obtained from our institution's ethics 
committee. Patient data was stored according to the requirements of the Data 
Protection Act and parental informed consent was obtained. The clinical data, 
samples and blood for EndoCAb in this chapter were obtained from a 
previously conducted double blind, observational cohort study in critically ill 
children. This wider study was conducted by the departments of Anaesthesia, 
Intensive Therapy and Respiratory Medicine, Immunobiology Unit and 
Infectious Disease and Microbiology Units, Institute of Child Health, UCL. I 
performed the EndoCAb assays. 
 
 
Consecutive admissions to our tertiary multi-disciplinary PICU were recruited, 
as part of the larger study into the role of mannose-binding lectin, over a 6 
month period. On enrolment, cases were assigned to one of two groups, 
infection or non-infection, according to the principal reason for PICU admission 
as documented by independent PICU physicians not involved in the study. 
Within each of these groups, patients were subdivided into those who did or did 
not develop ‘early’ SIRS i.e. within the first 48 hours of admission. MBL 
concentrations from the previous study were recorded as a potential 
confounder of any effect of EndoCAb. 
 
Subject selection  
Inclusion criteria were: age between birth and 17 years and the presence of at 
least one organ system failure for more than 12 hours (or death within the first 
12 hours). The following exclusions were applied: presence of multiple 
congenital abnormalities; known congenital immunodeficiency; known central 
neurological or neuromuscular disease (all considered to represent major risk 
factors for PICU admission resulting from infection); persistent pulmonary 
hypertension of the newborn; weight less than 2.2 kg; informed consent not 
available; suspected non-accidental injury; repeat PICU admission during the 
study period; lack of intravenous or intra-arterial access and anticipated short 
stay (less than 24 hours) on the PICU. 
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Clinical measurements  
Infection was defined as ‘proven’ if a causative organism was isolated from a 
normally sterile site and ‘presumed’ in those with a history and examination 
consistent with an infection e.g. fever, cough and coryza combined with chest 
x-ray changes consistent with pneumonia. Diagnoses of SIRS, sepsis and 
septic shock were made according to the American College of Chest 
Physicians/Society of Critical Care Medicine guidelines modified for age (1992). 
Essentially, SIRS was determined by the presence of 2 or more of the criteria in 
table 5.1. Respiratory rate was not included as a diagnostic criterion because of 
the high proportion of cases receiving mechanical ventilation. Cases meeting 
these criteria for SIRS with ‘proven’ or ‘presumed’ infection were classified as 
‘sepsis’ whilst septic shock was diagnosed in cases of sepsis who were 
hypotensive, defined against age specific values for mean blood pressure after 
fluid resuscitation requiring treatment with inotropes and/or vasopressor 
therapy (Fidler et al 2004). An electronic patient charting system (Care Vue, 
Hewlett Packard) was reviewed daily and maximum and minimum ventilator 
and physiological parameters for each 24-hour period were recorded 
prospectively onto a Microsoft Access database. Microbiological, biochemical 
and haematological information was recorded from the PICU and the referring 
hospital. Paediatric logistic organ dysfunction (PELOD) score, a measurement 
of the severity of multiple organ dysfunction syndrome was calculated daily 
(Leteurtre et al 2003) (see Appendix 4).  
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Diagnosis Criteria Range for diagnosis 
Central Temperature greater than 38.0 
oC or  
less than 36.0 oC 
White Cell Count greater than 12x10
9 cells/L   or   
less than 4x109 cells/L   
SIRS 
Heart Rate 
(beats/minute) 
newborn to 3 months:  95-145  
3-12 months: 110-175 
1-3 years: 105-170 
3-7 years: 80-140 
7-10 years: 70-120 
greater than 10 years: 60-100 
Sepsis SIRS with ‘proven’ or ‘presumed’ infection 
Septic shock Patients with sepsis who were *hypotensive after fluid 
resuscitation and treatment with inotropes and/or 
vasopressors  
 
Table 5.1: Diagnostic criteria for the Systemic Inflammatory Response 
Syndrome (SIRS) in children. The presence of SIRS in a patient was 
determined by the presence of 2 or more of the *age-specific criteria above  
(1992). Respiratory rate was not included due to the high proportion of cases 
receiving mechanical ventilation. 
 
 
 
Laboratory measurements  
Serum samples were taken within 48 hours of admission, spun, separated and 
the serum stored in aliquots at -80oC until analyzed. The investigators 
performing the endotoxin-core antibody (EndoCAb) serum concentrations and 
MBL serum concentrations were blinded to the diagnosis of SIRS. Similarly the 
clinician acquiring the clinical data was blinded to the laboratory data.  IgM and 
EndoCAb IgG were measured as described in chapter 2. MBL concentrations 
in serum were previously determined by a symmetrical sandwich ELISA using 
commercial kits from Antibody Shop, Copenhagen, Denmark according to the 
manufacturer’s instructions by another investigator. 
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Statistics 
As EndoCAb concentrations are not normally distributed, Medians and 
interquartile ranges are reported. Non parametric analytical statistics (Mann-
Whitney U test) were used apart from log transformed data for regression 
analysis. Normal distribution of the transformed data was confirmed using the 
Kolmogorov-Smirnov test. All statistical calculations and analyses were 
conducted using SPSS (SPSS 15, Chicago, IL, USA). 
  
5.5 Results 
After informed consent serum was obtained from 139 suitable patients: their 
characteristics are shown in Table 5.2. 71 children were admitted for non-
infectious indications (postoperative management, after head injury or with 
other non-infectious conditions) whilst 68 were admitted with infection (localised 
infection, sepsis or septic shock).   
 
In the unselected cases (n=139), IgG concentrations were lower (but the 
differences were not significant) in those with early SIRS (SIRS median: 99 
MU/mL vs Non-SIRS 119; p=0.215).  There was no difference in the IgM 
concentrations between the two groups (87 vs 86 p=0.588). There was a weak 
correlation between EndoCAb IgG and EndoCAb IgM concentrations 
(Spearman's Rank Correlation Coefficient, R =0.311, p=<0.001) but not 
between EndoCAb IgG and MBL level (R =0.071, p=0.406). Of the potential 
confounding variables (age, sex, initial PELOD score, CRP & MBL) only MBL 
level was significantly associated with the development of SIRS on univariate 
analysis (table 5.2). 
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 All patients Non-Infection Infection 
All SIRS Non-SIRS p value All SIRS Non-SIRS p value All SIRS Non-SIRS p value   
  
n= 139 n=82 n=57  n=71 n=32 n=39  n=68 n=50 n=18  
Age months* 26 (9-121) 25 (9-108) 34 (10-130) 0.389 57 (18-151) 57 (24-139) 64 (12-153) 0.959 14 (3-74) 13 (4-81) 17 (2-29) 0.956 
Initial PELOD score* 12 (10-21) 12 (11-21) 12 (2-21) 0.182 12 (10-21) 12 (11-12) 12 (10-21) 0.939 12 (11-21) 16 (11-22) 11 (1-21) 0.106 
Diagnosis (%, no)    
Septic Shock 18.7 (26) 31.7 (26) 0  0 0 0  38.2 (26) 52 (26) 0 (0)  
Sepsis 17.3 (24) 29.3 (24) 0  0 0 0  35.3 (24) 48 (24) 0 (0)  
Infection 12.9 (18) 0 31.6 (18)  0 0 0  26.5 (18) 0 (0) 100 (18)  
Postoperative 23.0 (32) 12.2 (10) 38.6 (22)  45 (32) 31.2 (10) 56 (22)  0 0 0  
Head Injury 23.7 (33) 19.5 (16) 29.8 (17)  46.5 (33) 50 (16) 44 (17)  0 0 0  
Other 4.3 (6) 7.3 (6) 0  8.5 (6) 18.8 (6) 0 (0)  0 0 0  
CRP mg/l* 75 (35-137) 84 (41-157) 66 (30-120) 0.149 73 (34-120) 75 (37-147) 62 (34-120) 0.408 76 (41-147) 89 (41-169) 70 (27-83) 0.315 
EndoCAb IgM MU/mL* 86 (45-159) 87 (44-152) 86 (51-200) 0.588 98 (57-179) 99 (72-158) 95 (54-208) 0.829 79 (30-138) 60 (30-131) 83 (23-141) 0.906 
EndoCAb IgG MU/mL* 101 (46-209) 99 (44-198) 119 (59-229) 0.215 100 (49-198) 72 (43 -153) 131 (80 -210) 0.009 106 (43-229) 111 (49-218) 80 (31-264) 0.518 
MBL ng/mL* 1851 (525-3886) 
754 
(325-2516) 
2831 
(993-4284) <0.001 
2091 
(633-4174) 
1185 
(408- 3860) 
2518 
(624-4344) 0.054 
947  
(293-3284) 
682 
(163-2379) 
3715 
(1078-4107) 0.001 
 
Table 5.2 Characteristics of the 139 study patients. Demographic, clinical and other characteristics of the study patients 
divided into 3 groups; the whole group and the two subgroups according to the primary reason for ICU admission: infection and 
non-infection. Each of these groups is further divided into those that did or did not develop SIRS in the first 48 hours following 
admission to PICU. P values were calculated using the Mann-Whitney U test. Definition of abbreviations: SIRS=Systemic 
Inflammatory Response Syndrome; PELOD= Paediatric logistic organ dysfunction; EndoCAb= Endotoxin core antibody; IgM= 
Immunoglobulin M type; IgG= Immunoglobulin G type; MBL= Mannose-binding lectin; *median, (interquartile range). 
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Figure 5.1 EndoCAb and SIRS in the 139 patients. IgG (left) and IgM (right) 
EndoCAb concentrations of the 139 critically ill children and the subsequent 
development of SIRS in the first 48 hours following admission to PICU. P 
values were calculated using the Mann-Whitney U test. No significant 
differences were seen in either IgG or EndoCAb IgM between patients with and 
without SIRS.  For abbreviations please see table 5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p = 0.215 p = 0.588 
IgM EndoCAb 
non-SIRS SIRS non-SIRS SIRS 
IgG EndoCAb 
  
 
 118 
5.5.1 Non- infected Sub-group 
The characteristics of the 70 children without infection are shown in table 5.2. 
EndoCAb IgG concentrations are significantly lower (p=0.009 Mann-Whitney U) 
in those children developing SIRS. There were no significant differences in 
EndoCAb IgM concentrations between those with and without early SIRS 
(p=0.829 Mann Whitney U) (figure 5.2).  
 
Log10 EndoCAb IgG remained independently associated with the development 
of SIRS in the non-infected population in a binary logistic regression analysis 
after correction for the effects of age, sex, initial PELOD scores, CRP and MBL. 
The odds ratio of SIRS in this group increases by over 2 ½ times if the 
EndoCAb IgG is below 57 MU/mL when compared to those patients with an 
EndoCAb IgG above 57 MU/mL (table 5.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3 SIRS and IgG EndoCAb. The occurrence of SIRS in the first 48 
hours following admission to PICU in the non-infected group according to a 
‘threshold’ of IgG EndoCAb: above and below 57 MU/mL. The likelihood of 
SIRS increases by over 2 ½ times if the EndoCAb IgG is below 57 MU/mL 
 
 
EndoCAb IgG 
(MU/mL)  
<57 >57 
non-SIRS  % (no) 25 (5) 66.6 (34) 
SIRS % (no) 75 (15) 33.3 (17) 
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Figure 5.2 EndoCAb and SIRS in the non-infected patients.  IgG (left) and 
IgM (right) EndoCAb concentrations in the 71 non-infected patients according 
to whether they did or did not develop SIRS in the first 48 hours following 
admission to PICU. P values were calculated using the Mann-Whitney U test. 
Significant differences were seen in EndoCAb IgG between patients with and 
without SIRS (p = 0.009).  For abbreviations please see table 5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p = 0.009 
IgM EndoCAb 
non-SIRS SIRS non-SIRS SIRS 
IgG EndoCAb 
p = 0.829 
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5.5.2 Infected Sub-group 
 
The characteristics of the 68 children with infection are shown in table 5.1. 
There were no significant differences in IgG or EndoCAb IgM concentrations 
between those children developing SIRS and those not (111 vs 80 MU/mL; 
p=0.518 and 60 vs 83 p=.906 respectively) (figure 5.3). There was no 
significant difference in the serum IgM & EndoCAb IgG concentrations in 
patients who had increasing severity of infection (localized infection vs sepsis 
vs septic shock, p=0.4 Kruskal-Wallis test for both EndoCAb IgG & IgM (data 
not shown). Of the potential confounding variables (age, sex, ethnicity, initial 
PELOD score, CRP & MBL) only MBL concentrations were associated with the 
development of SIRS in this group (p=0.001) as previously reported (Fidler et al 
2004). 
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Figure 5.3 EndoCAb and SIRS in the infected patients.   IgG (left) and IgM 
(right) EndoCAb concentrations in the 68 infected patients according to whether 
they did or did not develop SIRS in the first 48 hours following admission to 
PICU. P values were calculated using the Mann-Whitney U test. No significant 
differences were seen in either IgG or EndoCAb IgM between patients with 
SIRS and without SIRS.  For abbreviations please see table 5.2. 
 
 
 
5.6 Discussion 
This is the first study to investigate the concentrations of antibodies against 
endotoxin core in a mixed population of critically ill children. I have shown that 
cases admitted following trauma or surgery (or for other non-infectious reasons) 
who go on to develop an early systemic inflammatory response have lower 
EndoCAb IgG concentrations than those who do not develop SIRS. In addition 
it confirms that children have similar concentrations to those seen in large adult 
studies (Bennett-Guerrero et al 1997; Bennett-Guerrero et al 2001b; Goldie et 
al 1995; Mathew et al 2003; Strutz et al 1999). 
Several studies have found that high preoperative concentrations of these 
antibodies are associated with better outcomes, consistent with the theory that 
p =0.518 
IgM EndoCAb 
SIRS SIRS non-SIRS non-SIRS 
IgG EndoCAb 
p =0.9 
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they are capable of neutralising endotoxin (see chapter 1, introduction) 
(Bennett-Guerrero et al 1997; Bennett-Guerrero et al 2001b; Hamilton-Davies 
et al 1997; Mathew et al 2003; Mythen et al 1993).  
 
In contrast to studies in surgical patients the relationship between initial 
EndoCAb level and outcome is not so clear in sepsis (Goldie et al 1995; Maury 
et al 2003; Strutz et al 1999). Initial EndoCAb IgM concentrations in 146 septic 
adults were higher in survivors though this may have been explained by other 
factors as it was not predictive of mortality in a multivariate analysis (Goldie et 
al 1995). Their study found a subset of patients with very low initial EndoCAb 
IgG level (less than 10% of the median level in healthy adults) had greater 
mortality. In 205 ICU adult patients with sepsis, Nys found a strong relationship 
between the absence of IgM anti-core antibodies and subsequent septic shock 
whilst rising IgG anti-core antibodies were associated with a positive outcome 
(Nys et al 1993). Depressed concentrations of antibody to endotoxin core have 
also been associated with outcome in children with acute lymphoblastic 
leukaemia and adults with pancreatitis or abdominal sepsis  (Bose et al 2002; 
Jackson et al 1990; Wakefield et al 1998; Windsor et al 1993). Clearly there are 
many influences on the development of SIRS in critically ill individuals. There 
include the infecting dose of pathogen (e.g. in Neisseria meningitidis), the 
nature, length and severity of the insult (e.g. surgery, cardio-pulmonary bypass) 
and specific deficiencies in aspects of coagulation and innate immunity 
(Brandtzaeg et al 1989; Fidler et al 2004; Fourrier et al 1992; Khabar et al 
1997; Powars et al 1993). 
 
This study has several potential limitations. Firstly, the study was originally 
designed to look at the effect of MBL on the incidence and severity of SIRS and 
as such these results should be interpreted with caution. Data was not collected 
on whether patients received plasma products, which contain antibodies with 
the same concentrations and range as the donor adult population. Addition of 
hyperimmune plasma can raise EndoCAb concentrations, so any patient who 
receives plasma from a donor high (or low) in EndoCAb may have their level 
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altered  (Hamilton-Davies et al 1996; Rashid et al 2004). Patients with sepsis 
may be more likely to receive plasma products due to the coagulopathy and 
this may alter their level and in turn remove the effect of their apparent 
EndoCAb on outcome. Likewise patients receiving crystalloids or colloids 
(human albumin solution should not contain antibodies) may have their level of 
EndoCAb lowered.  
 
A second limitation is that the effect of EndoCAb IgG on SIRS may not be a 
specific effect, but a reflection of total IgG or associated with other factors. In 
chapter 4 (table 4.3 and 4.4) I showed that concentrations of EndoCAb IgM 
were associated with both total IgM and a panel of natural antibodies. I was not 
able to measure the natural antibody panel in this study due to the small size of 
the samples.  Previous studies in adults however, have found that total IgG and 
IgM and even ‘reference antigens’ such as anti-tetanus antibodies have been 
unrelated to EndoCAb IgG or IgM concentrations, although this does not 
preclude an effect in children (Bennett-Guerrero et al 1997; Bennett-Guerrero 
et al 2001b; Hamilton-Davies et al 1997). Furthermore in a previous study 
EndoCAb concentrations were independent of cardiovascular variables such as 
heat rate, blood pressure, cardiac output and stroke volume (Hamilton-Davies 
et al 1997). Thirdly, EndoCAb concentrations have been reported to vary with 
age in children: IgM and EndoCAb IgG climb from 3 months towards adult 
values by one year  (Barclay 1995). In this study there are no significant 
differences in age between the group that developed SIRS and those that did 
not. Furthermore, in the multivariate analysis of the non-infected group, age did 
not alter the effect of EndoCAb IgG on the development of SIRS. Lastly, our 
numbers are too small to detect an effect on mortality whilst the study 
population. However, despite all these potential limitations there was still a 
detectable effect of EndoCAb IgG on the development of SIRS in the non-
infected group. 
 
The hypothesis that EndoCAb has a direct protective role by mopping up 
endotoxin is appealing but not yet proven. If this were to be a specific effect of 
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EndoCAb IgG this opens up the question of immunotherapy aimed at reducing 
systemic inflammation even after the patients have entered the ICU.  
 
5.7 Conclusion 
This study shows that in children with at least one organ failure admitted to the 
intensive care after head injury, surgery or for other non-infectious reasons, 
depressed EndoCAb IgG concentrations are associated with the early 
development of the systemic inflammatory response syndrome. Whilst it does 
not show causation, why EndoCAb IgG not IgM is associated or whether this is 
necessarily a specific effect, the information provides a potential mechanism by 
which elevated EndoCAb concentrations are associated with an improved 
outcome.  
 
5.8 Further work 
Following on from chapter 4, where I showed a significant relationship between 
EndoCAb IgM and the natural antibody panel, it seems obvious to ask in the 
light of this chapters result “does a similar relationship exist between EndoCAb 
IgG and IgG natural antibodies?”. This was not originally performed as the 
majority of previous literature suggested that EndoCAb IgM, not IgG, was 
associated with perioperative outcome (Chapter 1, table 1.2).  A similar study 
could be done where those receiving plasma products could be excluded – at 
least in the postoperative group, where that limitation might not exclude such 
numbers as to make the study too impractical to run.   
What this study does not answer is the wider question as to whether more 
EndoCAb causes lower endotoxin concentrations which in turn results in less 
inflammation and a better outcome. That requires a different model, where the 
timing and concentrations of (putative) endotoxin binding substances are 
known.   
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Chapter 6 
 
Low dose endotoxin and variability in the 
inflammatory response in healthy volunteers  
 
 
6.1 Introduction 
6.2 Hypothesis  
6.3 Aims 
6.4 Methods 
6.5 Results 
6.6 Discussion 
6.7 Conclusions 
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6.1 Introduction  
As described in chapter 1, endotoxin is implicated as a cause of inflammation 
and organ dysfunction after surgery. Clinically, patients differ in their response 
to apparently broadly similar external insults such as infections or surgery, 
leading to differences in outcome. 
 
One of the problems in testing potential factors that modify or alter the 
response to endotoxin (whether drugs, genetic or blood born factors) is the 
current model of endotoxin volunteer studies. Currently volunteers receive a 
4ng/kg endotoxin bolus, causing a significant inflammatory response and 
symptoms in almost all the volunteers. Aside from its unpleasantness, this 
4ng/kg bolus does not result in a big range or variability of responses. This 
traditional human model of endotoxin challenge (4 ng/kg) also may not mirror 
the inter-individual variability, spread or dispersion in systemic inflammation 
that is characteristic of natural exposure and so might not be the best model for 
studying variability in the inflammatory response to endotoxin  (Bunnell et al 
2000; De Winter et al 1995; Elin and Csako 1989; Kumar et al 2004; Pajkrt et al 
1997; Pernerstorfer et al 1999; Rodrick et al 1992; Rossignol and Lynn 2002; 
Soop et al 2003; Suffredini et al 1989; Suffredini et al 1995; Wyshock et al 
1995; Zijlstra et al 2004).  
 
A lower dose may cause a significant response in some but not in others - 
allowing us to examine the difference in responders and non-responders (e.g. 
in EndoCAb levels). This aim of this alternative approach to investigate the 
human response to endotoxin involves a model using a lower dose of endotoxin 
to cause the largest range of change (variability or dispersion) in inflammatory 
markers. This could allow us to explore variations in threshold of effects. In 
such an ideal model some volunteers would exhibit no inflammatory symptoms 
or have no raised inflammatory markers whilst others would. This model might 
better allow us to 
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• Investigate the differences between individuals in endogenous 
factors (in plasma and genotype) that alter the response to endotoxin.  
This may take the form of asking the question “what are the factors that 
make some individuals display an exaggerated inflammatory response to 
endotoxin challenge whilst others appear to show little or no response”? 
• Model the postoperative clinical situation in which some patients get 
an overt SIRS whilst others appear not to 
• Avoid the very unpleasant 4 ng/kg dose with attendant symptoms 
and rare serious effects  (van Eijk et al 2004) 
 
A low dose of endotoxin may cause optimum inter-individual variability in 
markers of systemic inflammation by not ‘overwhelming’ the natural endotoxin 
binding capacity of the serum (Bennett-Guerrero et al 2001a). Previous studies 
that have used relatively low doses of endotoxin down to 0.8-1.0 ng/kg have 
shown a dose-response effect (i.e. less endotoxin, less change in inflammatory 
markers and symptoms), but have not focussed on the variability in response 
between individuals (Elin et al 1981; Korth et al 1996; Krabbe et al 2001a; 
Krabbe et al 2001b).  
 
A second way to increase inter-individual variability in systemic inflammation 
may be to use a slow infusion (as opposed to a bolus) of endotoxin. An infusion 
may better mimic the clinical scenario whereby endotoxin is thought to be 
released systemically in gram negative sepsis or by a compromised 
gastrointestinal tract over a period of time. It may be that by delivering a lower 
rate of endotoxin to the volunteer we may allow more time for endotoxin binding 
in plasma (e.g. BPI / HDL-Cholesterol and antibodies), resulting in a lower ‘free’ 
endotoxin level and so not cause as much inflammation. This approach has not 
been investigated before.  
  
As the minimal pyrogenic dose is thought to lie below 0.5 ng/kg we decided to 
use 0.25 ng/kg and 0.75 ng/kg as either a bolus or an infusion (Elin et al 1981). 
Our aim was to describe the variability between individuals in inflammatory 
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markers in the first 10 hours following these regimens. Unfortunately one of the 
research team responsible for collecting data was subsequently found to have 
been manufacturing some data. The whole of this suspect data (white cell 
count, C reactive protein and platelet counts) have not therefore been included 
(see ‘ethics and safety’ later in 6.4).  
 
6.2 Hypothesis  
My primary hypothesis was that the low dose endotoxin dosing regimens would 
result in a significant change in inflammatory markers compared to baseline. 
 
My secondary hypothesis was that low dose endotoxin dosing regimens can 
elicit variability in systemic inflammation i.e. changes (rises or falls) in 
inflammatory markers in some subjects but not in others. 
 
My third hypothesis was that infusions of endotoxin would produce greater 
variability in inflammatory marker changes (rises or falls) than boluses at the 
same total dose. 
 
6.3 Aim 
My aim was to measure the changes in inflammatory markers following low 
dose endotoxin dosing regimens.   
 
6.4 Methods 
This was a prospective volunteer study performed in collaboration with Dr Elliott 
Bennett-Guerrero and his team at the department of Cardiovascular 
Anaesthesia, Columbia Presbyterian Hospital New York, USA.   
 
Endotoxin 
Escherichia coli O:113 endotoxin (EC-6) was a kind gift from the National 
Institutes of Health, USA (Suffredini et al 1999). EC-6 is supplied as a 
lyophilized powder, and was reconstituted to the appropriate dilution according 
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to the manufacturer’s instructions by the investigational pharmacy at Columbia 
Presbyterian Hospital to a concentration of 200 ng/mL (2000 EU/mL) in 
pyrogen free water (US Pharmacopeia, Abbott Laboratories, Abbott Park, IL, 
USA). It was then further diluted in pyrogen free water (according to the 
volunteers weight and dosing regimen) to use in a syringe driver as an infusion 
over 30 minutes or as a bolus over 1 minute (Table 2) by the investigational 
pharmacy.  EC-6 is the standard endotoxin used in volunteer studies by the 
National Institutes of Health, USA and was prepared under good manufacturing 
practices specifically for experimental administration to humans.  
 
Volunteers 
After ethical approval, healthy male and female ambulant adults between the 
ages of 18 and 55 years were enrolled who, after written informed consent, 
underwent a screening examination (physical examination, electrocardiograph), 
blood tests (full blood count, electrolytes, liver function, cholesterol) and a 
urinary pregnancy test. Volunteers were excluded if they had any of the 
conditions listed in table 6.1 and were paid for their time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Exclusion criteria. Volunteers were excluded from participation in 
the study if they fulfilled any of the criteria above. ECG, electrocardiogram. 
 
Criteria 
Significant abnormal results on history, physical examination or ECG 
Abnormal baseline laboratory tests 
A positive pregnancy test in the previous week 
Chronic disease or hospitalisation within the past year  
Prescription drug use on a regular basis 
Any acute illness including ‘flu or ‘flu like symptoms 
Known or suspected controlled substance use 
Participation in another research protocol within the previous 2 months 
Receipt of a blood transfusion in the previous month 
Receipt of vaccination or known endotoxin within the past three months 
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Study course 
Volunteers were starved from midnight on the study day. On the morning of the 
study, two intravenous catheters were inserted into each volunteer, (one for 
blood sampling, the other in the opposite arm for the dosing regimen) after 
which baseline observations and bloods were taken. Using a computer-
generated schedule, subjects were randomised to receive one of 6 dosing 
regimens described in table 6.2. To ensure blinding (as the timing of the two 
treatments, bolus or infusion could not be hidden) a ‘double-dummy’ procedure 
was used. Each volunteer received a bolus (10 mL over 1 min) and an infusion 
(50 mL over 30 min) of either water or endotoxin according to which study 
group they were assigned to (see table 6.2). Because the effects of 4 ng and 0 
ng/kg endotoxin are very well described, most of the volunteers were 
randomised to the 0.25 and 0.75 ng/kg dosing regimens. Over the next 10 h, 
subjects’ vital signs were monitored by an investigator and symptoms 
(headache, ‘I feel like shivering’, myalgia and nausea) were recorded hourly by 
the volunteer on a self-reporting visual analogue scale from 0 to 10. For 
example, volunteers were asked “on a scale on 0 to 10, (0 being not present at 
all, 10 being the worst you can imagine), how nauseated do you feel?” To 
prevent dehydration, volunteers were given 30 mL/kg intravenous saline over 
the 10 hour study period, equal to 2100 mL for a 70 kg individual.   
 
Outcomes 
The primary marker of inflammation was temperature (oF). Original secondary 
outcomes included white cell count (WCC), platelet count, Interleukin-6, 10, 
TNFα and C-reactive protein (CRP), but WCC, CRP and platelets have been 
removed (see ‘ethics and safety later in 6.4). Heart rate and blood pressure 
were also measured for safety reasons and to allow comparison with previous 
other endotoxin dosing volunteer studies.  
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Measurements 
Blood samples were taken into sterile, additive-free tubes (Becton Dickinson, 
Franklin Lakes, NJ, USA), every half hour for the first 2 hours, hourly until the 
6th hour, then at 8th and 10th hour (See Figure 6.1). They were allowed to clot at 
4°C, spun at 2000 rpm for 10 minutes and the serum aliquoted and frozen at     
-80 °C for later analysis. Heart rate and blood pressure (Dynascope DS 5100E, 
Fukuda Denshi, Tokyo, Japan), oral temperature (IVAX 2080A, IVAC, San 
Diego) white cell count, platelet count, C-reactive protein (CRP), tumour 
necrosis factor (TNF α), interleukin 6 (IL-6) and interleukin 10 (IL-10) were 
measured but WCC, CRP and platelets are not included here. Clinical and 
laboratory measurements were performed blinded to the subjects’ endotoxin 
dose group. Baseline screening tests, white cell counts, platelet counts and 
CRP concentrations were performed at the New York Presbyterian Medical 
Centre (New York, NY, USA) according to methods from the College of 
American Pathologists. Cytokine assays were performed by myself using 
Biosource ELISA Cytoset kits (Biosource International CA, USA) according to 
the manufacturer’s instructions by myself, a single investigator, in duplicate, 
and in as large a batch as possible to reduce assay variability (see Methods, 
Chapter 2). A standard curve provided by the manufacturer and a quality 
control serum were included on each ELISA plate.  
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endotoxin 
dosing regimen number of volunteers bolus1 infusion2 
Positive control 3 4 ng/kg  water 
0.75 ng/kg bolus 5 0.75 ng/kg  water 
0.75 ng/kg infusion 7 water  0.75 ng/kg 
0.25 ng/kg bolus 7 0.25 ng/kg  water 
0.25 ng/kg infusion  6 water 0.25 ng/kg 
Placebo 2 water  water 
 
Table 6.2: Infusions and bolus in each of the dosing regimens. A ‘double-
dummy’ design was used as the timing of the two treatments (bolus or infusion) 
could not be concealed. 1Bolus (in 20 mL over 1 minute) and 2Infusion (in 50 
mL over 30 minutes).
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Event 
 
 
 
 
 
Endotoxin/Placebo      
Infusion      
Bolus  
 
Clinical 
Observations1 
 
Bloods2 
 
Self reported 
Symptom 
Questionnaire3 
 
 
Time  Before Study day   Study day (hours) 
0 ½  1 1½ 2 3 4 5 6 8 10 
 
 
Figure 6.1: Summary timeframe of volunteer protocol. 1Heart rate, Blood pressure, temperature were taken every 30 minutes. 
2Tumour necrosis factor alpha, interleukin 6 and interleukin 10. 3Nausea, vomiting, myalgia, headache, shivering were self reported 
hourly. 4Screening visit, consent and randomisation were performed before the study day. 
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Statistics 
As the data were not normally distributed non-parametric tests were applied. 
Changes from baseline were examined by the Wilcoxon Signed Ranks test. 
Within-group variability of the inflammatory markers was assessed by visual 
(semiquantitative) examination of the graphed results and ranges (excluding 
top and bottom values). Statistics were calculated using SPSS (Statistical 
Package for the Social Sciences 15, Chicago, IL, USA).  
 
Ethics and Safety 
The clinical part of the study was performed in a research institute (Irving 
Clinical Centre, Columbia Presbyterian Hospital, New York, USA) designed for 
human volunteer research according to the Institutions regulations. Ethical 
permission was obtained from both the institution where the volunteers 
received the regimens (Irving Clinical Centre) and the institution where the 
cytokines were measured and data analysed (Departments of Immunobiology, 
Infectious Disease and Microbiology, Institute of Child Health, University 
College London, London, UK). Some years after the study had been completed 
the Columbia Presbyterian Hospital started to have concerns about one of the 
local researchers in the team. Their investigation (which took several years) 
ended in January 2013 and concluded that they were unable to vouch for some 
of the data. The committee were unable to account for 29% of the white cell 
counts, platelet counts and C reactive protein measurements. These had been 
collected as surrogate measurements of inflammation and to allow comparison 
with previous endotoxin volunteer studies. Because of this the institution has 
asked that I, as corresponding author, withdraw the paper (Stephens et al 
2005). At that stage (January 2013) this thesis was being revised after the viva 
at the request of the examiners. At the time of final writing (April 2013) I am 
waiting for a response from the journals editors.  
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6.5 Results 
Thirty one volunteers were screened: one was excluded prior to randomisation 
because of an abnormal electrocardiogram. The other thirty were consented 
and randomised to one of six dosing regimens (table 6.2). Their characteristics 
are presented in table 6.3.  
 
6.5.1 Outcome changes from baseline 
Maximum increases from baseline in temperature, TNFα, IL-6 and IL-10 are 
shown in figure 6.2. Each bar represents a volunteer, with each volunteer 
appearing in the same order in all the graphs, allowing for a comparison of the 
results. 
 
 
 
 
 
 
 
 
Characteristic Result 
Age (median, interquartile range) in years  25 (21–32) 
Gender: number of males, females 10, 20 
Racial group (number)                            White Caucasian                                     
African-American  
Hispanic  
Other 
Asian  
14
8 
4 
3 
1 
Screening HDL-cholesterol (median, interquartile range)  
in mg/dl 
53 (45–59) 
Initial temperature (median, interquartile range) in °F  97.7 (97.1–98.2) 
 
Table 6.3: Summary of selected characteristics of the 30 volunteers. 
Abbreviations: HDL-cholesterol= High-density lipoprotein cholesterol.  
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Figure 6.2: Temperature, Tumour Necrosis Factor alpha, Interleukin 6 and 
Interleukin 10. Maximum increase from baseline in temperature, Tumour 
Necrosis Factor alpha (TNFα), Interleukin 6 (IL-6) and Interleukin 10 (IL-10) 
grouped according to the 6 dosing regimens. Each bar represents a volunteer, 
with each volunteer appearing in the same order in all the graphs, allowing for a 
comparison of the results The groups are presented in order of descending 
dose concentration, and within each dosing regimen, the results are in order of 
ascending temperature rise. Volunteers show a range of responses within 
dosing groups. 
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Those randomised to the 4 ng/kg endotoxin dosing regimen (positive control) 
experienced significant symptoms and had rises in inflammatory markers, 
whilst those subjects that received normal saline did not (figures 6.2 and tables 
6.4, 6.5).  
 
All 4 low dose regimens produced statistically significant changes within the 10 
hour period in most inflammatory markers (temperature and tumour necrosis 
factor alpha) and physiological measurements (heart rate, systolic and diastolic 
blood pressure) but not in interleukin-6 and interleukin-10 concentrations (table 
6.5).  
 
 
 
 
 
 
 
 
dosing regimen Headache  (%) 
‘Shivering’ 
 (%) 
Myalgia  
(%) 
Nausea  
(%) 
Any Symptom  
(%) 
Positive Control 100 100 100 100 100 
0.75 ng/kg bolus 33 50 50 20 80 
0.75 ng/kg infusion 29 29 14 0 43 
0.25 ng/kg bolus 29 29 29 14 43 
0.25 ng/kg infusion  67 33 33 17 67 
Placebo 0 0 0 0 0 
 
Table 6.4: Volunteers’ symptoms. The percentage of volunteers in each 
dosing regimen with a symptom scored at 1 (or more) out of 10 for at least 2 
consecutive time-points on a visual analogue scale recorded every hour.  
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dosing 
regimen 
(ng/kg) 
Temperature  
(°F) 
TNF α  
(pg/mL)  
IL-6  
(pg/mL) 
IL-10  
(pg/mL) 
Heart  
Rate 
(bpm) 
Systolic 
BP 
(mmHg) 
Diastolic 
BP 
(mmHg) 
0.75 bolus 2.5 (0.9-4.6)* 18 (16-70)* 5 (0-19) 1 (0-4) 20 (11-35)* 18 (10-30)* 4 (0-20) 
0.75 infusion 1.6 (0.2-3.9)* 26 (6-53)* 2 (0-11) 2 (0-11) 16 (0-20)* 10 (0-24)* 10 (0-12)* 
0.25 bolus 2.1 (0.2-3.4)* 15 (3-101)* 8 (0-54)* 4 (0-102)* 18 (6-32)* 10 (4-24)* 10 (0-18)* 
0.25 infusion 2.2 (0.7-3.2)* 14 (7-25)* 4 (2-8)* 2 (0-6) 24 (6-39)* 16 (8-28)* 18 (0-20)* 
 
Table 6.5: Changes from baseline in the measured variables. Median change in (range lowest to highest) temperature, Tumour 
Necrosis Factor alpha, Interleukin 6, Interleukin 10, heart rate, systolic and diastolic blood pressure in the 4 low dose regimens.  
^The units are cells x109 per litre. Cytokine values are quoted to the nearest whole unit. 
*= p < 0.05 for the change from baseline in a Wilcoxon Signed Ranks test. Systolic and diastolic blood pressure fell, whilst the other 
outcomes rose.  
 
Abbreviations: bpm, beats per minute; mmHg, millimetres of mercury; mg, milligramme; mL, millilitre; pg, picogramme; BP, blood 
pressure; ng, nanogramme; kg, kilogramme. TNFα, tumour necrosis factor alpha; IL-6, interleukin 6 and IL-10, interleukin 10.  
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6.5.2 Variability inflammatory outcomes 
Subjects administered infusions or boluses of endotoxin at both 0.25 and 0.75 
ng/kg doses exhibited changes in most inflammatory markers (figure 6.2 and 
table 6.5). In all four of these dosing regimens there was considerable within-
group range (variability) in response to endotoxin, i.e. some volunteers showed 
changes in temperature as small as some of those given saline placebo, whilst 
responses in others were as large as some of those in the 4 ng/kg group (figure 
6.2).  
 
Although there was a range of responses, there was no evidence that any one 
of the 4 regimens caused a greater variability in inflammatory markers than the 
others (ranges in table 6.5), apart from in IL-6. 
 
There is no evidence on either inspecting the graphed data (figure 6.2) or in 
terms of the range (table 6.6) that infusions (at either 0.25 or 0.75 ng/kg) of 
endotoxin produced greater variability in inflammatory markers than boluses at 
the same total dose. 
 
 
 
 
 
 
6.6 Discussion 
This is the first human volunteer study to identify several low-dose endotoxin 
regimens that elicit variability (spread or dispersion) in the inflammatory 
response between individuals. Other investigators have used relatively low 
doses of endotoxin (down to 0.8-1.0 ng/kg) before (Elin et al 1981; Korth et al 
1996; Krabbe et al 2001a; Krabbe et al 2001b). These have shown a dose-
response effect (i.e. less endotoxin, less change in inflammatory markers), but 
have not examined variability, whilst others have either used endotoxin other 
than the standard US E coli 0113 lot EC-5 or EC -6, used different extraction 
methods, chemically altered endotoxins, not specified the endotoxin, used male 
volunteers only or ‘old’ endotoxin, making direct comparisons difficult (Elin and 
Csako 1989; Fong et al 1990; Harris et al 2002; Korth et al 1996; Pollmacher et 
al 1996; Vedder et al 1999). However, the results are comparable to previously 
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reported values (Hochstein et al 1994; Kuhns et al 1995; Suffredini et al 1999). 
The results for the 1 ng/kg group in Suffredini’s 1999 reference study using 
similar endotoxin and methods are shown for comparison (with table 6.5) in 
table 6.6.  
 
Variability in groups as small as this is difficult to quantify precisely. If there was 
no variability within groups, the dispersion would be zero (i.e. if there were a 
uniform identical change in inflammatory markers with an endotoxin dosing 
regimen).  Given the small number of observations, there was insufficent power 
to analyse the data using repeated measures analysis of variance (ANOVA). 
Therefore I decided it would be more appropriate not to statistically over 
analyse the data.  I used the following to examine variability: visual and graphic 
(semiquantitative) examination of the raw values (figure 6.2) and ranges (table 
6.5).  
 
Semiquantitative examination of the raw values (6.2) reveals that in the primary 
outcome measure (temperature) all 4 of the low dose regimens had volunteers 
who had maximum temperature rises within 20% of the median positive (4 
ng/kg) control and had volunteers that had rises as low as median placebo (0 
ng/kg). In some of the secondary outcome measures (eg Interleukin 10) the 
majority of low dose regimes had changes as large as the smallest change in 
the 4 ng/kg group, but not as large as the median change in the positive 
control. So in the secondary outcomes there is a range of results, but none of 
the dosing regimens caused within-group variability as large as with fever: none 
had changes in inflammatory markers comparable with both the positive and 
negative (placebo) controls. In the case of IL-6 and the 0.25 ng/kg bolus the 
same one individual had the largest rise in IL-6, IL-10 and TNFα of all the low 
dose regimens and was the only person in that regimen to experience nausea.   
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Temperature 
(°F) TNFα* IL-6* IL-10* 
1.9 118 251 not measured 
 
Table 6.6: Mean maximum changes with 1 ng/kg compared to placebo. 
Presented for comparison are the results from volunteers receiving 1 ng/kg 
(n=4) in the paper from Suffredini and colleagues  (Suffredini et al 1999) using 
Escherichia coli O:113 lot EC-6. Tumour necrosis factor alpha and interleukin 
had peaked by 2 hrs from the study start. IL-10 was not recorded in their paper 
(Suffredini et al 1999).  The units are *picogrammes per millilitre (IL-6, IL-10 
and TNFα). Abbreviations: see table 6.5 
 
There are several factors that strengthen the observations in this study. Firstly, 
the design included both positive (4 ng/kg) and negative placebo (0 ng/kg) 
controls. Those receiving the 4 ng/kg (positive control) regimen had symptoms 
and rises in many inflammatory markers comparable to those reported in 
previous studies (Elin et al 1981; Suffredini et al 1999) suggesting that there 
was no binding of endotoxin to the dosing equipment, the volunteers received 
the designed doses and the assays were working correctly, were appropriately 
sensitive and blood was correctly taken from the right person at the right time. 
Secondly the fact that volunteers receiving the 0 ng/kg (placebo) dosing 
regimen experienced no symptoms and had no rise in serum markers of 
inflammation suggests there was no significant contamination in either the 
dosing equipment or the assays. The intermediate changes seen in the 0.25 
and 0.75 ng/kg dosing regimens support this conclusion. Lastly the study 
design was further strengthened by the fact that both volunteers and 
investigators were blinded to study group until after the measurements and 
assays had been completed. These facts also support the idea that blood was 
correctly taken from the right person at the right time and the research fraud in 
some measurements (white cell counts, platelet counts and C reactive protein) 
did not spill over to fever or cytokine measurements. 
 
The removal of the suspect data has reduced the number of inflammatory 
markers available reducing the study’s impact. However this chapter still has 
 
 
 142 
some relevance in determining the fever threshold and that variability is 
possible with low endotoxin doses as the primary outcome (fever) and 
cytokines still allow comparison with other volunteer studies.  
 
Although several different dose regimens cause variability, there are limitations 
to the study. I have not been able to demonstrate that any one regimen results 
in greater variability than the others. This is partly because there is no generally 
accepted measure of ‘variability’ in this context and due to the small numbers 
necessary for practical reasons. Also, the smaller numbers of positive controls 
(4 ng/kg), whilst ethically justifiable (as it is unpleasant, has been associated 
with serious effects and has been studied before) precludes reliable statistical 
comparison with the other regimens (van Eijk et al 2004). A further limitation is 
that I could not detect any differences between infusion and bolus regimens. 
Prior to the study, I had speculated that there may be differences in the 
systemic inflammatory response between infusions and bolus dosing regimens 
perhaps because an infusion over 30 minutes may allow more time for potential 
endotoxin neutralizing factors to act, but the results do not support this 
hypothesis.  
 
One potential drawback of a low dose model is that it may not produce enough 
inflammation. A model designed to induce no or little inflammation in some 
subjects whilst producing some inflammatory marker activation in others may 
not be suitable for all purposes.  For example, even though the 4 ng/kg 
endotoxin model is generally considered a good mimic of some of the early 
responses in septic shock it does not cause even low level changes (at the 
present rate of detection anyhow) in all the pathophysiological effects of sepsis 
eg microvascular permeability (Anel and Kumar 2005; van Eijk et al 2005). 
Whilst a low dose model may induce enough inflammation to examine some of 
the predictors of the inflammatory response, it probably will not cause enough 
inflammation to examine them all. 
 
In addition to causing variability in inflammatory responses there may be other 
potential benefits of this model. The 4 ng/kg model is unpleasant, causes nasty 
side effects and occasionally results in serious sequelae. Like many rare side 
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effects, it is likely that not all of these are reported.  I know of one unpublished 
UK- based case where 1 volunteer had to be admitted overnight with renal 
dysfunction (raised markers or renal function with reduced urine output) after 
endotoxin dosing (Stephens 2006). Of course, these side effects may partly be 
due to other factors such as starvation or fluid restriction, resulting in some to 
recommend to providing intravenous or oral fluid during the study, as we did 
(van Eijk et al 2004). The recent cases involving the role of healthy military 
‘volunteers’ and the unanticipated severe side effects of ‘TGN1412’, an anti-
CD28 monoclonal antibody given to healthy volunteers have led to increased 
awareness of the necessity to reduce any potential harm to human volunteers 
(Lee et al 2004; Sharp 2006; Suntharalingam et al 2006). A lower dose 
endotoxin model may play a part in this.  
 
Lastly, in an era where increasing research fraud is being uncovered in my own 
speciality (Hospital Presents Results of Final Report: Committee Completes 
Investigation in the Case of Dr Boldt, 2012) the sad discovery of  research 
misadventure in someone known to me has only caused me to try to be as 
clear and honest as I can be, especially where it really matters- with patients.	  
 
 
6.7 Conclusions 
In this study (which had to be altered due to research ethics concerns) I have 
shown that the effects of low dose EC-6 are broadly consistent with previous 
published studies. At doses of 0.25 and 0.75 ng/kg, whether by bolus or 
infusion over 30 minutes, markers of inflammation rise and volunteers 
experience symptoms. Furthermore the fever threshold of this endotoxin is less 
than 0.25 ng/kg. Low dose endotoxin regimens do cause variability in the 
inflammatory response as judged by fever, but less variability in other outcomes 
such as interleukin 6, 10 and tumour necrosis factor alpha. A low dose regime 
may be a useful and more palatable tool to investigate the differences between 
individuals in endogenous factors (plasma, receptor, pathway and genotype) 
that alter the response to endotoxin.  
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6.8 Further work 
One obvious application of a low dose endotoxin regimen such as 0.25 ng/kg is 
in teasing apart the various factors that alter an individuals’ response to 
endotoxin. Such a study, if appropriately powered may be able to answer 
whether specific antibodies (eg anti-0113) or more generic ones (e.g. EndoCAb 
or natural IgMs) are more important in the response to endotoxin, if at all. Of 
course, the choice of endotoxin may well be relevant in that study. Furthermore 
the purpose of that study could also be to elucidate the relative importance of 
other endotoxin binding substances such as HDL-Cholesterol, Bacterial 
Permeability-Increasing protein, Lipopolysaccharide Binding Protein and other 
factors in the endotoxin signalling cascade in preventing endotoxin induced 
inflammation.  Endotoxin dosing of volunteers has been more commonly used 
as a model of the effects of endotoxin during sepsis and after inflammatory 
insults on the host. Such a low dose regimen using 0.25 ng/kg endotoxin may 
not result in enough inflammation to cause, for example, cardiovascular or renal 
effects.  An appropriately powered study using volunteers may be outside the 
constraints of realistic cost.  
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Chapter 7 
 
Summary and final conclusions 
 
7.1 Aims of the thesis 
7.2 Summary of main findings 
7.3 Further work  
7.4 Conclusions 
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7.1 Aims of the thesis 
My original aim was to re-examine the original reported association between 
postoperative outcome and EndoCAb IgM in an observational study and then 
attempt to look at this association to see if the hypothesised mechanism - an 
exaggerated inflammatory response in those patients with low EndoCAb IgM - 
was present. In the end this I was only partially able to achieve these aims.  
 
7.2 Summary of main findings 
In the methods chapter 2 I showed I could repeatedly and accurately perform 
the assays needed for this thesis. 
 
In chapter 3, I showed that low EndoCAb IgM was associated with a poor 
outcome after first time coronary artery bypass graft surgery, independent of 
the other predictors (Euroscore and Diabetes Mellitus). Other conclusions 
should be taken with more caution as this chapter was performed by analysing 
data from another study and using stored blood samples.   
 
In chapter 4 I had intended to examine EndoCAb IgM’s effects with IgM 
fractions taken from different individuals in an in-vitro study using FACS 
markers and cytokines (in an endotoxin stimulation model) as the outcome. 
However I was not able to include those methods or experiments as although I 
was able to manufacture IgM fractions from people with low and high EndoCAb 
IgM, I was not able to make it in a sterile fashion. In conjunction with one of my 
supervisors (Dr Helen Baxendale) I decided to examine another hypothesis: 
that EndoCAb IgM shared similarities with the ‘natural IgM’ pool. In this I had 
partial success. I was able to show there were significant associations between 
natural IgM levels (A, B, gal and phosphorylcholine) and EndoCAb IgM. I also 
found that some umbilical cord blood had measurable levels of EndoCAb and 
the natural IgM panel- a stated feature of natural IgM. Some (2 out of 7) of the 
natural IgM hybridomas bound to EndoCAb IgM. 
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I looked in chapter 5 at another measure of inflammation- SIRS. Again although 
limited by the fact that I used data and stored blood samples from a previous 
study, I showed that low EndoCAb IgG was associated with more SIRS after 
non-septic admissions to the paediatric critical care unit.  
 
Lastly in Chapter 6, (despite ethical concerns) I showed that it was possible to 
use a novel low dose endotoxin dosing regimen (near the fever threshold) and 
get variability in response between volunteers – at least as judged by fever as a 
measure of inflammation.  
 
7.3 Further work  
In many ways this thesis raises more questions than it answered. Following on 
from chapters 3 and 4 it would be interesting to see if levels of the Natural IgM 
panel were associated with clinical outcome, SIRS or cytokine levels after 
surgery. To do this more robustly, sequential measurements (rather than a 6 
and 24 cytokine level) should be made. Perhaps levels of an ‘immune’ (ie not a 
natural) IgM such as tetanus could be included too.   
In chapter 4 I originally wanted to manufacture an IgM serum with different 
EndoCAb IgM levels in but was unable to do so in a sterile environment. Having 
shown that IgM EndoCAb levels are associated with levels of the Natural IgM 
panel this may not be such a useful too as a high IgM EndoCAb serum would 
be expected to also have high natural IgM levels.  
Ideally, following on from chapter 6 I would perform an appropriately powered 
endotoxin infusion study looking at levels of all the potential variables that 
modify endotoxin-induced inflammation. This would require a large number 
(>100) of volunteers: a more practical alternative would be an in vitro endotoxin 
study.  
 
7.4 Conclusions 
I have shown that low EndoCAb IgM is associated with poorer outcome after 
first time CABG surgery. In healthy blood donors, there were significant 
associations between natural IgM (A, B, gal and phosphorylcholine) and 
EndoCAb IgM levels, pointing to new mechanisms. Some umbilical cord blood 
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had measurable levels of EndoCAb and the natural IgM panel. Critically ill (non-
septic) children with lower IgG EndoCAb had more SIRS than those with higher 
levels. Lastly, low dose endotoxin dose regimens can cause varying 
inflammatory effects. Taken overall EndoCAb is clinically relevant, although I 
have not been able to show it causes the outcome differences seen between 
those with low and high levels.  
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Appendix 1: NYHA Classification 
 
NYHA Class Functional activity Symptoms 
I No limitation of activity Not from ordinary activities 
II Slight, mild limitation of activity Comfortable with rest or with mild exertion 
III Marked limitation of activity Comfortable only at rest 
IV Patient should be at complete rest, confined to bed or chair 
Any physical activity brings on discomfort; 
symptoms occur at rest 
 
New York Heart Association (NYHA) classification for Congestive cardiac 
failure.  A functional and therapeutic classification for prescription of physical 
activity for cardiac patients  (Miller-Davis et al 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 150 
Appendix 2: EuroSCORE 
 
Factor Criteria Score 
Patient-related factors 
Age  (per 5 years or part thereof over 60 years) 1 
Sex female  1 
Chronic pulmonary disease long term use of bronchodilators or steroids for lung disease 1 
Extracardiac arteriopathy *claudication, carotid occlusion or >50% stenosis, previous or planned intervention on the 
abdominal aorta, limb arteries or carotids 2 
Neurological dysfunction  severely affecting ambulation or day-to-day functioning 2 
Previous cardiac surgery requiring opening of the pericardium  3 
Serum creatinine >200µmol/L preoperatively 2 
Active endocarditis patient receiving antibiotics for endocarditis at the time of surgery 3 
Critical preoperative state *ventricular tachycardia or fibrillation or aborted sudden death, preoperative cardiac massage, 
ventilation, inotropes, IABP or ARF 3 
Cardiac-related factors d factors 
Unstable angina  angina requiring intravenous nitrates until arrival in the anaesthetic room  2 
LV dysfunction moderate or LVEF 30-50%  1 
 poor or LVEF <30% 3 
Recent myocardial infarct  less than 90 days ago 2 
Pulmonary hypertension Systolic Pulmonary Artery pressure>60 mmHg 2 
Operation- related factors 
Emergency carried out on referral before the beginning of the next working day 2 
Other than isolated CABG major cardiac procedure other than or in addition to CABG 2 
Surgery on thoracic aorta for disorder of ascending, arch or descending aorta 3 
Postinfarct septal rupture      4 
 
 
 
The components of the European System for Cardiac Operative Risk Evaluation ‘EuroSCORE’. Abbreviations: 
IABP=Intra-aortic balloon pump; ARF=Acute renal failure; LVEF= Left ventricular ejection fraction. CABG= Coronary artery 
bypass graft. *= any one or more of the criteria.  (Nashef et al 1999) 
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Appendix 3: Parsonnet Score 
Factor Criteria 
Patient-related factors 
Age  
Sex  
Morbid Obesity > 1.5 times ideal body weight 
Diabetes  
Hypertension  > 140/90 mmHg 
Renal Dialysis  
Catastrophic states For example acute structural defect, cardiogenic shock or acute renal failure 
Cardiac-related factors 
Ejection Fraction Good or > 50%, moderate or 30-50%, poor or <30% 
Recent myocardial infarct  less than 90 days ago 
Preoperative intra Aortic 
Balloon Pump 
 
Operation- related factors 
Reoperation  
Emergency  
CABG At the same time as valve s 
Aortic valve surgery +/- gradient > 120 mmHg 
Mitral Valve surgery +/- gradient > 60 mmHg 
Left Ventricular Aneurysm      
 
The components of the Parsonnet Score. Abbreviations: CABG= Coronary artery bypass graft.   
 (Parsonnet et al 1989) 
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Appendix 4: Paediatric Logistic Organ 
Dysfunction score: PELOD 
Factor Criteria 
Cardiovascular factors 
Heart rate Age specific thresholds 
Systolic blood pressure Age specific thresholds 
Respiratory factors 
Pa02 /Fi02 <9.31 kPa 
PaC02 >11.7 kPa 
Mechanical Ventilation  Presence of invasive mechanical ventilation 
Hepatic factors 
Aspartate transaminase >950iu/L 
International Normalised Ratio >1.4 
Neurological factors 
Glasgow Coma Score 3, 4-6, 7-11, 12-15 
Pupillary reactions Both reactive, both fixed 
Haematological factors 
Total White cell count <1.5, 1.5- 4.4, >4.5 x109/L 
Platelet count <35 x109/L 
Renal factors 
Creatinine Age specific ranges 
  
The components of the Paediatric Logistic Organ Dysfunction (PELOD) score 
(Leteurtre et al 2003). 
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